diff --git a/111/article_3113.tex b/111/article_3113.tex new file mode 100644 index 0000000..2cb6af5 --- /dev/null +++ b/111/article_3113.tex @@ -0,0 +1,217 @@ +\documentclass[ +journal=tmr, +journalname={{Traditional Medicine Research}}, +layout=largetwo, +year=2025,%年 +volume=10,%卷 +articletype=REVIWER, +no=9,%期 +page=57,%号 +]{../tmr-tex} + +\doi{10.53388/TMR20241121001} +\journalweb{https://www.tmrjournals.com/tmr} + +\usepackage{amsmath} +\usepackage{placeins} +\usepackage{flushend} +\usepackage[nopatch]{microtype} +\usepackage{booktabs} +\usepackage[backend=biber]{biblatex} +\usepackage{xcolor} +\usepackage{tabularray} +\addbibresource{references_3113.bib} +\setlength{\bibitemsep}{1pt} +\definecolor{evenRowColor}{RGB}{250,231,232} + + +\setlength{\parindent}{1em}%缩进大小 + +\title{Natural flavonoids for the treatment of chronic obstructive pulmonary disease: An overview} + +\author{Peng-Liang Shi} +\affiliation{School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.} +\firstauthor +\author{Guo-Xuan Zhang} +\affiliation{School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.} +\orcid{0000-0002-0472-0377} +\author{Pei-Yi Wang} +\affiliation{Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, China.} +\author{Zi-Qi Liu} +\affiliation{School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.} +\author{Bing-Qing Zheng} +\email{Zhengbq880223@126.com} +\affiliation{School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.} +%\orcid{0000-0002-0472-0377} + + +\Correspondence{Bing-Qing Zheng,School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.E-mail: Zhengbq880223@126.com.} + + +\keywords{keyword entry 1, keyword entry 2, keyword entry 3} %% First letter not capped + +\authorcontributions{Shi PL collected documents and wrote the manuscript; Zhang GX, Wang PY, and Liu ZQ helped with information collection and manuscript editing; Zheng BQ revised the manuscript for important content and the manuscript preparation and editing.} +\competinginterests{The authors declare no conflicts of interest.} +\Acknowledgments{This work was supported by the Shandong Provincial Traditional Chinese Medicine Science and Technology Project “Study on the mechanism of Astragalus polysaccharide inhibiting the occurrence of liver fibrosis through PD-1 regulating NK cell function (2020Q004)”; Shandong Provincial Medical and Health Science and Technology Development Project “Mechanism of STAT3 inhibition of liver fibrosis by regulating PD-1+NK cells (202002070991)”. Natural Science Foundation of Shandong Province “Astragalus polysaccharides inhibit liver fibrosis by regulating CD49a+NK cells (ZR2022QH111).”} +\Peerreviewinformation{Traditional Medicine Research thanks all anonymous reviewers for their contribution to the peer review of this paper} +\Abbreviations{COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; ROS, reactive oxygen species; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; NF-κB, nuclear factor kappa-B; TNF-α, tumor necrosis factor-alpha; TGF-β, transforming growth factor-β; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MMP9, matrix metalloproteinase 9; HDAC2, histone deacetylase-2; PI3K, phosphoinositide-3- kinase; Nrf2, nuclear factor erythroid 2-related factor 2; CXCL, C-X-C motif chemokine ligand; NE, neutrophil elastase; MAPK, mitogen-activated protein kinase; EGF, epidermal growth factor; LPS, lipopolysaccharide; TLR4, toll-like receptor 4; JNK, c-Jun N-terminal kinase; SOD, superoxide dismutase; GSH, glutathione; GSH-Px, glutathione peroxidase; HO-1, haem oxygenase 1; MDA, malondialdehyde; SIRT1, silent information regulator 1; NAD+, nicotinamide adenine dinucleotide; GPX4, glutathione peroxidase 4; NADPH, nicotinamide adenine dinucleotide phosphate; GR, glucocorticoid receptor; CSE, cigarette smoke extract; IκB, inhibitor kappa B; HBECs, human bronchial epithelial cells; TLRs, toll-like receptors; IRAK, interleukin-1 receptor-associated kinase; PKC, protein kinase C; NOX4, NADPH oxidase 4; TIMP, tissue inhibitors of metalloproteinase; EMT, epithelial-mesenchymal transition; α-SMA, alpha smooth muscle actin; ERK, extracellular regulated protein kinases; AKT, protein kinase B.} +\Citation{Shi PL, Zhang GX, Wang PY, et al. Natural flavonoids for the treatment of chronic obstructive pulmonary disease: An overview. \textit{Tradit Med Res}. 2025;10(9):57. doi:10.53388/TMR20241121001} +\received{22 November 2024} +%\revised{28 November 2024} +\accepted{27 February 2025} +\Availableonline{3 March 2025} +\EditorialAdvisoryBoard{lixiang} +\Executiveeditor{liuna} +\tmrabstract{

Chronic obstructive pulmonary disease (COPD) has been a major global public health issue due to its high prevalence, disability, and mortality rates. The pathogenesis of COPD is complex and remains incompletely understood, compounded by a lack of specific and effective clinical therapies. Key pathophysiological mechanisms include oxidative stress, inflammation, programmed cell death, and fibrosis, influenced by external risk factors such as cigarette smoke and internal factors like immune deficiency. Natural flavonoids emerge as promising adjuvant treatments or potential drug candidates for COPD, attributed to their multi-target properties and low toxicity. This article provides an overview of various types and sources of natural flavonoids that exhibit therapeutic effects on COPD, their specific pharmacological actions and detailed mechanisms of action. This review aims to serve as a reference for adjuvant treatment strategies in daily dietary practices and to inspire novel drug candidates for COPD.

} +\keywords{natural flavonoids; COPD; oxidative stress; inflammation; programmed cell death; fibrosis} + + +\KeywordImage{./image/c83075d3cbe5dd333419e6ecf1028e70.png} +\begin{document} + \twocolumn + \begin{highlight} +\highlightitem{Highlights}{

1. The effectiveness and diversity of traditional Chinese medicine in treating COPD promote the exploration of effective natural substances.

2. The structural diversity of natural flavonoids contributes to their ability to engage multiple pathways and mechanisms in the treatment of COPD.

3. The high safety and easy availability of natural flavonoids are significant advantages in both the prevention and treatment of COPD.

} +\highlightitem{Medical history of objective}{

Extensive research on flavonoids in the treatment of COPD highlights the effectiveness of TCM for long-term management of lung diseases. For instance, the flower buds of \emph{Tussilago farfara} L. were first documented in “\emph{Shennong’s Classic of Materia Medica}” (written during the Eastern Han Dynasty (25-220 C.E.)), which noted their ability to dissolve phlegm and relieve cough. Similarly, other ancient Chinese texts, such as “\emph{Newly Revised Materia Medica}” (Jing Zhang et al. wrote in Tang Dynasty (659 C.E.)) and “\emph{Compendium of Materia Medica}” (Shi-Zhen Li wrote in 1552-1578 C.E.), also recognized the same effects. Current pharmacological studies indicate that the flavonoids present in \emph{Tussilago farfara} L. can combat COPD through various mechanisms, such as anti-inflammatory and anti-oxidative stress.

} + +\end{highlight} + + \section{\textit{\textbf{Introduction}}} +\par +Chronic obstructive pulmonary disease (COPD) is a progressive condition defined by persistent airflow obstruction and debilitating respiratory symptoms, presenting a considerable public health challenge across the globe. This illness leads to significant health issues and increased death rates, highlighting its effect on healthcare systems and individuals’ quality of life. A report published by the World Health Organization indicated that COPD has escalated to the status of the third cause of death worldwide \parencite{ref_132721}. Furthermore, COPD will continue to increase in tandem with the aging global population \parencite{ref_132722}.\par +The main pathological features of COPD include airway inflammation, airflow limitation, excessive mucus production, and damage to lung tissue. These factors result in symptoms such as wheezing, coughing, and shortness of breath, often leading to acute exacerbations or even death. The lungs are damaged by exposure to cigarette smoke (CS), dust, biofuel exhaust, and pathogens \textcolor[HTML]{0082AA}{[3, 4]}. COPD often overlap with asthma and is often complicated by pulmonary hypertension and cardiovascular diseases, including systemic hypertension and atherosclerosis \textcolor[HTML]{0082AA}{[5, 6]}. Multiple theories have been used to elucidate the pathogenesis of COPD, including the regulation of local oxidative stress in the lungs, the degree of inflammation, the proteolytic homeostasis of the extracellular matrix (ECM), and the imbalance of autophagy and apoptosis [7-10]. Although the pathogenesis of COPD remains unclear, there is currently no specific treatment available. Palliative regimens focused on improving airflow limitation represent the primary clinical approaches. Thus, new strategies and drugs for blocking COPD development should be developed, and multiple pathological factors and targets should be considered.\par +Natural products are still a crucial source for drug screening and discovery because of their structural and functional diversity. Flavonoids are vital bioactive components found in natural plants, playing an essential role in maintaining health and alleviating diseases. Natural flavonoids are categorized based on their structural features and demonstrate various biological activities, including anti-inflammatory, antioxidative, cell-protective, antimicrobial, and ECM degradation \textcolor[HTML]{0082AA}{[11, 12]}. Furthermore, flavonoid intakes can not only alleviate COPD in experimental models but are also inversely associated with COPD incidence in smokers \textcolor[HTML]{0082AA}{[13, 14]}. Natural flavonoids, with the advantages of multi-target and low toxicity, have great potential in developing COPD drugs, but there are few reviews on the relevant content. The familiar sources of natural flavonoids and the mechanism of action in treating COPD are shown in Figure 1. This article mainly summarises the pharmacological effects and specific mechanisms of natural flavonoids on COPD and provides a reference for the adjuvant treatment of COPD in daily dietary life and opinions for identifying new prospective candidate drugs for COPD.\par +\par +\begin{figure*}[htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/file_682161fb0fcfd.png} +\end{figure*}\par +\par +\section{\textit{\textbf{Pathogenesis of COPD}}} +\par + +COPD is a progressive respiratory condition defined by significant airflow limitation, mucus overproduction, chronic bronchitis, emphysema, or damage to the alveolar septal walls. These manifestations lead to symptoms such as wheezing, coughing, and dyspnea, which can result in acute exacerbations, hospitalisation, and even death \parencite{ref_132735}.\par +CS, pathogens, and various environmental exposures are significant external risk factors contributing to the development of COPD; notably, the removal of these risk factors has the potential to halt the pathological progression of the disease \textcolor[HTML]{0082AA}{[4, 15]}. Other factors, including genetics, gender, occupation, airway hyperresponsiveness, lung growth and development, and infections, also significantly contribute to the pathogenesis of COPD \parencite{ref_132735,ref_132736,ref_132737}. COPD is characterised by persistent inflammation and fibrosis of the small airways and the deterioration of lung parenchyma, also known as emphysema \textcolor[HTML]{0082AA}{[18, 19]}. COPD is complicatedly regulated by various biological mechanisms and their crosstalk, including oxidative stress, inflammation, ECM homeostasis, apoptosis, pyroptosis, and mucous cell hyperplasia \textcolor[HTML]{0082AA}{[7, 20-24]}. Among these, the regulation mechanism of oxidative stress and inflammation has attracted much attention in the field of COPD research and drug discovery, and airway remodelling and fibrosis are critical pathological features of late-stage COPD.\par +\par +\subsection{\textbf{Oxidative stress}} +Increased oxidative stress in the lungs significantly drives the disease through various molecular mechanisms\textcolor[HTML]{0082AA}{ [25, 26]}. The anatomical structure of the lungs makes them highly vulnerable to damage from environmental oxidative stress. Reactive oxygen species (ROS) from mitochondrial respiration and responses to lung infections also play a regulatory role. In individuals diagnosed with COPD, there is a notable increase in both the quantity and activation of alveolar macrophages, leading to higher levels of ROS, such as superoxide anions and H$_{{2}}$O$_{{2}}$ \parencite{ref_132747}. The same outcome can also be triggered by an increase in neutrophils, particularly during exacerbations \parencite{ref_132748}. In addition, lung epithelial cells also produce oxidative stress due to mitochondrial respiration \parencite{ref_132749}. Excessive ROS production is induced by both exogenous stimulation and internal inflammatory conditions.\par +Increased oxidative stress can activate several signalling pathways to drive the pathophysiology of COPD. Oxidative stress releases a large amount of oxidants, leading to the inactivation of anti-proteases and disrupting the protease-antiprotease balance in lung homeostasis, particularly affecting α1-antitrypsin \parencite{ref_132750}. The oxidative system is linked to the secretion of airway epithelial mucus, lead to the accumulation of ROS and induce high levels of mucus genes like mucin 5AC (\textit{MUC5AC}) and mucin 5B (\textit{MUC5B}) \parencite{ref_132751,ref_132752,ref_132753}. Epidermal growth factor receptor (EGFR) resided in oxidants-activated airway cells, which up-regulated the transcription of mucus genes during COPD development \textcolor[HTML]{0082AA}{[34, 35]}. Oxidative stress also triggers an inflammatory response in the lungs by influencing activator protein 1, an oxidant-sensitive transcription factor, and nuclear factor kappa-B (NF-κB). These factors promote the expression of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) \parencite{ref_132756}. In addition, oxidative stress activates transforming growth factor-β (TGF-β) signalling pathways, leading to small airway fibrosis and increased expression of matrix metalloproteinase 9 (MMP9) \parencite{ref_132757}, which also enhances elastolysis by inactivating α1-antitrypsin and secretory leukoprotease inhibitor, resulting in heightened neutrophil elastase activity and emphysema \parencite{ref_132758}. Moreover, corticosteroids play a significant role in suppressing pro-inflammatory gene expression \parencite{ref_132759}. However, oxidative stress can directly promote the phosphorylation and ubiquitination of histone deacetylase-2 (HDAC2) by activating phosphoinositide-3-kinase (PI3K)-δ \parencite{ref_132760}, resulting in amplified inflammation and corticosteroid resistance \parencite{ref_132761}.\par +Notably, nuclear factor erythroid 2-related factor 2 (Nrf2) will dissociate in oxidative stress response and transport to the nucleus to activate antioxidant gene transcription. Research indicates that the reduced self-protective mechanism in COPD patients is linked to decreased levels of Nrf2, leading to lower production of endogenous antioxidants. So, oxidative stress is a crucial mechanism of CS that initiates lung injury and inflammation and provides us with several targets, such as ROS and Nrf2, for drug discovery \parencite{ref_132762}.\par +\par +\subsection{\textbf{Inflammation and inflammatory cells}} +Inflammation drives the progression and exacerbations of COPD. In the airway lumen of COPD patients, inflammation is characteristic of increased numbers of macrophages, neutrophils, eosinophils, T cells, B cells, epithelial cells, endothelial cells, and fibroblasts \parencite{ref_132763}. The cells with different functions release different cytokines that work together to stimulate and maintain inflammatory levels and promote the progression and exacerbation of COPD.\par +CS stimulates both airway epithelial cells and macrophages to produce a range of chemotactic cytokines and chemokines, including IL-6, IL-8, C-X-C motif chemokine ligand (CXCL) 10, and CXCL9. These factors recruit neutrophils and CD8$^{{+}}$ T cells to the airway \parencite{ref_132764}. CD8$^{{+}}$ T cells are known to release perforins and granzymes, which contribute to tissue destruction and apoptosis. This process results in the production of pro-inflammatory proteases and cytokines, including IFN-γ and TNF-α, which may play a significant role in the pathogenesis of emphysema \parencite{ref_132765}. IFN-γ secreted by Th1, CD8$^{{+}}$ cells, and B cells triggers a series of signalling cascades that induce macrophage polarized to M1 phenotype, which indeed produces pro-inflammatory cytokines. Such as, TNF-α promotes leukocyte accumulation by modulating endothelial adhesion molecules, which release elastase and ROS to destroy alveolar epithelium \textcolor[HTML]{0082AA}{[46, 47]}. Proteases such as MMP and neutrophil elastase (NE), released by neutrophils and macrophages, degrade connective tissue and elastin in the alveoli, leading to both localized (centrilobular) and generalized (panlobular) emphysema. MMP levels were significantly increased in COPD patients with emphysema, contributing to ECM degradation and initiating airway tissue remodelling \parencite{ref_132768}. While CS-induced protease-antiprotease imbalance provokes airway inflammation for COPD pathogenesis, MMP and NE play crucial roles in the progression of emphysema and COPD \parencite{ref_132769}. Additionally, EGFRs can be activated by EGF released from neutrophils, or they may be indirectly activated through the mechanisms of oxidative stress \parencite{ref_132754}. Then, EGFRs activate mitogen-activated protein kinases (MAPK), which upregulate the expression of MUC5AC and MUC5B and lead to hyperplasia of goblet cells and submucosal glands, resulting in mucus hypersecretion and hyperplasia \parencite{ref_132755}. Moreover, macrophages and epithelials tend to secret TGF-β to activate the fibrosis progress by proliferating epithelium, smooth muscle and fibroblasts. Thus, both the immune cells and airway epithelial cells are overly activated during the inflammation response and maintaining the stability of the pulmonary immune environment is a crucial problem in COPD treatment.\par +\par +\subsection{\textbf{Fibrosis}} +Most types of chronic lung injury, primarily COPD, can induce fibrosis in the lungs, which occurs during the airway remodelling phase induced by persistent inflammatory stimulation and irreversible lung injury. Initially targeted at susceptible lung cells, recurring injuries caused by viruses, cigarette smoke, and others provoke epithelial cell death. Repairing the injuries increased vascular permeability, allowing fibrinogen and fibronectin to format a provisional matrix. Meanwhile, recurring injuries promote bronchiolar and alveolar epithelial cell migration and proliferation, including the aberrant-activated epithelial cells producing diverse epidermal growth factors (EGF) and chemokines to encourage the response. MMP1 and MMP7 are significant contributors to the migration of epithelial cells \parencite{ref_132770}. Following the migration of fibroblasts and fibrocytes to the sites of injury, these cells release MMP2 and MMP9, which activate TGFβ1. This activation subsequently facilitates epithelial-mesenchymal transition and promotes the differentiation of fibroblasts into myofibroblasts \parencite{ref_132771}. Myofibroblasts secrete ECM accumulation in the foci, mainly fibrillar collagens and alpha smooth muscle actin (α-SMA), and can provoke additional epithelial apoptosis through different signalling ways \textcolor[HTML]{0082AA}{[52, 53]}.\par +In addition, lipopolysaccharide (LPS) and smoke stimulation can also promote the occurrence of epithelial-mesenchymal transition (EMT) by up-regulating NF-κB signalling, toll-like receptor 4 (TLR4)/c-Jun N-terminal kinase (JNK) signalling, and forkhead box O signalling \parencite{ref_132774}. Pulmonary fibrosis, a final stage of COPD, is a critical phase to prevent COPD from developing into a pulmonary malignant disease.\par +\par +\section{\textit{\textbf{Flavonoids in COPD regulation}}} +\par +Traditional Chinese medicine possesses distinctive advantages in the treatment of COPD due to its inherent natural properties and demonstrated efficacy. Noteworthy, flavonoids, as the principal constituents of natural ingredients, offer outstanding anti-inflammatory and antioxidant properties, prompting significant interest and attention in scientific and industrial domains. Flavonoids can be categorized into 7 subgroups based on their structural variances, which include chalcones, flavones, flavonoid glycosides, Isoflavones, catechins (flavanols), biflavones and others. We have summarized 28 flavonoids that have been used in the treatment of COPD and divided them into 6 categories, which can be visualized in \textcolor[HTML]{0082AA}{Figure 2}.\par +The different biological activities of flavonoids depend on the three rings C6-C3-C6 essential backbone and different substitution groups. In addition, we have made a detailed summary of the natural sources of flavonoids in order to provide a reference for the public’s daily diet. The leading information can be seen in \parencite{ref_132775,ref_132776,ref_132777,ref_132778,ref_132779,ref_132780,ref_132781,ref_132782,ref_132783,ref_132784,ref_132785,ref_132786,ref_132787,ref_132788,ref_132789,ref_132791,ref_132792,ref_132793,ref_132794,ref_132795,ref_132796,ref_132797,ref_132799,ref_132801,ref_132802,ref_132803,ref_132804,ref_132805,ref_132806,ref_132807,ref_132808,ref_132809,ref_132810,ref_132811,ref_132812,ref_132813,ref_132814,ref_132815,ref_132816,ref_132818,ref_132819,ref_132820,ref_132821,ref_132822,ref_132823,ref_132824,ref_132825,ref_132826,ref_132827,ref_132828,ref_132829,ref_132830,ref_132831,ref_132832,ref_132833,ref_132834,ref_132835,ref_132836,ref_132837,ref_132838,ref_132839,ref_132840,ref_132841,ref_132842,ref_132843,ref_132844,ref_132846,ref_132848}.\par +\par +\begin{figure*}[htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/image-60721.png} +\end{figure*}\par +\par +执行附表程序\par +\par +The use of natural compounds and traditional Chinese medicine for managing COPD has been increasingly recognised. Patients with COPD should consider integrating these treatments into their overall care plan. Specifically, flavonoids have the potential to regulate imbalances in protease-antiprotease activity, immune function, lung function changes, blood flow, and serum markers by addressing airway and lung inflammation, improving airway remodelling, reducing airway reactivity, and modulating oxidative-antioxidant processes. Below, we summarise the potential efficacy of flavonoids in the treatment of COPD by discussing the specific mechanisms of action of these compounds. The detailed experimental verification can be found in \parencite{ref_132775,ref_132776,ref_132777,ref_132778,ref_132779,ref_132780,ref_132781,ref_132782,ref_132783,ref_132784,ref_132785,ref_132786,ref_132787,ref_132788,ref_132789,ref_132791,ref_132792,ref_132793,ref_132794,ref_132795,ref_132796,ref_132797,ref_132799,ref_132801,ref_132802,ref_132803,ref_132804,ref_132805,ref_132806,ref_132807,ref_132808,ref_132809,ref_132810,ref_132811,ref_132812,ref_132813,ref_132814,ref_132815,ref_132816,ref_132818,ref_132819,ref_132820,ref_132821,ref_132822,ref_132823,ref_132824,ref_132825,ref_132826,ref_132827,ref_132828,ref_132829,ref_132830,ref_132831,ref_132832,ref_132833,ref_132834,ref_132835,ref_132836,ref_132837,ref_132838,ref_132839,ref_132840,ref_132841,ref_132842,ref_132843,ref_132844,ref_132846,ref_132848}.\par +\par +\par +\subsection{\textbf{Flavonoids targeting oxidative stress }} +\textbf{Targeting ROS and antioxidative enzymes. }Oxidative stress accelerates the pathogenesis of COPD \parencite{ref_132849}. Harmful substances such as CS can cause inflammatory cells such as neutrophils and macrophages to accumulate in the lungs, producing large amounts of ROS \parencite{ref_132850}. In turn, ROS stimulates the expression of various inflammatory mediators in the lungs and results in hyper-mucus secretion by airway epithelial cells \textcolor[HTML]{0082AA}{[125, 126]}, aggravating the development of COPD.\par +Flavonoids have been reported to prevent and inhibit lung injury by scavenging free radicals. Flavonoids enhance intrinsic antioxidant capacity by increasing the levels and activities of antioxidant enzymes such as catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px), while also inhibiting ROS-generating enzymes like xanthine oxidase. For example, puerarin reversed mitochondrial membrane potential levels and ATP levels and decreased ROS content in cigarette smoke extract (CSE)-stimulated human bronchial epithelial cells (HBECs) \parencite{ref_132830}. Baicalin exerted an antioxidant role in CS-induced COPD mice by enhancing SOD, haem oxygenase 1 (HO-1) and reducing malondialdehyde (MDA) levels \parencite{ref_132813}. Liquiritin inhibited oxidant stress by increasing the SOD levels of the lung in CS-induced ICR mice \parencite{ref_132825}. Biochanin A increased the levels of antioxidant enzymes such as GSH-Px and decreased MDA, lactate dehydrogenase and alkaline phosphatase in a rat model of PM$_{{2.5}}$ exposure \parencite{ref_132829}. Apigenin enhanced the activation of silent information regulator 1 (SIRT1), nicotinamide adenine dinucleotide (NAD+), and the NAD+/NADH ratio in H$_{{2}}$O$_{{2}}$-induced WI-38 cells \parencite{ref_132781}. By regulating the balance between the antioxidant and ROS-generating enzymes, the flavonoids above can alleviate lung tissue lesions in COPD.\par +\textbf{Targeting Nrf2/HO-1.} Nrf2 serves as a pivotal transcription factor that governs the expression of genes associated with antioxidant activity. In patients with COPD, low levels of Nrf2 can diminish the body’s antioxidant capacity \parencite{ref_132853}. Under normal conditions, Kelch-like ECH-associated protein 1 sequesters Nrf2 in the cytoplasm. However, under oxidative stress, Nrf2 is released and translocated to the nucleus, where it initiates the transcription of various antioxidant genes, including glutathione (GSH), glutathione peroxidase 4 (GPX4), nicotinamide adenine dinucleotide phosphate (NADPH), NADPH quinone dehydrogenase 1, HO-1, 6-phosphogluconate dehydrogenase, thioredoxin, and the glucocorticoid receptor (GR) \textcolor[HTML]{0082AA}{[128, 129]}.\par +Various flavonoid monomers have been shown to have protective effects on airway epithelial cells and inflammatory cells. In summary, flavonoids were found to inhibit oxidative stress and inflammatory responses by targeting Nrf2 in different cell types, including epithelial cells, macrophages, and lung cancer cells, The mechanism of action can be visually illustrated in \textcolor[HTML]{0082AA}{Figure 3}. Casticin enhanced SOD activity but decreased ROS and MDA by regulating Keap1-Nrf2/antioxidant response element signalling way in H$_{{2}}$O$_{{2}}$-induced BEAS-2B cells \parencite{ref_132801}. Oroxylin A reduced the inflammatory response by increasing Nrf2 levels in CS-damaged RAW 264.7 cells \parencite{ref_132782}. Luteolin decreased total ROS and mitochondrial ROS concentrations by inhibiting CYP2A13 expression while simultaneously increasing Nrf2 levels in CSE-treated A549 cells \parencite{ref_132803}.\par +\par +\begin{figure*}[htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/file_67aee377039e2.jpg} +\end{figure*}\par +\par +In mice and rat models of COPD, various flavonoids have likewise been proved to inhibit the development of COPD by modulating Nrf2-related oxidative stress to attenuate lung damage and inflammatory responses. In a four-days CS-induced mouse model, Oroxylin A increased GSH, GR, GPx-2 and HO-1 levels by promoting Nrf2 binding to antioxidant response element \parencite{ref_132782}. In a CS-induced mouse model, isoliquiritigenin reduced MDA levels by enhancing the expression of Nrf2 and HO-1 \parencite{ref_132777}. Fisetin was demonstrated to prevent lung damage and attenuate oxidative stress and inflammation via Nrf2-mediated antioxidant factors in CS-induced rat model, including decreasing inflammatory cytokines such as IL-4, IL-1β, TNF-α and increasing antioxidant enzymes such as SOD, GSH \parencite{ref_132794}. Epicatechin repressed the production of ROS by enhancing the Nrf2-induced anti-oxidant enzyme and then reduced IL-18 and IL-1β levels by inhibiting the NLRP3-Caspase-1 pathway in the CS-induced rat \parencite{ref_132833}. Luteolin inhibited oxidative stress by decreasing the TRPV1 and CYP2A13 proteins while increasing SIRT6 and Nrf2 levels in CSE-treated A549 cells and CS- and LPS-induced COPD mice \parencite{ref_132803}. Additionally, flavonoids could target Nrf2 and reverse dexamethasone tolerance during COPD treatment. Quercetin was reported to reverse the dexamethasone-tolerance in CSE-induced U937 cells by activating adenosine 5’-monophosphate-activated protein kinase (AMPK) and Nrf2 signalling way \parencite{ref_132785}.\par +Total flavonoids of natural plants have also been reported to inhibit oxidative stress in COPD by targeting Nrf2. Dandelion total flavonoids improved lung function and reduced oxidative stress-induced lung damage by upregulating antioxidant enzymes such as SOD and GSH in mice exposed to CS, linked to the activation of the Nrf2 signaling pathway \parencite{ref_132848}.\par +\par +\subsection{\textbf{Flavonoids targeting inflammation}} +Inflammation is a vital component in the initiation and advancement of COPD. The infiltration of neutrophils demonstrates a positive correlation with the severity of airflow obstruction. Harmful substances induce the respiratory tract epithelium to secrete inflammatory cytokines and chemokines. Likely, TNF-α facilitates leukocyte migration and accumulation by stimulating pulmonary endothelial cells, releasing lysosomal enzymes, elastase, and ROS, all detrimental to endothelial cells and the alveolar epithelium \parencite{ref_132856}. IL-6 activates neutrophils, releasing NE and ROS, which damage alveolar surfactants, increase pulmonary vascular permeability, and induce pulmonary edema \parencite{ref_132857}. Additionally, monocyte chemotactic protein-1 and macrophage inflammatory protein-1α serve as chemoattractants, recruiting inflammatory cells such as macrophages and lymphocytes into inflamed tissues.\par +Flavonoids possess strong anti-inflammatory properties in various inflammatory diseases, effectively inhibiting the onset and progression of COPD. Additionally, flavonoids play a significant role in addressing respiratory diseases closely linked to inflammation. We will focus on the anti-COPD effect of flavonoids and their related mechanisms of action, including their relationship with NF-κB signalling pathway, MAPK signalling pathway, EGFR signalling pathway, and immune cells migration. The different mechanisms of action that flavonoids protect COPD can be seen intuitively in \textcolor[HTML]{0082AA}{Figure 4}.\par +\textbf{Targeting NF-κ}\textbf{B pathway.} The activation of the NF-κB pathway is believed to play a pivotal role in inflammatory diseases, including airway and pulmonary inflammation. Under normal conditions, NF-κB remains inactive in the cytosol, as it is bound to the inhibitor kappa B (IκB). Upon stimulation of airway epithelial receptors, IκB kinase is activated, leading to the phosphorylation of IκBα or IκBβ. This phosphorylation results in the dissociation of IκBα or IκBβ from NF-κB. Subsequently, NF-κB (comprising p50 and p65 subunits) translocates to the nucleus, where it activates the expression of genes encoding inflammatory cytokines and chemokines, such as \textit{TNF-α}, \textit{IL-1β}, and \textit{IL-6} \parencite{ref_132858}. Notably, activated NF-κB in the lung tissue of COPD patients were significantly elevated, while IκB levels were notably reduced \parencite{ref_132859}. Furthermore, the inhibition of the NF-κB pathway led to a decrease in the presence of respiratory mucus, specifically MUC5AC and MUC5B \parencite{ref_132860}.\par +\par +\begin{figure*}[htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/file_68999e3c72e62.png} +\end{figure*}\par +\par +Researchers have identified a range of natural products that modulate NF-κB signalling in COPD, acknowledging NF-κB’s significance in chronic inflammatory conditions. Casticin was reported to inhibit the apoptosis and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, and IFN-γ) production by down-regulating p-p65 but increasing Nrf2 in LPS-induced BEAS-2B cell \parencite{ref_132799}. Epigallocatechin gallate diminished the lipid peroxidation, ROS production and inflammation mediator levels (COX-2, NADPH oxidase 4 (NOX4), NOS2, IL-6 and IL-8) by suppressing the activation of NF-κB pathway in CSE-stimulated airway epithelial cells \parencite{ref_132834}. Baicalin inhibited the TNF-α, IL-8, and MUC5AC levels by decreasing NF-κB p65 phosphorylation in IL-1β-induced NCI-H292 cells \parencite{ref_132818}, in CSE-induced type II pneumocytes and in CS-exposed rat \parencite{ref_132811}. In a CS-induced mouse model, Isoliquiritigenin reduced the phosphorylation of p65 and IκB, attenuating the inflammatory response and reducing the inflammatory factors \parencite{ref_132777}. Casticin improved lung function and reduced the number of white blood cells, neutrophils, and macrophages and the level of leptin, C-reactive protein, and pro-inflammatory cytokines by inhibiting the NF-ĸB and iNOS pathway \parencite{ref_132797}. Taxifolin significantly suppressed elevated IL-1β, IL-6 and TNF-α levels in COPD mouse lung tissue and CSE-treated HBECs by inhibiting the phosphorylation p65 NF-κB \parencite{ref_132810}.\par +In addition, glucocorticoid drugs are often used to improve airflow limitation and attenuate the inflammation of COPD in clinical, which usually induces drug tolerance at the same time. Several kinds of flavonoids decreased the inflammation levels and reversed the glucocorticoid drug tolerance at the same time. In CS exposure mice and pig models, naringenin not only significantly improved the pulmonary function but decreased the accumulation of inflammatory cells and pro-inflammatory cytokines such as IL-8, TNF-α, and MMP9 by inhibiting phosphorylation of NF-κB but increasing GR, which indicate that naringenin enhances the corticosteroid sensibility \textcolor[HTML]{0082AA}{[48, 82]}. Icariin demonstrated a significant reduction in inflammation, airway remodelling, and ROS production that is induced by CSE. Furthermore, it alleviated glucocorticoid resistance through the down-regulation of the Nrf2 and NF-κB signalling pathways \parencite{ref_132822}.\par +Flavonoids can directly act on the NF-κB pathway to improve COPD inflammation. However, as a core pathway, its upstream regulators, including toll-like receptors (TLRs) and sirtuins, also regulate its activation.\par +TLRs are a family of receptors that detect pathogens and tissue damage. Among them, TLR2 recognizes lipoteichoic acid from gram-positive bacteria, and TLR4 is activated by LPS and other endogenous ligands \parencite{ref_132861}, which were reported to be up-regulated and activated during COPD initiation and development, especially in the COPD co-infection model. Upon stimulation, myeloid differentiation primary response gene 88 recruits the interleukin-1 receptor-associated kinase (IRAK) family member IRAK4 to TLRs and induces the phosphorylation of IRAK1, which subsequently activates the NF-κB pathway \parencite{ref_132862}. In CS and LPS co-induced COPD rat model, baicalin reduced TLR2 and TLR4, followed by lowering MYD88, phosphorylation of p65, and increasing phosphorylation of IκBa \parencite{ref_132819}, Total flavonoids of \textit{Trollius altaicus} downregulated TLR4 to reduce the activation of IRAK-1, thereby reducing the activation of the NF-κB and reducing IL-1β, IL-6, IL-8, TNF-α \parencite{ref_132844}. In long-term cs-exposed rats, casticin reduced TLR4 expression to inhibit the NF-κB phosphorylation and increase the IκBα phosphorylation level, thereby reducing inflammation \parencite{ref_132797}. TLRs are crucial targets of flavonoids in inhibiting COPD-associated inflammation, especially in infection-associated COPD development.\par +SIRT1, one of seven-number families with different subcellular localisations and functions, is the first sirtuin that regulates inflammatory, oxidative stress, autophagy, and apoptosis, which can inhibit the activation of NF-κB. The heightened inflammatory response may reduce SIRT1 levels in patients with COPD \parencite{ref_132863}, and a high level of SIRT1 inhibits inflammatory reactions in lung cells stimulated by CS \parencite{ref_132864}. Quercetin increased SIRT1 levels to reduce inflammatory responses and oxidative stress in mice with COPD induced by LPS and elastase \parencite{ref_132784}. Myricetin reduced IL-6 and IL-8 levels in TNF-α-induced A549 cells by regulating the SIRT1/NF-κB pathway \parencite{ref_132795}. Hesperetin alleviated inflammation and oxidative stress responses by SIRT1/PGC-1a/NF-κB signalling axis in CES-induced COPD mice \parencite{ref_132807}. Besides, total flavonoids of \textit{Scutellaria baicalensis }Georgi also inhibited inflammatory and oxidative stress by increasing SIRT1 and PGC-1a levels in CS- and LPS- co-induced mice models \parencite{ref_132842}.\par +There are also several other targets for flavonoids to regulate NF-κB during COPD inflammation, such as protein kinase C (PKC)δ, peroxisome proliferator-activated receptor γ, HDAC2 and NOX4. Fisetin has been reported to directly bind to PKCδ, preventing the activation of NF-κB and the expression of IL-8 in HEK293T and NCI-H292 cells induced by TNF-α \parencite{ref_132793}. Icariin promoted lung function and reduced TNF-α and IL-6 levels in bronchoalveolar lavage fluid and serum of COPD rat model, and indeed up-regulated the peroxisome proliferator-activated receptor γ expression and inhibited the activation of p65 of lung and epithelial cells \parencite{ref_132824}. Baicalin treatment markedly attenuated the inflammatory effects through down-regulating airway inflammatory infiltration and decreasing the inflammatory factors (the levels of TNF-α and IL-1β) in CS/CSE-exposed rats and cells, which attributed to the enhancement of HDAC2 protein expression and inhibition of NF-κB or even targeting its downstream effector PAI-1 \textcolor[HTML]{0082AA}{[89, 92]}. Luteolin reduces inflammation and oxidative stress via the NOX4-mediated NF-κB pathway in CS-induced cell and mice \parencite{ref_132802}.\par +Total flavonoid extract also has the effect of inhibiting the NF-κB pathway. For example, total flavonoids from \textit{Nigella glandulifera} relieved the pathological state, inhibited the infiltration of neutrophils and macrophages into the lung and decreased levels of TNF-α and IL-8 via the NF-κB pathway \parencite{ref_132840}. Total flavonoids from loquat (\textit{Eriobotrya }\textit{japonica}) leaves alleviated oxidative stress-induced lung injury, emphysema and inflammation by inhibiting NF-κB and JNK phosphorylation \parencite{ref_132843}.\par +\textbf{Targeting MAPK pathway. }MAPKs represent a diverse family of kinases that are critical components of various signal transduction pathways. The MAPK family comprises four subfamilies: extracellular regulated protein kinases (ERK)1/2 (extracellular signal-regulated kinases 1 and 2), ERK5, JNKs, and p38s (p38 MAPKs). Notably, p38 MAPK is activated in response to environmental stress and inflammatory stimuli. Of its subtypes, p38α is particularly abundant in inflammatory cells \parencite{ref_132865}. Moreover, elevated levels of p38 MAPK have been detected in the airways and sputum of COPD patients \parencite{ref_132866}. Furthermore, it has been demonstrated that pathogens can augment MUC5AC mucin secretion by activating the p38 MAPK pathway while simultaneously inhibiting the PI3K-Akt pathway \parencite{ref_132867}.\par +In mice exposed to CS, astragalin demonstrated an ability to attenuate inflammation and oxidative stress induced by pulmonary thrombus. This effect was mediated by a reduction of PAR-1 and PAR-2, which subsequently inhibited the production of ROS and the expression of COX-2, iNOS, and ICAM-1. The mechanism involved the inhibition of the ERK, p38, and JNK signalling pathways \parencite{ref_132821}. Silymarin significantly alleviated the thickening of the airway epithelium and infiltration of peribronchial inflammatory cells (including total cells, macrophages, and neutrophils) while also reducing levels of pro-inflammatory factors such as TNF-α, IL-1β, and IL-8 by attenuating the phosphorylation of ERK and p38 in CS-exposed mice, the results were also proved in CSE-induced Beas-2B cells \textcolor[HTML]{0082AA}{[113, 114]}. The total flavonoids of \textit{Trollius altaicus} protected lung function by inhibiting the activation of p38 and ERK in CS-induced mice \parencite{ref_132846}.\par +Bacterial infection stands as a primary culprit behind acute exacerbations of COPD. These exacerbations correlate with a notable rise in both airway and systemic inflammation \parencite{ref_132868}. Flavonoids alleviate the pathological inflammation associated with COPD combined with bacterial infection by inhibiting the activation of MAPKs. Appling LPS/CSE-induced acute exacerbations of COPD mouse models, researchers discovered that: Hydroxysafflor yellow A decreased levels of IL-6, IL-1β, and TNF-α by inhibiting the phosphorylation of ERK, p38, and JNK, and to inhibit inflammatory mediator by decreasing levels of p-p38 and p-p65, as well as in platelet-activating factor (PAF)-stimulated HSAECs \textcolor[HTML]{0082AA}{[59, 60]}; Baicalin reversed elevated levels of IL-8, IL-6, TNF-α and MUC5AC which is associated with the inhibition of JNK activation \parencite{ref_132814}; Silibinin inhibited the expression of MUC5AC, IL-6, and IL-1β by suppressing the activation of ERK and specificity protein 1, as well as in CS condensate-stimulated NCI-H292 cells \parencite{ref_132835}. Total flavonoids of sea buckthorn inhibited expression of IL-1β, IL-6, CXCL1, prostaglandin E2, cyclooxygenase-2, and MUC5AC through the inhibition of the ERK, PI3K/Akt, and PKCα pathways, as well as in LPS/CSE-induced HBE16 cells \parencite{ref_132841}.\par +\textbf{Targeting EGFR pathway.} The EGF and its receptor (EGFR) are essential for causing and promoting various cell growth, proliferation, and transformation processes. Patients with COPD have higher levels of EGFR in their lungs compared to smokers without COPD symptoms \parencite{ref_132869}. This suggests that EGFR plays a significant role in the development of COPD. The increased EGFR levels are linked to the growth of airway epithelial goblet cells and more mucus production \parencite{ref_132754}. EGFR activation initiates key signaling pathways, including PI3K/protein kinase B (AKT)/mTOR, RAS/MEK/ERK, and MAPK p38 \parencite{ref_132870}.\par +Flavonoids inhibit the activation of the EGFR signalling pathway, making them promising for treating lung diseases. In CS-exposed mice and CSE-induced NCI-H292 cells, phloretin decreased EGFR phosphorylation, reducing ERK phosphorylation and p38 expression and decreasing mucin expression and inflammation \parencite{ref_132775}. In the LPS-induced airway mucus hypersecretion rat model, quercetin reduced the expression level of MUC5AC by inhibiting the activation of the EGFR, as evidenced by decreased levels of p-EGFR/EGFR, p-PI3K/PI3K, p-PKC/PKC, p-AKT/AKT, and NF-κB \parencite{ref_132789}. Additionally, in EGF-stimulated H292 cells or A549 cells, tilianin also reduced MUC5AC expression by modulating the expression of AKT, ERK, and p38 in EGF-stimulated NCI-H292 human airway epithelial cells. However, it did not affect A549 cells \parencite{ref_132826}. Furthermore, icariin was shown to promote lung function and reduce pro-inflammatory cytokines by inhibiting the phosphorylation of PI3K, AKT, and p38 \parencite{ref_132823}.\par +\textbf{Immune cells migration. }The inflammatory process of COPD is characterized by the persistent migration of inflammatory cells from the blood vessels to the lungs. This includes neutrophils, macrophages, and T cells, which produce a plethora of cytokines that exacerbate inflammation.\par +Casticin was found to inhibit immune cell infiltration in the lungs, including neutrophils, macrophages, and lymphocytes. This effect was accompanied by a downregulation of TNF-α, IL-6, IL-1β, and monocyte chemotactic protein-1 levels in bronchoalveolar lavage fluid of CS-exposed mice \parencite{ref_132796}. Phloretin was shown to reduce the level of CXCL1, a neutrophil chemoattractant, which was induced by nontypeable \textit{Haemophilus influenzae} in a COPD model of infection \parencite{ref_132776}. Quercetin improved the lung function and alleviated goblet cells metaplasia and emphysematous by down-regulating the inflammation mediators levels (such as CXCL-1, CXCL-10, TNF-α, IFN-γ IL-13 and IL-17A) and infiltration of immune cells (such as leukocytes, total lymphocytes, CD11b$^{{+}}$CD11c$^{{+}}$ macrophages, neutrophils and CD8$^{{+}}$T cells) in both CS-induced and rhinovirus/CS-induced COPD mice \textcolor[HTML]{0082AA}{[66, 70]}. Quercetin also improved epithelial regeneration and reduced TGF-β, IL-6 and IL-8 airway basal cells of COPD patients \parencite{ref_132792}. Tilianin inhibited neutrophil infiltration in the lung by affecting CXCL2, IL-17/STAT3 signal pathways in the COPD mice model \parencite{ref_132827}. Ginkgetin decreased CCL2 levels by downregulating the c/EBPβ signalling pathway in CSE-induced A549 cells, which is associated with immune cell migration such as macrophages \parencite{ref_132839}. Additionally, naringenin inhibited the M1 polarization of macrophages induced by extracellular vesicles from CSE-induced epithelial cells and reduced inflammatory cells and myeloperoxidase in CS-exposed guinea pigs \textcolor[HTML]{0082AA}{[81, 83]}. Additionally, naringin has a protective effect on NEP activity by reducing SP and the expression of the NK-1 receptor, thereby relieving the cough symptoms in CS-exposed guinea pigs \parencite{ref_132828}.\par +\par +\subsection{\textbf{Flavonoids targeting airway remodelling and fibrosis}} +There is currently insufficient data on how flavonoids affect the anti-COPD fibrosis process. These studies primarily focus on the formation and degradation of ECM and the process by which fibrotic cells are formed. \textcolor[HTML]{0082AA}{Figure 5} offers more detailed insights into the specific mechanisms of action involved.\par +\par +\begin{figure*}[htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/zipimg67aea6fbb71406.png} +\end{figure*}\par +\par +\textbf{ECM degradation.} Proteases are key in remodelling tissue and promoting inflammation \parencite{ref_132768}. An imbalance between proteases and anti-proteases disrupts ECM, which is essential for maintaining the dynamic integrity of organs. MMPs, serine proteases, and caspases are the three main elastase types responsible for hydrolysis peptides and other proteins. MMP-2, MMP-8, MMP-9, and NE are most involved in emphysema and COPD \textcolor[HTML]{0082AA}{[49, 145-147]}. Among them, MMPs are a prominent and influential family. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs; usually, TIMP-1 inhibits active MMPs, and TIMP-1 binds to pro-MMP-9 to prevent the activation of pro-MMP-9. However, under harmful conditions, the combination of TIMP-1 and pro-MMP-9 dissociates by NE action, and MMP-3 activates pro-MMP-9 to MMP-9 \parencite{ref_132874}. NE, cathepsin G, and proteinase-3 are three main types of serine proteases that are also destroyed by degrading ECM components of lung tissue \parencite{ref_132875}. ECM degradation releases collagen and elastin, which attract immune cells and cause ongoing airway inflammation in the lungs.\par +In CS-exposed mice, quercetin \parencite{ref_132784}, naringenin \parencite{ref_132805}, hesperidin \parencite{ref_132808}, and baicalein all downregulated MMP9 levels and reduced inflammation \parencite{ref_132813}. Baicalein also reduced TIMP-1, MMP2, MMP9, and MMP8 \parencite{ref_132812}. In CSE-induced BEAS-2B cells, icariin reduced the expression of MMP-9 and TIMP1 \parencite{ref_132822}. Thus, flavonoids inhibited ECM degradation and maintained alveolar integrity in the early phase of COPD development.\par +\textbf{Fibrosis.} In patients with COPD, airway epithelial cells show higher levels of TGF-β1 expression, which contributes to fibrotic airway remodelling and a decline in lung function \parencite{ref_132876}. TGF-β activates TGFBR, promoting the phosphorylation of Smad2/3. The phosphorylated Smad2/3 subsequently binds to Smad4, initiating the transcription of genes related to airway remodellings, such as \textit{α-SMA} and collagen. This process alters the EMT \parencite{ref_132877}. Additionally, TGF-β signalling upregulates MMPs, facilitating EMT and resulting in the degradation and destruction of lung tissue. Furthermore, TGF-β induces the EGF/EGFR signalling pathway, which synergistically promotes EMT-related phenotypic changes. TGF-β1 also stimulates the activity of neutrophils, macrophages, and mast cells.\par +Hydroxysafflor yellow A reduced the expression of TGF-β1 in a rat model of LPS-CS co-infection and alleviated pulmonary fibrosis by decreasing the accumulation of α-SMA and collagen I, thereby improving lung function \parencite{ref_132778}. In four-day CS-exposure mice, liquiritin apioside reduced inflammatory response and TGF-β1 level. The same results were performed in CSE-induced A549 \parencite{ref_132825}. In a three-month CS-exposed mouse model, quercetin also reduced TGF-β1 and α-SMA in the lungs \parencite{ref_132787}. In the CS-exposed mouse model, silibinin decreased collagen accumulation by modulating the TGF-β1/p-Smad 2/3 signalling axis and simultaneously attenuated the expression of inflammatory factors \parencite{ref_132836}. Besides, in the LPS-CS co-induced rat model, total flavonoids of \textit{Trollius altaicus} were shown to decrease TGF-β1 levels \parencite{ref_132844}. Both short-term and long-term exposure to smoke can result in lung inflammation and cellular damage, leading to the production of TGF-β1, implicating the initiation of pulmonary fibrosis. However, flavonoids, such as hydroxysafflor yellow A, liquiritin apioside, quercetin, silibinin, and total flavonoids of \textit{Trollius altaicus} may help prevent the progression of COPD to pulmonary fibrosis by reducing TGF-β. Compared with the anti-inflammatory and antioxidant studies of flavonoids, there are few studies on anti-pulmonary fibrosis, and most of them only reduce TGF-β, which suggests that more extensive and in-depth research is needed.\par +\par +\subsection{\textbf{Flavonoids targeting programmed cell death}} +\textbf{Targeting apoptosis.} Apoptosis is a physiological or pathological response of cells to various stimuli, including DNA damage, oxidative stress, and inflammation. This process is complex and tightly regulated by multiple genes, such as the \textit{Bcl-2} family, the caspase family, the oncogene \textit{C-myc}, and the tumour suppressor gene \textit{P53}, as well as by various molecular signals, including the death receptor pathway and the mitochondrial pathway \parencite{ref_132878}. Research shows that the apoptosis (cell death) of lung structural cells is a crucial factor in the development of COPD. In patients with COPD, there is an observed increase in the apoptosis of alveolar epithelial and endothelial cells. This increase cannot be compensated for by the proliferation of structural cells, leading to the destruction of lung tissue and the development of emphysema \parencite{ref_132879}.\par +Flavonoids have been reported to act as positive protectors against apoptosis in the pathogenesis of COPD. For instance, baicalin has been shown to inhibit the expression of HSP72 and alleviate apoptosis in CSE-treated MLE-12 cells, which are mouse lung type II epithelial cells \parencite{ref_132814}. Additionally, baicalin mitigates the apoptosis of LPS- or CSE-induced 16HBE cells by increasing Bcl-2 and CyclinD1 but increasing B-cell lymphoma 2-associated X (Bax) and P21 \textcolor[HTML]{0082AA}{[92, 93, 96]}. Taxifolin inhibited apoptosis by suppressing Bax and CCP3 levels and increasing Bcl-2 levels in COPD mouse lung tissue and CSE-treated HBECs \parencite{ref_132810}. Hesperetin is capable of suppressing the protein expression of AKT1, IL6, VEGFA, and MMP9 while up-regulating the protein expression of TP53, thereby impeding COPD to lung cancer \parencite{ref_132808}. Furthermore, flavonoids regulate autophagy-related apoptosis. Puerarin has been demonstrated to inhibit FUNDC1-mediated mitochondrial autophagy and CSE-induced apoptosis in human bronchial epithelial cells by activating the PI3K/AKT/mTOR signalling pathway \parencite{ref_132830}. Puerarin also protects lung function and inhibits apoptosis by down-regulating the Bax level and up-regulating Bcl-2 in the lung, a process that depends on the PINK1-parkin signalling pathway mediated mitophagy \parencite{ref_132831}. Moreover, formononetin can attenuate CS-induced inflammation, endoplasmic reticulum stress, and apoptosis in bronchial epithelial cells through the inhibition of AhR/CYP1A1 and AKT/mTOR signalling pathways \parencite{ref_132832}. In addition, flavonoids inhibit apoptosis associated with inflammation. Biochanin A has been shown to reduce PM2.5-induced apoptosis and the production of pro-inflammatory factors, such as TNF-α, IL-2, IL-6, and IL-8 \parencite{ref_132829}.\par +\textbf{Targeting ferroptosis.} Ferroptosis, a form of regulated cell death, is driven by an excessive accumulation of iron, ROS, and lipid peroxides. This process leads to a decrease in GSH and the inactivation of GPX4 \parencite{ref_132880}. Ferroptosis is increasingly recognised as a critical factor in COPD, with levels elevated in free iron, lipid peroxidation, and inflammatory responses in mice, which are reversed by the overexpression of the GPX4 \parencite{ref_132881}. GPX4, a negative regulator of ferroptosis, was significantly downregulated in HBECs, which correlates with exacerbations of airway obstruction. Additionally, acyl-CoA synthetase long-chain family member 4 (ACSL4) has been identified as a significant contributor to sensitivity to ferroptosis and was significantly upregulated \parencite{ref_132882}. Furthermore, Nrf2 plays a protective role by inhibiting ferroptosis through the scavenging of ROS and the promotion of GSH synthesis \parencite{ref_132883}.\par +Scutellarein may help treat COPD by inhibiting ferroptosis through iron chelation and interaction with the enzyme arachidonate 15-lipoxygenase, which is involved in fatty acid oxidation. Besides, scutellarein significantly inhibited Ras-selective lethal small molecule 3-induced ferroptosis and mitochondria injury \parencite{ref_132783}. Dihydroquercetin significantly inhibited the ferroptosis induced by CS through the Nrf2-dependent signalling pathway. It notably impeded the increasing of lipid peroxidation and morphological changes in the mitochondria by up-regulating SLC7A11, GPx4, and SOD by down-regulating MDA and ROS \parencite{ref_132809}. Naringenin increased the extracellular vesicles miR-23a-3p level of CSE-induced alveolar macrophages and inhibited lung epithelial ferroptosis by targeting ACSL4 \parencite{ref_132806}. Thus, flavonoids could alleviate the ferroptosis-induced injury and oxidative stress by chelating iron and activating the downstream anti-oxidant pathway during the progression of COPD.\par +\par +\subsection{\textbf{Flavonoids’ safety}} +Flavonoids have a long history of consumption in diets with high-rich flavonoids, and a high intake of flavonoids has not caused any side effects. As a result, it is unlikely that dietary sources could provide doses sufficient to cause mutations or cytotoxicity. However, pharmacological and clinical experiments have shown that a variety of flavonoid preparations have certain toxicity, consult \textcolor[HTML]{0082AA}{Table 3 [68, 158-171]} for additional details. For example, chalcones, such as isoliquiritigenin has mortality and malformationand \parencite{ref_132884}, hydroxysafflor yellow A has a slight nephrotoxicity in long term \parencite{ref_132885}; Flavone glycosidescertain, baicalin has certain renal toxicity \parencite{ref_132886}. Isoflavones, such as puerarin has the severity of adverse drug reactions depends on the choice of infusion solvent \parencite{ref_132887}, not the dosage of puerarin, formononetin has mortality at acute dose 300 mg/kg and LD50 at 103.6 mg/kg \parencite{ref_132888}. Bisflavonoid, such as ginkgetin has potential hepatic and renal toxicity \parencite{ref_132889}. There are tens of thousands of types of flavonoids, and the safety of each flavonoid compound is extensive, so it is of great significance to investigate the side effects of daily flavonoid supplementation.\par +\section{\textit{\textbf{Conclusion and prospect}}} +\par +Natural flavonoids are a class of compounds commonly found in various foods, and herbs derives its properties from a wide range of plants, including apples, celery, bayberry, citrus, tea, and ginkgo, as well as astragalus and licorice. A significant body of research exists regarding the flavonoid content in different food sources. Among the flavonols and flavones, quercetin is the most prevalent compound which is particularly abundant in onions and tea. Other noteworthy flavonoids include kaempferol, myricetin, as well as the flavones apigenin and luteolin.\par +COPD is a prevalent and fatal chronic lung disease that poses a significant burden on global healthcare systems. Despite its high incidence, the mechanisms underlying the development of COPD remain elusive, and there are currently no drugs available to prevent or reverse its initiation and progression. As discussed in this review, flavonoids can target multiple pathways to inhibit the development of COPD, including regulating oxidative stress by targeting ROS and Nrf2/HO-1, reduce inflammation by targeting NF-κB, MAPK, and EGFR pathway, remodel airway by reducing ECM and fibrosis, and regulate programmed cell death by targeting apoptosis and ferroptosis. All of this indicates that flavonoids offer unique advantages in drug discovery and adjuvant therapy but also suggests that foods rich in flavonoids can be used to prevent the occurrence of COPD.\par +The structure of flavonoids is both complex and diverse. As discussed in this review, the structures of flavonoids exhibiting therapeutic effects on COPD vary significantly. Notably, the number and position of hydroxyl groups influence flavonoids’ activity and mechanism of action, with the ortho-hydroxyl group playing a particularly critical role. Additionally, glycosylation represents another important structural feature that impacts efficacy. However, research related to COPD has not thoroughly and specifically addressed the structure-activity relationships of flavonoids. Elucidating these relationships, along with conducting structural modifications and optimisations, is essential for guiding the development of anti-COPD drugs.\par +A variety of flavonoids have been developed into pharmaceuticals, cosmetics, and health foods, such as ginkgo flavonoids, tea polyphenols, and puerarin. Flavonoids as dietary supplements are not regulated as strictly as drugs, do not need to be reviewed by the FDA, and are not thoroughly evaluated for potential toxicity. When people use these drugs, cosmetics, or health foods, the recommended intake of flavonoids is much higher than in the daily diet, usually at the gram level. Therefore, people need to pay attention to the dosage when supplementing with additional flavonoid preparations to avoid adverse reactions.\par +Many flavonoid compounds, as well as flavonoid-rich diets and medications, are utilized in clinical treatments, demonstrating their relative safety for human health, only quercetin has explicitly been tested in clinical trials for treating COPD \parencite{ref_132788}. Consequently, which flavonoid is most suitable for COPD therapy remains unclear, underscoring the need for further preclinical and clinical research. Currently, there have been only two clinical trials involving quercetin and a flavonoid-rich diet for COPD \textcolor[HTML]{0082AA}{[13, 14]}. Nonetheless, numerous other clinical trials have established the safety of flavonoids, which can serve as a reference for conducting trials related to COPD. In addition, the combination of flavonoid compounds with other drugs is also an important strategy.\par +This article provides a comprehensive overview of flavonoids employed in the treatment of COPD. It delineates their primary sources, structural classifications, and the various mechanisms of action and therapeutic targets. This information serves as a crucial reference for the dietary management and treatment strategies for patients suffering from COPD. Furthermore, it offers valuable insights for researchers concerning structural attributes, pharmacological effects, and potential toxicities. Additionally, the article establishes a foundation for future clinical trials aimed at advancing the treatment methodologies for COPD.\par +\par +\textit{\textbf{Author contributions}}\par +Shi PL collected documents and wrote the manuscript; Zhang GX, Wang PY, and Liu ZQ helped with information collection and manuscript editing; Zheng BQ revised the manuscript for important content and the manuscript preparation and editing.\par +\textit{\textbf{Competing interests}}\par +The authors declare no conflicts of interest.\par +\textit{\textbf{Acknowledgments}}\par +This work was supported by the Shandong Provincial Traditional Chinese Medicine Science and Technology Project “Study on the mechanism of Astragalus polysaccharide inhibiting the occurrence of liver fibrosis through PD-1 regulating NK cell function (2020Q004)”; Shandong Provincial Medical and Health Science and Technology Development Project “Mechanism of STAT3 inhibition of liver fibrosis by regulating PD-1$^{{+}}$NK cells (202002070991)”. Natural Science Foundation of Shandong Province “Astragalus polysaccharides inhibit liver fibrosis by regulating CD49a$^{{+}}$NK cells (ZR2022QH111).”\par +\textit{\textbf{Peer rev}}\textit{\textbf{iew information}}\par +\textit{Traditional Medicine Research} thanks Hai-Jing Zhong, He Li and another anonymous reviewer for their contribution to the peer review of this paper.\par +\textit{\textbf{Abbreviations}}\par +COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; ROS, reactive oxygen species; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; NF-κB, nuclear factor kappa-B; TNF-α, tumor necrosis factor-alpha; TGF-β, transforming growth factor-β; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MMP9, matrix metalloproteinase 9; HDAC2, histone deacetylase-2; PI3K, phosphoinositide-3- kinase; Nrf2, nuclear factor erythroid 2-related factor 2; CXCL, C-X-C motif chemokine ligand; NE, neutrophil elastase; MAPK, mitogen-activated protein kinase; EGF, epidermal growth factor; LPS, lipopolysaccharide; TLR4, toll-like receptor 4; JNK, c-Jun N-terminal kinase; SOD, superoxide dismutase; GSH, glutathione; GSH-Px, glutathione peroxidase; HO-1, haem oxygenase 1; MDA, malondialdehyde; SIRT1, silent information regulator 1; NAD+, nicotinamide adenine dinucleotide; GPX4, glutathione peroxidase 4; NADPH, nicotinamide adenine dinucleotide phosphate; GR, glucocorticoid receptor; CSE, cigarette smoke extract; IκB, inhibitor kappa B; HBECs, human bronchial epithelial cells; TLRs, toll-like receptors; IRAK, interleukin-1 receptor-associated kinase; PKC, protein kinase C; NOX4, NADPH oxidase 4; TIMP, tissue inhibitors of metalloproteinase; EMT, epithelial-mesenchymal transition; α-SMA, alpha smooth muscle actin; ERK, extracellular regulated protein kinases; AKT, protein kinase B.\par +\textit{\textbf{Citation}}\par +Shi PL, Zhang GX, Wang PY, Liu ZQ, Zheng BQ. Natural flavonoids for the treatment of chronic obstructive pulmonary disease: An overview. \textit{Tradit Med Res}. 2025;10(9):57. doi: 10.53388/TMR20241121001.\par +\par +\begin{figure*}[!htbp] + \centering + \includegraphics[width=0.9\textwidth]{./image/zipimg67aea6fbb71406.png} +\end{figure*}\par +\textbf{Executive editor: }Xin-Yue Zhang.\par +\textbf{Received: }22 November 2024; \textbf{Revised:} 01 January 2025; \textbf{Accepted: }27 February 2025; \textbf{Available online:} 03 March 2025.\par +© 2025 By Author(s). Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license. (https://creativecommons.org/licenses/by/4.0/)\par + + \FloatBarrier + \nocite{*} + \printbibliography[title={References}] + +\end{document} \ No newline at end of file diff --git a/111/image/2e1a016cbe73185352e2defa285e5599.png b/111/image/2e1a016cbe73185352e2defa285e5599.png new file mode 100644 index 0000000..63b6517 Binary files /dev/null and b/111/image/2e1a016cbe73185352e2defa285e5599.png differ diff --git a/111/image/c83075d3cbe5dd333419e6ecf1028e70.png b/111/image/c83075d3cbe5dd333419e6ecf1028e70.png new file mode 100644 index 0000000..bac7b39 Binary files /dev/null and b/111/image/c83075d3cbe5dd333419e6ecf1028e70.png differ diff --git a/111/image/ce2ac5c9695bbf4e6ddf433a3c11f4e1.png b/111/image/ce2ac5c9695bbf4e6ddf433a3c11f4e1.png new file mode 100644 index 0000000..0eea3d2 Binary files /dev/null and b/111/image/ce2ac5c9695bbf4e6ddf433a3c11f4e1.png differ diff --git a/111/image/file_67aee377039e2.jpg b/111/image/file_67aee377039e2.jpg new file mode 100644 index 0000000..a1106bd Binary files /dev/null and b/111/image/file_67aee377039e2.jpg differ diff --git a/111/image/file_67be74d65f458.png b/111/image/file_67be74d65f458.png new file mode 100644 index 0000000..a9da34d Binary files /dev/null and b/111/image/file_67be74d65f458.png differ diff --git a/111/image/file_67be752349316.png b/111/image/file_67be752349316.png new file mode 100644 index 0000000..0eea3d2 Binary files /dev/null and b/111/image/file_67be752349316.png differ diff --git a/111/image/file_67c187e9a21fe.png b/111/image/file_67c187e9a21fe.png new file mode 100644 index 0000000..cc9b4f2 Binary files /dev/null and b/111/image/file_67c187e9a21fe.png differ diff --git a/111/image/file_67c5589dd2aff.png b/111/image/file_67c5589dd2aff.png new file mode 100644 index 0000000..cfae019 Binary files /dev/null and b/111/image/file_67c5589dd2aff.png differ diff --git a/111/image/file_67c558b8c3bad.png b/111/image/file_67c558b8c3bad.png new file mode 100644 index 0000000..c4048b0 Binary files /dev/null and b/111/image/file_67c558b8c3bad.png differ diff --git a/111/image/file_67c55ded4eece.png b/111/image/file_67c55ded4eece.png new file mode 100644 index 0000000..d1df53a Binary files /dev/null and b/111/image/file_67c55ded4eece.png differ diff --git a/111/image/file_682161fb0fcfd.png b/111/image/file_682161fb0fcfd.png new file mode 100644 index 0000000..3d6dc39 Binary files /dev/null and b/111/image/file_682161fb0fcfd.png differ diff --git a/111/image/file_68999e3c72e62.png b/111/image/file_68999e3c72e62.png new file mode 100644 index 0000000..f444053 Binary files /dev/null and b/111/image/file_68999e3c72e62.png differ diff --git a/111/image/image-60721.png b/111/image/image-60721.png new file mode 100644 index 0000000..4a01a0c Binary files /dev/null and b/111/image/image-60721.png differ diff --git a/111/image/zipimg67aea6fbb71406.png b/111/image/zipimg67aea6fbb71406.png new file mode 100644 index 0000000..61fac56 Binary files /dev/null and b/111/image/zipimg67aea6fbb71406.png differ diff --git a/111/references_3113.bib b/111/references_3113.bib new file mode 100644 index 0000000..e7d9051 --- /dev/null +++ b/111/references_3113.bib @@ -0,0 +1,1827 @@ +% BibTeX file generated for article ID: 3113 +% Generated on 2026-01-09 16:19:00 + +@misc{ref_132721, + title={World Health Organization. Global health estimates: leading causes of death. Cause specific mortality 2000–2019. https://www.who.int/data/gho/. Published 2019. Accessed May 08, 2024} +} + +@article{ref_132722, + author={CD, Mathers and D, Loncar}, + title={Projections of global mortality and burden of disease from 2002 to 2030}, + journal={PLoS Med}, + year={2006}, + volume={3}, + number={11}, + pages={e442}, + doi={10.1371/journal.pmed.0030442} +} + +@article{ref_132723, + author={JA, Wedzicha}, + title={Causes of Death in Smokers: Implications for Chronic Obstructive Pulmonary Disease Management across Disease Severity}, + journal={Am J Respir Crit Care Med}, + year={2023}, + volume={208}, + number={4}, + pages={354}, + doi={10.1164/rccm.202306-1065ED} +} + +@article{ref_132724, + author={IA, Yang and CR, Jenkins and SS, Salvi}, + title={Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment}, + journal={Lancet Respir Med}, + year={2022}, + volume={10}, + number={5}, + pages={497}, + doi={10.1016/S2213-2600(21)00506-3} +} + +@article{ref_132725, + author={MF, Mart and Jr, Peebles RS}, + title={Asthma-chronic obstructive pulmonary disease overlap syndrome}, + journal={Curr Opin Immunol}, + year={2020}, + volume={66}, + pages={161}, + doi={10.1016/j.coi.2020.10.006} +} + +@article{ref_132726, + author={AJ, Shah and E, Quek and JS, Alqahtani and JR, Hurst and S, Mandal}, + title={Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis}, + journal={Sleep Med Rev}, + year={2022}, + volume={63}, + pages={101627}, + doi={10.1016/j.smrv.2022.101627} +} + +@article{ref_132727, + author={PJ, Barnes}, + title={Oxidative stress-based therapeutics in COPD}, + journal={Redox Biol}, + year={2020}, + volume={33}, + pages={101544}, + doi={10.1016/j.redox.2020.101544} +} + +@article{ref_132728, + author={C, Brightling and N, Greening}, + title={Airway inflammation in COPD: progress to precision medicine}, + journal={Eur Respir J}, + year={2019}, + volume={54}, + number={2}, + pages={1900651}, + doi={10.1183/13993003.00651-2019} +} + +@article{ref_132729, + author={JH, Yun and J, Morrow and CA, Owen and al, et}, + title={Transcriptomic Analysis of Lung Tissue from Cigarette Smoke–Induced Emphysema Murine Models and Human Chronic Obstructive Pulmonary Disease Show Shared and Distinct Pathways}, + journal={Am J Respir Cell Mol Biol}, + year={2017}, + volume={57}, + number={1}, + pages={47}, + doi={10.1165/rcmb.2016-0328OC} +} + +@article{ref_132730, + author={HH, Hou and SL, Cheng and KP, Chung and al, et}, + title={Elastase induces lung epithelial cell autophagy through placental growth factor}, + journal={Autophagy}, + year={2014}, + volume={10}, + number={9}, + pages={1509}, + doi={10.4161/auto.29190} +} + +@article{ref_132731, + author={N, Shen and T, Wang and Q, Gan and S, Liu and L, Wang and B, Jin}, + title={Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity}, + journal={Food Chem}, + year={2022}, + volume={383}, + pages={132531}, + doi={10.1016/j.foodchem.2022.132531} +} + +@article{ref_132732, + author={X, Zeng and Y, Xi and W, Jiang}, + title={Protective roles of flavonoids and flavonoid-rich plant extracts against urolithiasis: A review}, + journal={Crit Rev Food Sci Nutr}, + year={2019}, + volume={59}, + number={13}, + pages={2125}, + doi={10.1080/10408398.2018.1439880} +} + +@article{ref_132733, + author={F, Hirayama and AH, Lee and CW, Binns and N, Hiramatsu and M, Mori and K, Nishimura}, + title={Dietary intake of isoflavones and polyunsaturated fatty acids associated with lung function, breathlessness and the prevalence of chronic obstructive pulmonary disease: Possible protective effect of traditional Japanese diet}, + journal={Mol Nutr Food Res}, + year={2010}, + volume={54}, + number={7}, + pages={909}, + doi={10.1002/mnfr.200900316} +} + +@article{ref_132734, + author={NP, Bondonno and BH, Parmenter and F, Dalgaard and al, et}, + title={Flavonoid intakes inversely associate with COPD in smokers}, + journal={Eur Respir J}, + year={2022}, + volume={60}, + number={2}, + pages={2102604}, + doi={10.1183/13993003.02604-2021} +} + +@article{ref_132735, + author={SA, Christenson and BM, Smith and M, Bafadhel and N, Putcha}, + title={Chronic obstructive pulmonary disease}, + journal={Lancet}, + year={2022}, + volume={399}, + number={10342}, + pages={2227}, + doi={10.1016/S0140-6736(22)00470-6} +} + +@article{ref_132736, + author={DL, DeMeo}, + title={Sex and Gender Omic Biomarkers in Men and Women With COPD}, + journal={Chest}, + year={2021}, + volume={160}, + number={1}, + pages={104}, + doi={10.1016/j.chest.2021.03.024} +} + +@article{ref_132737, + author={M, MacLeod and A, Papi and M, Contoli and al, et}, + title={Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact}, + journal={Respirology}, + year={2021}, + volume={26}, + number={6}, + pages={532}, + doi={10.1111/resp.14041} +} + +@article{ref_132738, + author={JC, Hogg and W, Timens}, + title={The Pathology of Chronic Obstructive Pulmonary Disease}, + journal={Annu Rev Pathol Mech Dis}, + year={2009}, + volume={4}, + pages={435}, + doi={10.1146/annurev.pathol.4.110807.092145} +} + +@article{ref_132739, + author={PJ, Barnes and PGJ, Burney and EK, Silverman and al, et}, + title={Chronic obstructive pulmonary disease}, + journal={Nat Rev Dis Primers}, + year={2015}, + volume={1}, + pages={15076}, + doi={10.1038/nrdp.2015.76} +} + +@article{ref_132740, + author={F, Polverino and DD, Sin}, + title={Type 2 airway inflammation in COPD}, + journal={Eur Respir J}, + year={2024}, + volume={63}, + number={5}, + pages={2400150}, + doi={10.1183/13993003.00150-2024} +} + +@article{ref_132741, + author={B, David and M, Bafadhel and L, Koenderman and A, De Soyza}, + title={Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait}, + journal={Thorax}, + year={2020}, + volume={76}, + number={2}, + pages={188}, + doi={10.1136/thoraxjnl-2020-215167} +} + +@article{ref_132742, + author={JK, Burgess and DJ, Weiss and G, Westergren-Thorsson and al, et}, + title={Extracellular Matrix as a Driver of Chronic Lung Diseases}, + journal={Am J Respir Cell Mol Biol}, + year={2024}, + volume={70}, + number={4}, + pages={239}, + doi={10.1165/rcmb.2023-0176PS} +} + +@article{ref_132743, + author={YY, Feng and M, Li and XT, Yangzhong and al, et}, + title={Pyroptosis in inflammation-related respiratory disease}, + journal={J Physiol Biochem}, + year={2022}, + volume={78}, + number={4}, + pages={721}, + doi={10.1007/s13105-022-00909-1} +} + +@article{ref_132744, + author={X, Cao and Y, Wang and Y, Chen and al, et}, + title={Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease}, + journal={J Ethnopharmacol}, + year={2023}, + volume={307}, + pages={116229}, + doi={10.1016/j.jep.2023.116229} +} + +@article{ref_132745, + author={PA, Kirkham and PJ, Barnes}, + title={Oxidative Stress in COPD}, + journal={Chest}, + year={2013}, + volume={144}, + number={1}, + pages={266}, + doi={10.1378/chest.12-2664} +} + +@article{ref_132746, + author={A, McGuinness and E, Sapey}, + title={Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms}, + journal={J Clin Med}, + year={2017}, + volume={6}, + number={2}, + pages={21}, + doi={10.3390/jcm6020021} +} + +@article{ref_132747, + author={T, Schaberg and U, Klein and M, Rau and J, Eller and H, Lode}, + title={Subpopulations of alveolar macrophages in smokers and nonsmokers: relation to the expression of CD11/CD18 molecules and superoxide anion production}, + journal={Am J Respir Crit Care Med}, + year={1995}, + volume={151}, + number={5}, + pages={1551}, + doi={10.1164/ajrccm.151.5.7735614} +} + +@article{ref_132748, + author={A, Noguera and S, Batle and C, Miralles and al, et}, + title={Enhanced neutrophil response in chronic obstructive pulmonary disease}, + journal={Thorax}, + year={2001}, + volume={56}, + number={6}, + pages={432}, + doi={10.1136/thx.56.6.432} +} + +@article{ref_132749, + author={M, van der Toorn and D, Rezayat and HF, Kauffman and al, et}, + title={Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells}, + journal={Am J Physiol Lung Cell Mol Physiol}, + year={2009}, + volume={297}, + number={1}, + pages={L109}, + doi={10.1152/ajplung.90461.2008} +} + +@article{ref_132750, + author={C, Strange}, + title={Alpha-1 Antitrypsin Deficiency Associated COPD}, + journal={Clin Chest Med}, + year={2020}, + volume={41}, + number={3}, + pages={339}, + doi={10.1016/j.ccm.2020.05.003} +} + +@article{ref_132751, + author={MG, Roy and A, Livraghi-Butrico and AA, Fletcher and al, et}, + title={Muc5b is required for airway defence}, + journal={Nature}, + year={2014}, + volume={505}, + number={7483}, + pages={412}, + doi={10.1038/nature12807} +} + +@article{ref_132752, + author={Md, Samsuzzaman and MdS, Uddin and MA, Shah and B, Mathew}, + title={Natural inhibitors on airway mucin: Molecular insight into the therapeutic potential targeting MUC5AC expression and production}, + journal={Life Sci}, + year={2019}, + volume={231}, + pages={116485}, + doi={10.1016/j.lfs.2019.05.041} +} + +@article{ref_132753, + author={YM, Shih and YJ, Chang and MS, Cooke and al, et}, + title={Alkylating and oxidative stresses in smoking and non-smoking patients with COPD: Implications for lung carcinogenesis}, + journal={Free Radical Biol Med}, + year={2021}, + volume={164}, + pages={99}, + doi={10.1016/j.freeradbiomed.2020.12.442} +} + +@article{ref_132754, + author={PR, Burgel}, + title={Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium}, + journal={Thorax}, + year={2004}, + volume={59}, + number={11}, + pages={992}, + doi={10.1136/thx.2003.018879} +} + +@article{ref_132755, + author={MXG, Shao and T, Nakanaga and JA, Nadel}, + title={Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-α-converting enzyme in human airway epithelial (NCI-H292) cells}, + journal={Am J Physiol Lung Cell Mol Physiol}, + year={2004}, + volume={287}, + number={2}, + pages={L420}, + doi={10.1152/ajplung.00019.2004} +} + +@article{ref_132756, + author={G, Lee and TC, Walser and SM, Dubinett}, + title={Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer}, + journal={Curr Opin Pulm Med}, + year={2009}, + volume={15}, + number={4}, + pages={303}, + doi={10.1097/MCP.0b013e32832c975a} +} + +@article{ref_132757, + author={MR, Gorowiec and LA, Borthwick and SM, Parker and JA, Kirby and GC, Saretzki and AJ, Fisher}, + title={Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-β1-dependent mechanism}, + journal={Free Radical Biol Med}, + year={2012}, + volume={52}, + number={6}, + pages={1024}, + doi={10.1016/j.freeradbiomed.2011.12.020} +} + +@article{ref_132758, + author={C, Taggart and D, Cervantes-Laurean and G, Kim and al, et}, + title={Oxidation of either Methionine 351 or Methionine 358 in α1-Antitrypsin Causes Loss of Anti-neutrophil Elastase Activity}, + journal={J Biol Chem}, + year={2000}, + volume={275}, + number={35}, + pages={27258}, + doi={10.1016/S0021-9258(19)61505-X} +} + +@article{ref_132759, + author={PJ, Barnes}, + title={Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease}, + journal={J Allergy Clin Immunol}, + year={2013}, + volume={131}, + number={3}, + pages={636}, + doi={10.1016/j.jaci.2012.12.1564} +} + +@article{ref_132760, + author={Y, To and K, Ito and Y, Kizawa and al, et}, + title={Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease}, + journal={Am J Respir Crit Care Med}, + year={2010}, + volume={182}, + number={7}, + pages={897}, + doi={10.1164/rccm.200906-0937OC} +} + +@article{ref_132761, + author={HW, Yao and I, Rahman}, + title={Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD}, + journal={Am J Physiol Lung Cell Mol Physiol}, + year={2012}, + volume={303}, + number={7}, + pages={L557}, + doi={10.1152/ajplung.00175.2012} +} + +@article{ref_132762, + author={SE, Cheng and IT, Lee and CC, Lin and YR, Kou and CM, Yang}, + title={Cigarette smoke particle-phase extract induces HO-1 expression in human tracheal smooth muscle cells: role of the c-Src/NADPH oxidase/MAPK/Nrf2 signaling pathway}, + journal={Free Radical Biol Med}, + year={2010}, + volume={48}, + number={10}, + pages={1410}, + doi={10.1016/j.freeradbiomed.2010.02.026} +} + +@article{ref_132763, + author={GG, Brusselle and GF, Joos and KR, Bracke}, + title={New insights into the immunology of chronic obstructive pulmonary disease}, + journal={Lancet}, + year={2011}, + volume={378}, + number={9795}, + pages={1015}, + doi={10.1016/S0140-6736(11)60988-4} +} + +@article{ref_132764, + author={S, Grumelli and DB, Corry and LZ, Song and al, et}, + title={An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema}, + journal={PLoS Med}, + year={2004}, + volume={1}, + number={1}, + pages={e8}, + doi={10.1371/journal.pmed.0010008} +} + +@article{ref_132765, + author={J, Majo and H, Ghezzo and MG, Cosio}, + title={Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema}, + journal={Eur Respir J}, + year={2001}, + volume={17}, + number={5}, + pages={946}, + doi={10.1183/09031936.01.17509460} +} + +@article{ref_132766, + author={H, Huang and H, Feng and D, Zhuge}, + title={M1 Macrophage Activated by Notch Signal Pathway Contributed to Ventilator-Induced Lung Injury in Chronic Obstructive Pulmonary Disease Model}, + journal={J Surg Res}, + year={2019}, + volume={244}, + pages={358}, + doi={10.1016/j.jss.2019.06.060} +} + +@article{ref_132767, + author={H, Takiguchi and CX, Yang and CWT, Yang and al, et}, + title={Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures}, + journal={Sci Rep}, + year={2021}, + volume={11}, + number={1}, + pages={8282}, + doi={10.1038/s41598-021-87720-y} +} + +@article{ref_132768, + author={V, Lagente and B, Manoury and S, Nénan and C, Le Quément and C, Martin-Chouly and E, Boichot}, + title={Role of matrix metalloproteinases in the development of airway inflammation and remodeling}, + journal={Braz J Med Biol Res}, + year={2005}, + volume={38}, + number={10}, + pages={1521}, + doi={10.1590/S0100-879X2005001000009} +} + +@article{ref_132769, + author={JJ, Sng and S, Prazakova and PS, Thomas and C, Herbert}, + title={MMP-8, MMP-9 and Neutrophil Elastase in Peripheral Blood and Exhaled Breath Condensate in COPD}, + journal={COPD}, + year={2017}, + volume={14}, + number={2}, + pages={238}, + doi={10.1080/15412555.2016.1249790} +} + +@article{ref_132770, + author={P, Chen and WC, Parks}, + title={Role of matrix metalloproteinases in epithelial migration}, + journal={J Cell Biochem}, + year={2009}, + volume={108}, + number={6}, + pages={1233}, + doi={10.1002/jcb.22363} +} + +@article{ref_132771, + author={M, Selman and G, Carrillo and A, Estrada and al, et}, + title={Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern}, + journal={PLoS One}, + year={2007}, + volume={2}, + number={5}, + pages={e482}, + doi={10.1371/journal.pone.0000482} +} + +@article{ref_132772, + author={R, Wang and C, Ramos and I, Joshi and al, et}, + title={Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides}, + journal={Am J Physiol}, + year={1999}, + volume={277}, + number={6}, + pages={L1158}, + doi={10.1152/ajplung.1999.277.6.L1158} +} + +@article{ref_132773, + author={M, Waghray and Z, Cui and JC, Horowitz and al, et}, + title={Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts}, + journal={FASEB J}, + year={2005}, + volume={19}, + number={7}, + pages={854}, + doi={10.1096/fj.04-2882fje} +} + +@article{ref_132774, + author={HM, Al‐Tamari and S, Dabral and A, Schmall and al, et}, + title={FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis}, + journal={EMBO Mol Med}, + year={2017}, + volume={10}, + number={2}, + pages={276}, + doi={10.15252/emmm.201606261} +} + +@article{ref_132775, + author={H, Wang and T, Yang and T, Wang and al, et}, + title={Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke}, + journal={Int Immunopharmacol}, + year={2018}, + volume={55}, + pages={112}, + doi={10.1016/j.intimp.2017.12.009} +} + +@article{ref_132776, + author={RL, Birru and K, Bein and N, Bondarchuk and al, et}, + title={Antimicrobial and Anti-Inflammatory Activity of Apple Polyphenol Phloretin on Respiratory Pathogens Associated With Chronic Obstructive Pulmonary Disease}, + journal={Front Cell Infect Microbiol}, + year={2021}, + volume={11}, + pages={652944}, + doi={10.3389/fcimb.2021.652944} +} + +@article{ref_132777, + author={D, Yu and X, Liu and G, Zhang and Z, Ming and T, Wang}, + title={Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF-κB Signaling Pathways}, + journal={Front Pharmacol}, + year={2018}, + volume={9}, + pages={1001}, + doi={10.3389/fphar.2018.01001} +} + +@article{ref_132778, + author={Y, Wang and C, Xue and F, Dong and al, et}, + title={Hydroxysafflor Yellow A Attenuates Small Airway Remodeling in a Rat Model of Chronic Obstructive Pulmonary Disease}, + journal={Biol Pharm Bull}, + year={2014}, + volume={37}, + number={10}, + pages={1591}, + doi={10.1248/bpb.b14-00198} +} + +@article{ref_132779, + author={X, Guo and M, Zheng and R, Pan and B, Zang and M, Jin}, + title={Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells}, + journal={Front Pharmacol}, + year={2018}, + volume={9}, + pages={859}, + doi={10.3389/fphar.2018.00859} +} + +@article{ref_132780, + author={M, Jin and C, Xue and Y, Wang and al, et}, + title={Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats}, + journal={Chin J Integr Med}, + year={2019}, + volume={25}, + number={10}, + pages={750}, + doi={10.1007/s11655-018-2577-2} +} + +@article{ref_132781, + author={BS, Li and RZ, Zhu and SH, Lim and JH, Seo and BM, Choi}, + title={Apigenin Alleviates Oxidative Stress-Induced Cellular Senescence via Modulation of the SIRT1-NAD+-CD38 Axis}, + journal={Am J Chin Med}, + year={2021}, + volume={49}, + number={5}, + pages={1235}, + doi={10.1142/S0192415X21500592} +} + +@article{ref_132782, + author={J, Li and D, Tong and J, Liu and F, Chen and Y, Shen}, + title={Oroxylin A attenuates cigarette smoke-induced lung inflammation by activating Nrf2}, + journal={Int Immunopharmacol}, + year={2016}, + volume={40}, + pages={524}, + doi={10.1016/j.intimp.2016.10.011} +} + +@article{ref_132783, + author={L, Liu and Y, Zhang and L, Wang and al, et}, + title={Scutellarein alleviates chronic obstructive pulmonary disease through inhibition of ferroptosis by chelating iron and interacting with arachidonate 15‐lipoxygenase}, + journal={Phytother Res}, + year={2023}, + volume={37}, + number={10}, + pages={4587}, + doi={10.1002/ptr.7928} +} + +@article{ref_132784, + author={S, Ganesan and AN, Faris and AT, Comstock and al, et}, + title={Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression}, + journal={Respir Res}, + year={2010}, + volume={11}, + number={1}, + pages={131}, + doi={10.1186/1465-9921-11-131} +} + +@article{ref_132785, + author={A, Mitani and A, Azam and C, Vuppusetty and K, Ito and N, Mercado and PJ, Barnes}, + title={Quercetin restores corticosteroid sensitivity in cells from patients with chronic obstructive pulmonary disease}, + journal={Exp Lung Res}, + year={2017}, + volume={43}, + number={9–10}, + pages={417}, + doi={10.1080/01902148.2017.1393707} +} + +@article{ref_132786, + author={M, Farazuddin and R, Mishra and Y, Jing and V, Srivastava and AT, Comstock and US, Sajjan}, + title={Quercetin prevents rhinovirus-induced progression of lung disease in mice with COPD phenotype}, + journal={PLoS One}, + year={2018}, + volume={13}, + number={7}, + pages={e0199612}, + doi={10.1371/journal.pone.0199612} +} + +@article{ref_132787, + author={P, Wei and ZB, Chen and CE, Wang and DZ, Li and KQ, Chen and al, et}, + title={Protective function and mechanism of quercetin in chronic obstructive pulmonary disease}, + journal={Chin J Immunol}, + year={2019}, + volume={35}, + number={21}, + pages={2570} +} + +@article{ref_132788, + author={MK, Han and TA, Barreto and FJ, Martinez and AT, Comstock and US, Sajjan}, + title={Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease}, + journal={BMJ Open Resp Res}, + year={2020}, + volume={7}, + number={1}, + pages={e000392}, + doi={10.1136/bmjresp-2018-000392} +} + +@article{ref_132789, + author={XP, Wu and YZ, Tao and L, Liu and J, Han and WJ, Liu}, + title={Quercetin reduces airway mucus hypersecretion in rats based on EGFR signaling pathway}, + journal={Chin J Immunol}, + year={2022}, + volume={38}, + number={8}, + pages={940}, + doi={10.3969/j.issn.1000-484X.2022.08.008} +} + +@article{ref_132791, + author={NP, da Silva Araújo and NA, de Matos and M, Oliveira and al, et}, + title={Quercetin Improves Pulmonary Function and Prevents Emphysema Caused by Exposure to Cigarette Smoke in Male Mice}, + journal={Antioxidants (Basel)}, + year={2022}, + volume={11}, + number={2}, + pages={181}, + doi={10.3390/antiox11020181} +} + +@article{ref_132792, + author={ES, McCluskey and N, Liu and A, Pandey and N, Marchetti and U, Sajjan}, + title={Quercetin improves epithelial regeneration from airway basal cells of COPD patients}, + journal={Res Sq}, + year={2023}, + volume={2023}, + doi={10.21203/rs.3.rs-3185241/v1} +} + +@article{ref_132793, + author={S, Lee and H, Ro and HJ, In and al, et}, + title={Fisetin inhibits TNF-α/NF-κB-induced IL-8 expression by targeting PKCδ in human airway epithelial cells}, + journal={Cytokine}, + year={2018}, + volume={108}, + pages={247}, + doi={10.1016/j.cyto.2018.01.004} +} + +@article{ref_132794, + author={T, Hussain and OS, Al‐Attas and S, Alamery and M, Ahmed and HAM, Odeibat and S, Alrokayan}, + title={The plant flavonoid, fisetin alleviates cigarette smoke‐induced oxidative stress, and inflammation in Wistar rat lungs}, + journal={J Food Biochem}, + year={2019}, + volume={43}, + number={8}, + pages={e12962}, + doi={10.1111/jfbc.12962} +} + +@article{ref_132795, + author={M, Chen and Z, Chen and D, Huang and al, et}, + title={Myricetin inhibits TNF-α-induced inflammation in A549 cells via the SIRT1/NF-κB pathway}, + journal={Pulm Pharmacol Ther}, + year={2020}, + volume={65}, + pages={102000}, + doi={10.1016/j.pupt.2021.102000} +} + +@article{ref_132796, + author={H, Lee and KH, Jung and H, Lee and S, Park and W, Choi and H, Bae}, + title={Casticin, an active compound isolated from Vitex Fructus, ameliorates the cigarette smoke-induced acute lung inflammatory response in a murine model}, + journal={Int Immunopharmacol}, + year={2015}, + volume={28}, + number={2}, + pages={1097}, + doi={10.1016/j.intimp.2015.07.041} +} + +@article{ref_132797, + author={J, Li and C, Qiu and P, Xu and Y, Lu and R, Chen}, + title={Casticin Improves Respiratory Dysfunction and Attenuates Oxidative Stress and Inflammation via Inhibition of NF-ĸB in a Chronic Obstructive Pulmonary Disease Model of Chronic Cigarette Smoke-Exposed Rats}, + journal={Drug Des Devel Ther}, + year={2020}, + volume={14}, + pages={5019}, + doi={10.2147/DDDT.S277126} +} + +@article{ref_132799, + author={LJ, Lu and H, Tian and Y, Zheng and HJ, Hu}, + title={Effects of casticin on Lipopolysaccharide-induced BEAS-2B cell damage and NF-κB-KEAP1-NRF2/ARE pathway}, + journal={Chin J Immunol}, + year={2023}, + volume={40}, + number={3}, + pages={546}, + doi={10.3969/j.issn.1000-484X.2024.03.018} +} + +@article{ref_132801, + author={LJ, Lu and H, Tian and Y, Zheng and HJ, Hu}, + title={Study on the effect of casticin on oxidative stress injury in BEAS-2B cells}, + journal={Chin J Clin Pharmacol}, + year={2023}, + volume={39}, + number={1}, + pages={42}, + doi={10.13699/j.cnki.1001-6821.2023.01.009} +} + +@article{ref_132802, + author={MF, Li and HF, Wang and Y, Lu and JW, Cai}, + title={Luteolin suppresses inflammation and oxidative stress in chronic obstructive pulmonary disease through inhibition of the NOX4‐mediated NF‐κB signaling pathway}, + journal={Immun Inflamm Dis}, + year={2023}, + volume={11}, + number={4}, + pages={e820}, + doi={10.1002/iid3.820} +} + +@article{ref_132803, + author={L, Zhou and T, Jian and Y, Wan and al, et}, + title={Luteolin Alleviates Oxidative Stress in Chronic Obstructive Pulmonary Disease Induced by Cigarette Smoke via Modulation of the TRPV1 and CYP2A13/NRF2 Signaling Pathways}, + journal={Int J Mol Sci}, + year={2023}, + volume={25}, + number={1}, + pages={369}, + doi={10.3390/ijms25010369} +} + +@article{ref_132804, + author={YL, Luo and CC, Zhang and PB, Li and al, et}, + title={Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke}, + journal={Int Immunopharmacol}, + year={2012}, + volume={13}, + number={3}, + pages={301}, + doi={10.1016/j.intimp.2012.04.019} +} + +@article{ref_132805, + author={J, Liu and J, Yao and J, Zhang}, + title={Naringenin attenuates inflammation in chronic obstructive pulmonary disease in cigarette smoke induced mouse model and involves suppression of NF-κB}, + journal={J Microbiol Biotechnol}, + year={2018}, + volume={2018} +} + +@article{ref_132806, + author={Z, Chen and H, Wu and W, Fan and al, et}, + title={Naringenin suppresses BEAS-2B-derived extracellular vesicular cargoes disorder caused by cigarette smoke extract thereby inhibiting M1 macrophage polarization}, + journal={Front Immunol}, + year={2022}, + volume={13}, + pages={930476}, + doi={10.3389/fimmu.2022.930476} +} + +@article{ref_132807, + author={S, Wang and N, He and H, Xing and Y, Sun and J, Ding and L, Liu}, + title={Function of hesperidin alleviating inflammation and oxidative stress responses in COPD mice might be related to SIRT1/PGC-1α/NF-κB signaling axis}, + journal={J Recept Signal Transduct}, + year={2020}, + volume={40}, + number={4}, + pages={388}, + doi={10.1080/10799893.2020.1738483} +} + +@article{ref_132808, + author={L, Zhou and W, Gu and F, Kui and al, et}, + title={The mechanism and candidate compounds of aged citrus peel (chenpi) preventing chronic obstructive pulmonary disease and its progression to lung cancer}, + journal={Food Nutr Res}, + year={2021}, + volume={65}, + pages={7526}, + doi={10.29219/fnr.v65.7526} +} + +@article{ref_132809, + author={X, Liu and Y, Ma and L, Luo and al, et}, + title={Dihydroquercetin suppresses cigarette smoke induced ferroptosis in the pathogenesis of chronic obstructive pulmonary disease by activating Nrf2-mediated pathway}, + journal={Phytomedicine}, + year={2022}, + volume={96}, + pages={153894}, + doi={10.1016/j.phymed.2021.153894} +} + +@article{ref_132810, + author={X, Liu and Y, Ma and L, Luo and Z, Zeng and D, Zong and Y, Chen}, + title={Taxifolin ameliorates cigarette smoke-induced chronic obstructive pulmonary disease via inhibiting inflammation and apoptosis}, + journal={Int Immunopharmacol}, + year={2023}, + volume={115}, + pages={109577}, + doi={10.1016/j.intimp.2022.109577} +} + +@article{ref_132811, + author={LX, Zeng and JC, Dong and WQ, Yu and JH, Huang and BJ, Liu and XT, Feng}, + title={Baicalin attenuates inflammation by inhibiting NF-κB activation in cigarette smoke induced inflammatory models}, + journal={Pulm Pharmacol Ther}, + year={2010}, + volume={23}, + number={5}, + pages={411}, + doi={10.1016/j.pupt.2010.05.004} +} + +@article{ref_132812, + author={L, Li and H, Bao and J, Wu and al, et}, + title={Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity}, + journal={Int Immunopharmacol}, + year={2012}, + volume={13}, + number={1}, + pages={15}, + doi={10.1016/j.intimp.2012.03.001} +} + +@article{ref_132813, + author={G, Wang and N, Mohammadtursun and Y, Lv and H, Zhang and J, Sun and J, Dong}, + title={Baicalin Exerts Anti-Airway Inflammation and Anti-Remodelling Effects in Severe Stage Rat Model of Chronic Obstructive Pulmonary Disease}, + journal={Evid Based Complement Alternat Med}, + year={2018}, + volume={2018}, + pages={7591348}, + doi={10.1155/2018/7591348} +} + +@article{ref_132814, + author={DX, Hao and YS, Li and J, Shi and JG, Jiang}, + title={Baicalin alleviates chronic obstructive pulmonary disease through regulation of HSP72-mediated JNK pathway}, + journal={Mol Med}, + year={2021}, + volume={27}, + number={1}, + pages={53}, + doi={10.1186/s10020-021-00309-z} +} + +@article{ref_132815, + author={H, Zhang and BJ, Liu and S, Jiang and al, et}, + title={Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF-κB/PAI-1 signalling}, + journal={Pulm Pharmacol Ther}, + year={2021}, + volume={70}, + pages={102061}, + doi={10.1016/j.pupt.2021.102061} +} + +@article{ref_132816, + author={XF, Xiao and SL, Zhao and W, Wang and Y, Fu}, + title={Baicalin upregulates miR-4451effect on lipopolysaccharide-induced apoptosis and inflammatory response in HBE16 cells}, + journal={Lishizhen Med Res}, + year={2022}, + volume={33}, + number={7}, + pages={1630} +} + +@article{ref_132818, + author={Y, Zhang and CL, Zhang and Y, Liu and al, et}, + title={Effects of baicalin on expression of mucin 5AC and cystic fibrosis transmembrane conductance regulator in airway epithelium through NF-κB signaling pathway}, + journal={J Army Med Univ}, + year={2022}, + volume={44}, + number={5}, + pages={441}, + doi={10.16016/j.2097-0927.202109016} +} + +@article{ref_132819, + author={J, Ju and Z, Li and Q, Shi}, + title={Baicalin Inhibits Inflammation in Rats with Chronic Obstructive Pulmonary Disease by the TLR2/MYD88/NF-κBp65 Signaling Pathway}, + journal={Evid Based Complement Alternat Med}, + year={2022}, + volume={2022}, + pages={7273387}, + doi={10.1155/2022/7273387} +} + +@article{ref_132820, + author={X, Jing and J, Huo and L, Li and T, Wang and JY, Xu}, + title={Baicalin Relieves Airway Inflammation in COPD by Inhibiting miR-125a}, + journal={Appl Biochem Biotechnol}, + year={2024}, + volume={196}, + number={6}, + pages={3374}, + doi={10.1007/s12010-023-04671-y} +} + +@article{ref_132821, + author={YH, Kim and MK, Kang and EJ, Lee and al, et}, + title={Astragalin Inhibits Cigarette Smoke-Induced Pulmonary Thrombosis and Alveolar Inflammation and Disrupts PAR Activation and Oxidative Stress-Responsive MAPK-Signaling}, + journal={Int J Mol Sci}, + year={2021}, + volume={22}, + number={7}, + pages={3692}, + doi={10.3390/ijms22073692} +} + +@article{ref_132822, + author={L, Hu and F, Liu and L, Li and al, et}, + title={Effects of icariin on cell injury and glucocorticoid resistance in BEAS‑2B cells exposed to cigarette smoke extract}, + journal={Exp Ther Med}, + year={2020}, + volume={20}, + number={1}, + pages={283}, + doi={10.3892/etm.2020.8702} +} + +@article{ref_132823, + author={R, Lu and K, Xu and Y, Qin and al, et}, + title={Network Pharmacology and Experimental Validation to Reveal Effects and Mechanisms of Icariin Combined with Nobiletin against Chronic Obstructive Pulmonary Diseases}, + journal={Evid Based Complement Alternat Med}, + year={2022}, + volume={2022}, + pages={4838650}, + doi={10.1155/2022/4838650} +} + +@article{ref_132824, + author={QP, Li and HY, Zhang and XP, Yan and al, et}, + title={Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation}, + journal={Pulm Pharmacol Ther}, + year={2023}, + volume={79}, + pages={102197}, + doi={10.1016/j.pupt.2023.102197} +} + +@article{ref_132825, + author={Y, Guan and FF, Li and L, Hong and al, et}, + title={Protective effects of liquiritin apioside on cigarette smoke‐induced lung epithelial cell injury}, + journal={Fundam Clin Pharmacol}, + year={2011}, + volume={26}, + number={4}, + pages={473}, + doi={10.1111/j.1472-8206.2011.00956.x} +} + +@article{ref_132826, + author={WY, Song and YS, Song and HW, Ryu and SR, Oh and J, Hong and DY, Yoon}, + title={Tilianin Inhibits MUC5AC Expression Mediated Via Down-Regulation of EGFR-MEK-ERK-Sp1 Signaling Pathway in NCI-H292 Human Airway Cells}, + journal={J Microbiol Biotechnol}, + year={2017}, + volume={27}, + number={1}, + pages={49}, + doi={10.4014/jmb.1610.10012} +} + +@article{ref_132827, + author={SH, Kim and JH, Hong and WK, Yang and al, et}, + title={Herbal Combinational Medication of Glycyrrhiza glabra, Agastache rugosa Containing Glycyrrhizic Acid, Tilianin Inhibits Neutrophilic Lung Inflammation by Affecting CXCL2, Interleukin-17/STAT3 Signal Pathways in a Murine Model of COPD}, + journal={Nutrients}, + year={2020}, + volume={12}, + number={4}, + pages={926}, + doi={10.3390/nu12040926} +} + +@article{ref_132828, + author={YL, Luo and PB, Li and CC, Zhang and al, et}, + title={Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure}, + journal={Inflamm Res}, + year={2013}, + volume={62}, + number={12}, + pages={1053}, + doi={10.1007/s00011-013-0664-6} +} + +@article{ref_132829, + author={Z, Xue and A, Li and X, Zhang and al, et}, + title={Amelioration of PM2.5-induced lung toxicity in rats by nutritional supplementation with biochanin A}, + journal={Ecotoxicol Environ Saf}, + year={2020}, + volume={202}, + pages={110878}, + doi={10.1016/j.ecoenv.2020.110878} +} + +@article{ref_132830, + author={L, Wang and W, Jiang and J, Wang and Y, Xie and W, Wang}, + title={Puerarin inhibits FUNDC1-mediated mitochondrial autophagy and CSE-induced apoptosis of human bronchial epithelial cells by activating the PI3K/AKT/mTOR signaling pathway}, + journal={Aging (Albany NY)}, + year={2022}, + volume={14}, + number={3}, + pages={1253}, + doi={10.18632/aging.203317} +} + +@article{ref_132831, + author={XJ, Pan and JQ, Fan and GQ, Xia}, + title={Puerarin inhibits alveolar epithelial cell apoptosis in rats with chronic obstructive pulmonary disease by regulating PINK1-parkin signaling pathway-mediated mitophagy}, + journal={Chin J Pathophysiol}, + year={2022}, + volume={38}, + number={10}, + pages={1833} +} + +@article{ref_132832, + author={XM, Li and XH, Jiang and RH, Zeng and al, et}, + title={Formononetin attenuates cigarette smoke-induced COPD in mice by suppressing inflammation, endoplasmic reticulum stress, and apoptosis in bronchial epithelial cells via AhR/CYP1A1 and AKT/mTOR signaling pathways}, + journal={Phytother Res}, + year={2024}, + volume={38}, + number={3}, + pages={1278}, + doi={10.1002/ptr.8104} +} + +@article{ref_132833, + author={X, Tian and Y, Xue and G, Xie and al, et}, + title={(−)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD}, + journal={Toxicol Appl Pharmacol}, + year={2021}, + volume={429}, + pages={115674}, + doi={10.1016/j.taap.2021.115674} +} + +@article{ref_132834, + author={SP, Lakshmi and AT, Reddy and LD, Kodidhela and NCh, Varadacharyulu}, + title={Epigallocatechin gallate diminishes cigarette smoke-induced oxidative stress, lipid peroxidation, and inflammation in human bronchial epithelial cells}, + journal={Life Sci}, + year={2020}, + volume={259}, + pages={118260}, + doi={10.1016/j.lfs.2020.118260} +} + +@article{ref_132835, + author={JW, Park and NR, Shin and IS, Shin and al, et}, + title={Silibinin Inhibits Neutrophilic Inflammation and Mucus Secretion Induced by Cigarette Smoke via Suppression of ERK‐SP1 Pathway}, + journal={Phytother Res}, + year={2016}, + volume={30}, + number={12}, + pages={1926}, + doi={10.1002/ptr.5686} +} + +@article{ref_132836, + author={JW, Ko and NR, Shin and SH, Park and al, et}, + title={Silibinin inhibits the fibrotic responses induced by cigarette smoke via suppression of TGF-β1/Smad 2/3 signaling}, + journal={Food Chem Toxicol}, + year={2017}, + volume={106}, + number={Pt A}, + pages={424}, + doi={10.1016/j.fct.2017.06.016} +} + +@article{ref_132837, + author={DD, Li and D, Xu and T, Wang and al, et}, + title={Silymarin Attenuates Airway Inflammation Induced by Cigarette Smoke in Mice}, + journal={Inflammation}, + year={2014}, + volume={38}, + number={2}, + pages={871}, + doi={10.1007/s10753-014-9996-9} +} + +@article{ref_132838, + author={D, Li and J, Hu and T, Wang and al, et}, + title={Silymarin attenuates cigarette smoke extract-induced inflammation via simultaneous inhibition of autophagy and ERK/p38 MAPK pathway in human bronchial epithelial cells}, + journal={Sci Rep}, + year={2016}, + volume={6}, + pages={37751}, + doi={10.1038/srep37751} +} + +@article{ref_132839, + author={Z, Tao and S, Bai and G, Wu and al, et}, + title={Therapeutic effect of ginkgetin on smoke-induced airway inflammation by down-regulating the c/EBPβ signaling pathway and CCL2 expression}, + journal={J Ethnopharmacol}, + year={2024}, + volume={331}, + pages={118284}, + doi={10.1016/j.jep.2024.118284} +} + +@article{ref_132840, + author={XL, Chen and DS, Geng}, + title={Effect of Total Flavonoids from Nigella glandulifera on Inflammation of Chronic Obstructive Pulmonary Disease Model Rats and Its Mechanism}, + journal={Chin Pharm J}, + year={2014}, + volume={49}, + number={4}, + pages={294} +} + +@article{ref_132841, + author={QC, Ren and XH, Li and QY, Li and al, et}, + title={Total flavonoids from sea buckthorn ameliorates lipopolysaccharide/cigarette smoke‐induced airway inflammation}, + journal={Phytother Res}, + year={2019}, + volume={33}, + number={8}, + pages={2102}, + doi={10.1002/ptr.6404} +} + +@article{ref_132842, + author={JM, Yang and HZ, Wang and QX, Shi and XJ, Luo and YL, Chen}, + title={Effect and Mechanism of Total Flavonoids from Scutellaria Baicalensis Georgi in the Inflammation and Oxidative Stress in Rats with Chronic Obstructive Pulmonary Disease}, + journal={Chin Pharm}, + year={2020}, + volume={23}, + number={6}, + pages={1069} +} + +@article{ref_132843, + author={T, Jian and J, Chen and X, Ding and al, et}, + title={Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways}, + journal={Food Funct}, + year={2020}, + volume={11}, + number={4}, + pages={3516}, + doi={10.1039/C9FO02921D} +} + +@article{ref_132844, + author={Y, Li and J, Zhao and H, Shao and W, Jia and D, Su and T, Liu}, + title={Preventive effect of total flavonoids of Trollius altaicus on a chronic obstructive pulmonary disease rat model based on the TLR4/NF-κB pathway}, + journal={Ann Transl Med}, + year={2022}, + volume={10}, + number={4}, + pages={222}, + doi={10.21037/atm-22-331} +} + +@article{ref_132846, + author={HD, Ding and RN, Wu and M, Ao and Z, Liu}, + title={Protective effect of nasturtium total flavonoids on emphysema in elderly mice and its effect on the expression of p38MAPK signaling pathway in lung tissue}, + journal={Chin J Gerontol}, + year={2023}, + volume={43}, + number={7}, + pages={1721}, + doi={10.3969/j.issn.1005-9202.2023.07.048} +} + +@article{ref_132848, + author={C, Wang and F, Chen and KS, Hu and al, et}, + title={Antioxidant Protective Effect and Mechanism of Total Flavonoids from Dandelion on Cigarette Smoke – Induced Chronic Obstructive Pulmonary Disease}, + journal={Int J Geriatr}, + year={2023}, + volume={44}, + number={3}, + pages={257}, + doi={10.3969/j.issn.1674-7593.2023.03.001} +} + +@article{ref_132849, + author={JE, Repine and A, Bast and I, Lankhorst}, + title={Oxidative Stress in Chronic Obstructive Pulmonary Disease}, + journal={Am J Respir Crit Care Med}, + year={1997}, + volume={156}, + number={2 Pt 1}, + pages={341}, + doi={10.1164/ajrccm.156.2.9611013} +} + +@article{ref_132850, + author={SF, Van Eeden and DD, Sin}, + title={Oxidative Stress in Chronic Obstructive Pulmonary Disease: A Lung and Systemic Process}, + journal={Can Respir J}, + year={2013}, + volume={20}, + number={1}, + pages={27}, + doi={10.1155/2013/509130} +} + +@article{ref_132851, + author={GR, Van Pottelberge and KR, Bracke and GF, Joos and GG, Brusselle}, + title={The Role of Dendritic Cells in the Pathogenesis of COPD: Liaison Officers in the Front Line}, + journal={COPD}, + year={2009}, + volume={6}, + number={4}, + pages={284}, + doi={10.1080/15412550903049124} +} + +@article{ref_132852, + author={KB, Adler and WJ, Holden-Stauffer and JE, Repine}, + title={Oxygen metabolites stimulate release of high-molecular-weight glycoconjugates by cell and organ cultures of rodent respiratory epithelium via an arachidonic acid-dependent mechanism}, + journal={J Clin Invest}, + year={1990}, + volume={85}, + number={1}, + pages={75}, + doi={10.1172/JCI114436} +} + +@article{ref_132853, + author={M, Suzuki and T, Betsuyaku and Y, Ito and al, et}, + title={Down-Regulated NF-E2–Related Factor 2 in Pulmonary Macrophages of Aged Smokers and Patients with Chronic Obstructive Pulmonary Disease}, + journal={Am J Respir Cell Mol Biol}, + year={2008}, + volume={39}, + number={6}, + pages={673}, + doi={10.1165/rcmb.2007-0424OC} +} + +@article{ref_132854, + author={DA, Abed and M, Goldstein and H, Albanyan and H, Jin and L, Hu}, + title={Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agents}, + journal={Acta Pharm Sin B}, + year={2015}, + volume={5}, + number={4}, + pages={285}, + doi={10.1016/j.apsb.2015.05.008} +} + +@article{ref_132855, + author={C, Tonelli and IIC, Chio and DA, Tuveson}, + title={Transcriptional Regulation by Nrf2}, + journal={Antioxid Redox Signal}, + year={2018}, + volume={29}, + number={17}, + pages={1727}, + doi={10.1089/ars.2017.7342} +} + +@article{ref_132856, + author={IMJ, Eurlings and NL, Reynaert and C, van de Wetering and al, et}, + title={Involvement of c-Jun N-Terminal Kinase in TNF-α–Driven Remodeling}, + journal={Am J Respir Cell Mol Biol}, + year={2017}, + volume={56}, + number={3}, + pages={393}, + doi={10.1165/rcmb.2015-0195OC} +} + +@article{ref_132857, + author={JL, Johnson and EE, Moore and DY, Tamura and G, Zallen and WL, Biffl and CC, Silliman}, + title={Interleukin-6 Augments Neutrophil Cytotoxic Potential via Selective Enhancement of Elastase Release}, + journal={J Surg Res}, + year={1998}, + volume={76}, + number={1}, + pages={91}, + doi={10.1006/jsre.1998.5295} +} + +@article{ref_132858, + author={ND, Perkins}, + title={Integrating cell-signalling pathways with NF-κB and IKK function}, + journal={Nat Rev Mol Cell Biol}, + year={2007}, + volume={8}, + number={1}, + pages={49}, + doi={10.1038/nrm2083} +} + +@article{ref_132859, + author={M, Schuliga}, + title={NF-kappaB Signaling in Chronic Inflammatory Airway Disease}, + journal={Biomolecules}, + year={2015}, + volume={5}, + number={3}, + pages={1266}, + doi={10.3390/biom5031266} +} + +@article{ref_132860, + author={JM, Lora and DM, Zhang and SM, Liao and al, et}, + title={Tumor Necrosis Factor-α Triggers Mucus Production in Airway Epithelium through an IκB Kinase β-dependent Mechanism}, + journal={J Biol Chem}, + year={2005}, + volume={280}, + number={43}, + pages={36510}, + doi={10.1074/jbc.M507977200} +} + +@article{ref_132861, + author={KA, Fitzgerald and JC, Kagan}, + title={Toll-like Receptors and the Control of Immunity}, + journal={Cell}, + year={2020}, + volume={180}, + number={6}, + pages={1044}, + doi={10.1016/j.cell.2020.02.041} +} + +@article{ref_132862, + author={O, Takeuchi and K, Takeda and K, Hoshino and O, Adachi and T, Ogawa and S, Akira}, + title={Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades}, + journal={Int Immunol}, + year={2000}, + volume={12}, + number={1}, + pages={113}, + doi={10.1093/intimm/12.1.113} +} + +@article{ref_132863, + author={S, Rajendrasozhan and SR, Yang and VL, Kinnula and I, Rahman}, + title={SIRT1, an Antiinflammatory and Antiaging Protein, Is Decreased in Lungs of Patients with Chronic Obstructive Pulmonary Disease}, + journal={Am J Respir Crit Care Med}, + year={2008}, + volume={177}, + number={8}, + pages={861}, + doi={10.1164/rccm.200708-1269OC} +} + +@article{ref_132864, + author={H, Yao and S, Chung and J, Hwang and al, et}, + title={SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice}, + journal={J Clin Invest}, + year={2012}, + volume={122}, + number={6}, + pages={2032}, + doi={10.1172/JCI60132} +} + +@article{ref_132865, + author={MR, Lee and C, Dominguez}, + title={MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein}, + journal={Curr Med Chem}, + year={2005}, + volume={12}, + number={25}, + pages={2979}, + doi={10.2174/092986705774462914} +} + +@article{ref_132866, + author={CP, Huang and MY, Xie and XH, He and H, Gao}, + title={Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV1 in COPD patients}, + journal={Med Sci Monit}, + year={2013}, + volume={19}, + pages={1229}, + doi={10.12659/MSM.889880} +} + +@article{ref_132867, + author={B, Wang and DJ, Lim and J, Han and YS, Kim and CB, Basbaum and JD, Li}, + title={Novel Cytoplasmic Proteins of Nontypeable Haemophilus influenzae Up-regulate Human MUC5AC Mucin Transcription via a Positive p38 Mitogen-activated Protein Kinase Pathway and a Negative Phosphoinositide 3-Kinase-Akt Pathway}, + journal={J Biol Chem}, + year={2002}, + volume={277}, + number={2}, + pages={949}, + doi={10.1074/jbc.M107484200} +} + +@article{ref_132868, + author={C, Chang and H, Zhu and N, Shen and al, et}, + title={Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-sectional Study}, + journal={COPD}, + year={2014}, + volume={12}, + number={1}, + pages={19}, + doi={10.3109/15412555.2014.898043} +} + +@article{ref_132869, + author={M, Mahmood and SS, Sohal and SD, Shukla and al, et}, + title={Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction}, + journal={Int J Chron Obstruct Pulmon Dis}, + year={2015}, + volume={10}, + pages={1515}, + doi={10.2147/COPD.S81032} +} + +@article{ref_132870, + author={K, Oda and Y, Matsuoka and A, Funahashi and H, Kitano}, + title={A comprehensive pathway map of epidermal growth factor receptor signaling}, + journal={Mol Syst Biol}, + year={2005}, + volume={1}, + pages={2005}, + doi={10.1038/msb4100014} +} + +@article{ref_132871, + author={T, Bormann and R, Maus and J, Stolper and al, et}, + title={Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice}, + journal={Respir Res}, + year={2022}, + volume={23}, + number={1}, + pages={180}, + doi={10.1186/s12931-022-02105-7} +} + +@article{ref_132872, + author={S, Dimic-Janjic and MA, Hoda and B, Milenkovic and al, et}, + title={The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity}, + journal={Eur J Med Res}, + year={2023}, + volume={28}, + number={1}, + pages={127}, + doi={10.1186/s40001-023-01094-7} +} + +@article{ref_132873, + author={IK, Demedts and A, Morel-Montero and S, Lebecque and al, et}, + title={Elevated MMP-12 protein levels in induced sputum from patients with COPD}, + journal={Thorax}, + year={2006}, + volume={61}, + number={3}, + pages={196}, + doi={10.1136/thx.2005.042432} +} + +@article{ref_132874, + author={H, Palosaari and CJ, Pennington and M, Larmas and DR, Edwards and L, Tjäderhane and T, Salo}, + title={Expression profile of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in mature human odontoblasts and pulp tissue}, + journal={Eur J Oral Sci}, + year={2003}, + volume={111}, + number={2}, + pages={117}, + doi={10.1034/j.1600-0722.2003.00026.x} +} + +@article{ref_132875, + author={MA, Antunes and PRM, Rocco}, + title={Elastase-induced pulmonary emphysema: insights from experimental models}, + journal={An Acad Bras Ciênc}, + year={2011}, + volume={83}, + number={4}, + pages={1385}, + doi={10.1590/S0001-37652011005000039} +} + +@article{ref_132876, + author={A, Soltani and EH, Walters and D, Reid and al, et}, + title={Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD}, + journal={Int J Chron Obstruct Pulmon Dis}, + year={2016}, + volume={11}, + pages={2359}, + doi={10.2147/COPD.S113176} +} + +@article{ref_132877, + author={MQ, Mahmood and D, Reid and C, Ward and al, et}, + title={Transforming growth factor (TGF) β1 and Smad signalling pathways: A likely key to EMT‐associated COPD pathogenesis}, + journal={Respirology}, + year={2017}, + volume={22}, + number={1}, + pages={133}, + doi={10.1111/resp.12882} +} + +@article{ref_132878, + author={JW, Park and SW, Ryter and AMK, Choi}, + title={Functional Significance of Apoptosis in Chronic Obstructive Pulmonary Disease}, + journal={COPD}, + year={2007}, + volume={4}, + number={4}, + pages={347}, + doi={10.1080/15412550701603775} +} + +@article{ref_132879, + author={S, Hodge and G, Hodge and M, Holmes and PN, Reynolds}, + title={Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation}, + journal={Eur Respir J}, + year={2005}, + volume={25}, + number={3}, + pages={447}, + doi={10.1183/09031936.05.00077604} +} + +@article{ref_132880, + author={J, Li and F, Cao and H, Yin and al, et}, + title={Ferroptosis: past, present and future}, + journal={Cell Death Dis}, + year={2020}, + volume={11}, + number={2}, + pages={88}, + doi={10.1038/s41419-020-2298-2} +} + +@article{ref_132881, + author={M, Yoshida and S, Minagawa and J, Araya and al, et}, + title={Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis}, + journal={Nat Commun}, + year={2019}, + volume={10}, + number={1}, + pages={3145}, + doi={10.1038/s41467-019-10991-7} +} + +@article{ref_132882, + author={Y, Wang and S, Xia}, + title={Relationship Between ACSL4-Mediated Ferroptosis and Chronic Obstructive Pulmonary Disease}, + journal={Int J Chron Obstruct Pulmon Dis}, + year={2023}, + volume={18}, + pages={99}, + doi={10.2147/COPD.S391129} +} + +@article{ref_132883, + author={ZX, Zhang and CL, Fu and JX, Liu and al, et}, + title={Hypermethylation of the Nrf2 Promoter Induces Ferroptosis by Inhibiting the Nrf2-GPX4 Axis in COPD}, + journal={Int J Chron Obstruct Pulmon Dis}, + year={2021}, + volume={16}, + pages={3347}, + doi={10.2147/COPD.S340113} +} + +@article{ref_132884, + author={L, Wang and L, Mou and S, Guan and al, et}, + title={Isoliquiritigenin induces neurodevelopmental-toxicity and anxiety-like behavior in zebrafish larvae}, + journal={Comp Biochem Physiol C Toxicol Pharmacol}, + year={2023}, + volume={266}, + pages={109555}, + doi={10.1016/j.cbpc.2023.109555} +} + +@article{ref_132885, + author={Z, Liu and C, Li and M, Li and D, Li and K, Liu}, + title={The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats}, + journal={Toxicology}, + year={2004}, + volume={203}, + number={1–3}, + pages={139}, + doi={10.1016/j.tox.2004.06.007} +} + +@article{ref_132886, + author={M, Wu and N, Zheng and X, Zhan and al, et}, + title={Icariin induces developmental toxicity via thyroid hormone disruption in zebrafish larvae}, + journal={Food Chem Toxicol}, + year={2023}, + volume={182}, + pages={114155}, + doi={10.1016/j.fct.2023.114155} +} + +@article{ref_132887, + author={J, Wu and X, Zhang and B, Zhang}, + title={Efficacy and safety of puerarin injection in treatment of diabetic peripheral neuropathy: a systematic review and Meta-analysis of randomized controlled trials}, + journal={J Tradit Chin Med}, + year={2014}, + volume={34}, + number={4}, + pages={401}, + doi={10.1016/S0254-6272(15)30039-X} +} + +@article{ref_132888, + author={TD, Pingale and GL, Gupta}, + title={Acute and sub-acute toxicity study reveals no dentrimental effect of formononetin in mice upon repeated i.p. dosing}, + journal={Toxicol Mech Methods}, + year={2023}, + volume={33}, + number={8}, + pages={688}, + doi={10.1080/15376516.2023.2234026} +} + +@article{ref_132889, + author={YY, Li and XY, Lu and JL, Sun and al, et}, + title={Potential hepatic and renal toxicity induced by the biflavonoids from Ginkgo biloba}, + journal={Chin J Nat Med}, + year={2019}, + volume={17}, + number={9}, + pages={672}, + doi={10.1016/S1875-5364(19)30081-0} +} + +@article{ref_132890, + author={KS, Hodgin and EK, Donovan and S, Kekes-Szabo and al, et}, + title={A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea)}, + journal={Int J Environ Res Public Health}, + year={2021}, + volume={18}, + number={5}, + pages={2483}, + doi={10.3390/ijerph18052483} +} + +@article{ref_132891, + author={CJ, Rebello and RA, Beyl and JJL, Lertora and al, et}, + title={Safety and pharmacokinetics of naringenin: A randomized, controlled, single‐ascending‐dose clinical trial}, + journal={Diabetes Obes Metab}, + year={2020}, + volume={22}, + number={1}, + pages={91}, + doi={10.1111/dom.13868} +} + +@article{ref_132892, + author={M, Moriwaki and K, Kito and R, Nakagawa and al, et}, + title={Mutagenic, Acute, and Subchronic Toxicity Studies of the Hesperetin-7-Glucoside–β-Cyclodextrin Inclusion Complex}, + journal={Int J Toxicol}, + year={2022}, + volume={42}, + number={1}, + pages={50}, + doi={10.1177/10915818221134022} +} + +@article{ref_132893, + author={Products, EFSA Panel on Dietetic and (NDA), Nutrition and Allergies and D, Turck and al, et}, + title={Statement on the safety of taxifolin‐rich extract from Dahurian Larch (Larix gmelinii)}, + journal={EFSA J}, + year={2017}, + volume={15}, + number={11}, + pages={e05059}, + doi={10.2903/j.efsa.2017.5059} +} + +@article{ref_132895, + author={YY, Zhang and J, Bai and MY, Xu and F, Zhang and CX, Bu}, + title={Study on baicalin on liver and kidney toxicity in male rats. Chin J Ind Hyg Occup Dis}, + journal={Chin J Ind Hyg Occup Dis.}, + year={2021}, + volume={39}, + number={3}, + pages={169}, + doi={10.3760/cma.j.cn121094-20200326-00158} +} + +@article{ref_132896, + author={CF, Barnett and A, Moreno-Ulloa and S, Shiva and al, et}, + title={Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers}, + journal={Food Funct}, + year={2015}, + volume={6}, + number={3}, + pages={824}, + doi={10.1039/C4FO00596A} +} + +@article{ref_132897, + author={IJ, Chen and CY, Liu and JP, Chiu and CH, Hsu}, + title={Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial}, + journal={Clin Nutr}, + year={2016}, + volume={35}, + number={3}, + pages={592}, + doi={10.1016/j.clnu.2015.05.003} +} + +@article{ref_132898, + author={MW, Fried and VJ, Navarro and N, Afdhal and al, et}, + title={Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy}, + journal={JAMA}, + year={2012}, + volume={308}, + number={3}, + pages={274}, + doi={10.1001/jama.2012.8265} +} + diff --git a/article_3113.log b/article_3113.log index 2ab80c9..a4a703d 100644 --- a/article_3113.log +++ b/article_3113.log @@ -1,4 +1,4 @@ -This is LuaHBTeX, Version 1.22.0 (TeX Live 2025) (format=lualatex 2025.11.6) 12 FEB 2026 11:33 +This is LuaHBTeX, Version 1.22.0 (TeX Live 2025) (format=lualatex 2025.11.6) 12 FEB 2026 11:38 restricted system commands enabled. **article_3113.tex (./article_3113.tex @@ -39,4683 +39,30 @@ Inserting `luaotfload.aux.fixup_fontdata' in `luaotfload.patch_font_unsafe'. Inserting `luaotfload.aux.set_capheight' in `luaotfload.patch_font'. Inserting `luaotfload.aux.set_xheight' in `luaotfload.patch_font'. Inserting `luaotfload.rewrite_fontname' in `luaotfload.patch_font'. -Inserting `tracingstacklevels' in `input_level_string'. (./tmr-tex.cls -Document Class: tmr-tex 2025/11/27 v1.0 Submission to TMR journals -(d:/texlive/2025/texmf-dist/tex/latex/base/article.cls -Document Class: article 2025/01/22 v1.4n Standard LaTeX document class -(d:/texlive/2025/texmf-dist/tex/latex/base/size10.clo -File: size10.clo 2025/01/22 v1.4n Standard LaTeX file (size option) -luaotfload | db : Font names database loaded from D:/texlive/2025/texmf-var/luat -ex-cache/generic/names/luaotfload-names.luc.gz) -\c@part=\count273 -\c@section=\count274 -\c@subsection=\count275 -\c@subsubsection=\count276 -\c@paragraph=\count277 -\c@subparagraph=\count278 -\c@figure=\count279 -\c@table=\count280 -\abovecaptionskip=\skip49 -\belowcaptionskip=\skip50 -\bibindent=\dimen147 -) -(d:/texlive/2025/texmf-dist/tex/latex/xkeyval/xkeyval.sty -Package: xkeyval 2025/11/04 v2.10 package option processing (HA) +Inserting `tracingstacklevels' in `input_level_string'. -(d:/texlive/2025/texmf-dist/tex/generic/xkeyval/xkeyval.tex -(d:/texlive/2025/texmf-dist/tex/generic/xkeyval/xkvutils.tex -\XKV@toks=\toks17 -\XKV@tempa@toks=\toks18 -\XKV@tempb@toks=\toks19 +! LaTeX Error: File `../tmr-tex.cls' not found. -(d:/texlive/2025/texmf-dist/tex/generic/xkeyval/keyval.tex)) -\XKV@depth=\count281 -File: xkeyval.tex 2014/12/03 v2.7a key=value parser (HA) -)) -(d:/texlive/2025/texmf-dist/tex/latex/geometry/geometry.sty -Package: geometry 2020/01/02 v5.9 Page Geometry +Type X to quit or to proceed, +or enter new name. (Default extension: cls) -(d:/texlive/2025/texmf-dist/tex/generic/iftex/ifvtex.sty -Package: ifvtex 2019/10/25 v1.7 ifvtex legacy package. Use iftex instead. +Enter file name: +! Emergency stop. + + +l.11 + +*** (cannot \read from terminal in nonstop modes) -(d:/texlive/2025/texmf-dist/tex/generic/iftex/iftex.sty -Package: iftex 2024/12/12 v1.0g TeX engine tests -)) -\Gm@cnth=\count282 -\Gm@cntv=\count283 -\c@Gm@tempcnt=\count284 -\Gm@bindingoffset=\dimen148 -\Gm@wd@mp=\dimen149 -\Gm@odd@mp=\dimen150 -\Gm@even@mp=\dimen151 -\Gm@layoutwidth=\dimen152 -\Gm@layoutheight=\dimen153 -\Gm@layouthoffset=\dimen154 -\Gm@layoutvoffset=\dimen155 -\Gm@dimlist=\toks20 -) -(d:/texlive/2025/texmf-dist/tex/latex/changepage/changepage.sty -Package: changepage 2009/10/20 v1.0c check page and change page layout -\c@cp@cntr=\count285 -\cp@tempcnt=\count286 -) -(d:/texlive/2025/texmf-dist/tex/latex/stringstrings/stringstrings.sty -Package: stringstrings 2020/12/08 v1.24 Extensive array of string manipulation -routines for cosmetic and programming application -(d:/texlive/2025/texmf-dist/tex/latex/base/ifthen.sty -Package: ifthen 2024/03/16 v1.1e Standard LaTeX ifthen package (DPC) -) -\c@@letterindex=\count287 -\c@@@letterindex=\count288 -\c@@@@letterindex=\count289 -\c@@wordindex=\count290 -\c@@iargc=\count291 -\c@@gobblesize=\count292 -\c@@maxrotation=\count293 -\c@@stringsize=\count294 -\c@@@stringsize=\count295 -\c@@@@stringsize=\count296 -\c@@revisedstringsize=\count297 -\c@@gobbleindex=\count298 -\c@@charsfound=\count299 -\c@@alph=\count300 -\c@@alphaindex=\count301 -\c@@capstrigger=\count302 -\c@@fromindex=\count303 -\c@@toindex=\count304 -\c@@previousindex=\count305 -\c@@flag=\count306 -\c@@matchloc=\count307 -\c@@matchend=\count308 -\c@@matchsize=\count309 -\c@@matchmax=\count310 -\c@@skipped=\count311 -\c@@lcwords=\count312 -\c@@@matchloc=\count313 -) -(d:/texlive/2025/texmf-dist/tex/latex/textpos/textpos.sty -Package: textpos 2022/07/23 v1.10.1 -Package textpos Info: choosing support for LaTeX3 on input line 60. -\TP@textbox=\box53 -\TP@holdbox=\box54 -\TPHorizModule=\dimen156 -\TPVertModule=\dimen157 -\TP@margin=\dimen158 -\TP@absmargin=\dimen159 - -Grid set 16 x 16 = 37.34424pt x 52.81541pt -\TPboxrulesize=\dimen160 -\TP@ox=\dimen161 -\TP@oy=\dimen162 -\TP@tbargs=\toks21 -TextBlockOrigin set to 0pt x 0pt -) (d:/texlive/2025/texmf-dist/tex/latex/xcolor/xcolor.sty -Package: xcolor 2024/09/29 v3.02 LaTeX color extensions (UK) - -(d:/texlive/2025/texmf-dist/tex/latex/graphics-cfg/color.cfg -File: color.cfg 2016/01/02 v1.6 sample color configuration -) -Package xcolor Info: Driver file: luatex.def on input line 274. - -(d:/texlive/2025/texmf-dist/tex/latex/graphics-def/luatex.def -File: luatex.def 2025/09/29 v1.2f Graphics/color driver for luatex -) -(d:/texlive/2025/texmf-dist/tex/latex/graphics/mathcolor.ltx) -Package xcolor Info: Model `cmy' substituted by `cmy0' on input line 1349. -Package xcolor Info: Model `hsb' substituted by `rgb' on input line 1353. -Package xcolor Info: Model `RGB' extended on input line 1365. -Package xcolor Info: Model `HTML' substituted by `rgb' on input line 1367. -Package xcolor Info: Model `Hsb' substituted by `hsb' on input line 1368. -Package xcolor Info: Model `tHsb' substituted by `hsb' on input line 1369. -Package xcolor Info: Model `HSB' substituted by `hsb' on input line 1370. -Package xcolor Info: Model `Gray' substituted by `gray' on input line 1371. -Package xcolor Info: Model `wave' substituted by `hsb' on input line 1372. -) -(d:/texlive/2025/texmf-dist/tex/latex/colortbl/colortbl.sty -Package: colortbl 2024/10/29 v1.0k Color table columns (DPC) - -(d:/texlive/2025/texmf-dist/tex/latex/tools/array.sty -Package: array 2025/09/25 v2.6n Tabular extension package (FMi) -\col@sep=\dimen163 -\ar@mcellbox=\box55 -\extrarowheight=\dimen164 -\NC@list=\toks22 -\extratabsurround=\skip51 -\backup@length=\skip52 -\ar@cellbox=\box56 -) -\everycr=\toks23 -\minrowclearance=\skip53 -\rownum=\count314 -) -(d:/texlive/2025/texmf-dist/tex/latex/xcolor/svgnam.def -File: svgnam.def 2024/09/29 v3.02 Predefined colors according to SVG 1.1 (UK) -) -(d:/texlive/2025/texmf-dist/tex/latex/tabularray/tabularray.sty -Package: tabularray 2025-08-29 v2025B Typeset tabulars and arrays with LaTeX3 - -(d:/texlive/2025/texmf-dist/tex/latex/ninecolors/ninecolors.sty -Package: ninecolors 2022-02-13 v2022D Select colors with proper color contrast - -(d:/texlive/2025/texmf-dist/tex/latex/l3packages/xparse/xparse.sty -(d:/texlive/2025/texmf-dist/tex/latex/l3kernel/expl3.sty -Package: expl3 2025-10-24 L3 programming layer (loader) - -(d:/texlive/2025/texmf-dist/tex/latex/l3backend/l3backend-luatex.def -File: l3backend-luatex.def 2025-10-09 L3 backend support: PDF output (LuaTeX) -\l__color_backend_stack_int=\count315 -Inserting `l3color' in `luaotfload.parse_color'.)) -Package: xparse 2025-10-09 L3 Experimental document command parser -)) -\l__tblr_a_int=\count316 -\l__tblr_c_int=\count317 -\l__tblr_r_int=\count318 -\l__tblr_d_dim=\dimen165 -\l__tblr_h_dim=\dimen166 -\l__tblr_o_dim=\dimen167 -\l__tblr_p_dim=\dimen168 -\l__tblr_q_dim=\dimen169 -\l__tblr_r_dim=\dimen170 -\l__tblr_s_dim=\dimen171 -\l__tblr_t_dim=\dimen172 -\l__tblr_v_dim=\dimen173 -\l__tblr_w_dim=\dimen174 -\l__tblr_a_box=\box57 -\l__tblr_b_box=\box58 -\l__tblr_c_box=\box59 -\l__tblr_d_box=\box60 -\c@tblrcount=\count319 -\c@colnum=\count320 -\c@rowcount=\count321 -\c@colcount=\count322 -\abovesep=\dimen175 -\belowsep=\dimen176 -\leftsep=\dimen177 -\rightsep=\dimen178 -\gTblrLevelInt=\count323 -\g__tblr_data_row_key_count_int=\count324 -\g__tblr_data_column_key_count_int=\count325 -\g__tblr_data_cell_key_count_int=\count326 -\g__tblr_array_int=\count327 -\l__tblr_key_count_int=\count328 -\l__tblr_key_quotient_int=\count329 -\l__tblr_key_quotient_two_int=\count330 -\l__tblr_key_remainder_int=\count331 -\g__tblr_data_str_value_count_int=\count332 -\lTblrChildTotalInt=\count333 -\lTblrChildHtotalInt=\count334 -\lTblrChildVtotalInt=\count335 -\l__child_diff_h_int=\count336 -\l__child_diff_v_int=\count337 -\l__child_sign_h_int=\count338 -\l__child_sign_v_int=\count339 -\l__child_step_int=\count340 -\lTblrDefaultHruleWidthDim=\dimen179 -\lTblrDefaultVruleWidthDim=\dimen180 -\l__tblr_split_balance_int=\count341 -\l__tblr_strut_dp_dim=\dimen181 -\l__tblr_strut_ht_dim=\dimen182 -\g__tblr_cell_wd_dim=\dimen183 -\g__tblr_cell_ht_dim=\dimen184 -\g__tblr_cell_head_dim=\dimen185 -\g__tblr_cell_foot_dim=\dimen186 -\l__tblr_measured_cell_box=\box61 -\g__tblr_last_box=\box62 -\l__tblr_temp_box=\box63 -\l__tblr_column_target_dim=\dimen187 -\l__tblr_hfuzz_dim=\dimen188 -\l__tblr_caption_box=\box64 -\l__tblr_caption_left_box=\box65 -\lTblrRowHeadInt=\count342 -\lTblrRowFootInt=\count343 -\l__tblr_row_head_box=\box66 -\l__tblr_row_foot_box=\box67 -\l__tblr_row_head_foot_dim=\dimen189 -\lTblrTableWidthDim=\dimen190 -\l__tblr_table_firsthead_box=\box68 -\l__tblr_table_middlehead_box=\box69 -\l__tblr_table_lasthead_box=\box70 -\l__tblr_table_firstfoot_box=\box71 -\l__tblr_table_middlefoot_box=\box72 -\l__tblr_table_lastfoot_box=\box73 -\l__tblr_remain_height_dim=\dimen191 -\l__tblr_long_from_int=\count344 -\l__tblr_long_to_int=\count345 -\l__tblr_curr_i_int=\count346 -\l__tblr_prev_i_int=\count347 -\lTblrTablePageInt=\count348 -\l__tblr_table_head_box=\box74 -\l__tblr_table_foot_box=\box75 -\l__tblr_table_head_foot_dim=\dimen192 -\l__tblr_table_head_body_foot_dim=\dimen193 -\l__tblr_table_box=\box76 -\lTblrRowFirstInt=\count349 -\lTblrRowLastInt=\count350 -\l__tblr_table_hlines_box=\box77 -\l__tblr_hline_box=\box78 -\l__tblr_row_box=\box79 -\l__tblr_col_o_wd_dim=\dimen194 -\l__tblr_col_b_wd_dim=\dimen195 -\l__tblr_hline_leftskip_dim=\dimen196 -\l__tblr_hline_rightskip_dim=\dimen197 -\l__tblr_row_ht_dim=\dimen198 -\l__tblr_row_dp_dim=\dimen199 -\l__tblr_row_abovesep_dim=\dimen256 -\l__tblr_row_belowsep_dim=\dimen257 -\l__tblr_row_vlines_box=\box80 -\l__tblr_vline_box=\box81 -\l__tblr_cell_box=\box82 -\l__tblr_row_upper_dim=\dimen258 -\l__tblr_row_lower_dim=\dimen259 -\l__tblr_row_vpace_dim=\dimen260 -\l__tblr_vline_aboveskip_dim=\dimen261 -\l__tblr_vline_belowskip_dim=\dimen262 -\lTblrCellRowSpanInt=\count351 -\lTblrCellColSpanInt=\count352 -\l__tblr_cell_wd_dim=\dimen263 -\l__tblr_cell_ht_dim=\dimen264 -\lTblrCellAboveBorderWidthDim=\dimen265 -\lTblrCellBelowBorderWidthDim=\dimen266 -\lTblrCellLeftBorderWidthDim=\dimen267 -\lTblrCellRightBorderWidthDim=\dimen268 -\l__tblr_diag_box=\box83 -\l__tblr_cell_inner_wd_dim=\dimen269 -\l__tblr_cell_inner_dp_dim=\dimen270 -\l__tblr_cell_hanchor_dim=\dimen271 -\l__tblr_last_cell_table_ht_dim=\dimen272 -\l__tblr_last_cell_table_dp_dim=\dimen273 -\l__tblr_last_vline_wd_dim=\dimen274 -\l__tblr_tikz_node_box=\box84 -) -(d:/texlive/2025/texmf-dist/tex/latex/hyphenat/hyphenat.sty -Package: hyphenat 2009/09/02 v2.3c hyphenation utilities -\langwohyphens=\language2 -LaTeX Info: Redefining \_ on input line 43. -) -(d:/texlive/2025/texmf-dist/tex/latex/caption/caption.sty -Package: caption 2023/08/05 v3.6o Customizing captions (AR) - -(d:/texlive/2025/texmf-dist/tex/latex/caption/caption3.sty -Package: caption3 2023/07/31 v2.4d caption3 kernel (AR) -\caption@tempdima=\dimen275 -\captionmargin=\dimen276 -\caption@leftmargin=\dimen277 -\caption@rightmargin=\dimen278 -\caption@width=\dimen279 -\caption@indent=\dimen280 -\caption@parindent=\dimen281 -\caption@hangindent=\dimen282 -Package caption Info: Standard document class detected. -) -\c@caption@flags=\count353 -\c@continuedfloat=\count354 -Package caption Info: changepage package is loaded. -\caption@adjustwidth@hsize=\dimen283 -\caption@adjustwidth@linewidth=\dimen284 -) -(d:/texlive/2025/texmf-dist/tex/latex/floatrow/floatrow.sty -Package: floatrow 2008/08/02 v0.3b floatrow: float package extension -\c@float@type=\count355 -\float@exts=\toks24 -\float@box=\box85 -\@floatcapt=\box86 -Package floatrow Info: Modified float package code loaded on input line 455. -Package floatrow Info: Modified rotfloat package code loaded on input line 473. - -\FR@everyfloat=\toks25 -\flrow@foot=\insert252 -\FB@wd=\dimen285 -\FBo@wd=\dimen286 -\FBc@wd=\dimen287 -\FBo@ht=\skip54 -\FBc@ht=\skip55 -\FBf@ht=\skip56 -\FBo@max=\skip57 -\FBc@max=\skip58 -\FBf@max=\skip59 -\c@FBl@b=\count356 -\floatbox@depth=\count357 -\c@FRobj=\count358 -\c@FRsobj=\count359 -\Xhsize=\skip60 -\sXhsize=\skip61 -\Zhsize=\skip62 -\sZhsize=\skip63 -\flrow@rowbox=\box87 -\FR@Zunitlength=\dimen288 -\c@FBcnt=\count360 -\FPOScnt=\count361 -\LTleft=\skip64 -\LTright=\skip65 -\LTleft=\skip66 -\LTright=\skip67 -\flrow@types=\toks26 -) -(d:/texlive/2025/texmf-dist/tex/latex/graphics/graphicx.sty -Package: graphicx 2024/12/31 v1.2e Enhanced LaTeX Graphics (DPC,SPQR) - -(d:/texlive/2025/texmf-dist/tex/latex/graphics/graphics.sty -Package: graphics 2024/08/06 v1.4g Standard LaTeX Graphics (DPC,SPQR) - -(d:/texlive/2025/texmf-dist/tex/latex/graphics/trig.sty -Package: trig 2023/12/02 v1.11 sin cos tan (DPC) -) -(d:/texlive/2025/texmf-dist/tex/latex/graphics-cfg/graphics.cfg -File: graphics.cfg 2016/06/04 v1.11 sample graphics configuration -) -Package graphics Info: Driver file: luatex.def on input line 106. -) -\Gin@req@height=\dimen289 -\Gin@req@width=\dimen290 -) -(d:/texlive/2025/texmf-dist/tex/latex/url/url.sty -\Urlmuskip=\muskip17 -Package: url 2013/09/16 ver 3.4 Verb mode for urls, etc. -) -(d:/texlive/2025/texmf-dist/tex/latex/mdframed/mdframed.sty -Package: mdframed 2013/07/01 1.9b: mdframed - -(d:/texlive/2025/texmf-dist/tex/latex/kvoptions/kvoptions.sty -Package: kvoptions 2022-06-15 v3.15 Key value format for package options (HO) - -(d:/texlive/2025/texmf-dist/tex/generic/ltxcmds/ltxcmds.sty -Package: ltxcmds 2023-12-04 v1.26 LaTeX kernel commands for general use (HO) -) -(d:/texlive/2025/texmf-dist/tex/latex/kvsetkeys/kvsetkeys.sty -Package: kvsetkeys 2022-10-05 v1.19 Key value parser (HO) -)) -(d:/texlive/2025/texmf-dist/tex/latex/etoolbox/etoolbox.sty -Package: etoolbox 2025/10/02 v2.5m e-TeX tools for LaTeX (JAW) -\etb@tempcnta=\count362 -) -(d:/texlive/2025/texmf-dist/tex/latex/zref/zref-abspage.sty -Package: zref-abspage 2025-06-08 v2.36 Module abspage for zref (HO) - -(d:/texlive/2025/texmf-dist/tex/latex/zref/zref-base.sty -Package: zref-base 2025-06-08 v2.36 Module base for zref (HO) - -(d:/texlive/2025/texmf-dist/tex/generic/infwarerr/infwarerr.sty -Package: infwarerr 2019/12/03 v1.5 Providing info/warning/error messages (HO) -) -(d:/texlive/2025/texmf-dist/tex/generic/kvdefinekeys/kvdefinekeys.sty -Package: kvdefinekeys 2019-12-19 v1.6 Define keys (HO) -) -(d:/texlive/2025/texmf-dist/tex/generic/pdftexcmds/pdftexcmds.sty -Package: pdftexcmds 2020-06-27 v0.33 Utility functions of pdfTeX for LuaTeX (HO -) -Package pdftexcmds Info: \pdf@primitive is available. -Package pdftexcmds Info: \pdf@ifprimitive is available. -Package pdftexcmds Info: \pdfdraftmode found. -\pdftexcmds@toks=\toks27 -) -(d:/texlive/2025/texmf-dist/tex/generic/etexcmds/etexcmds.sty -Package: etexcmds 2019/12/15 v1.7 Avoid name clashes with e-TeX commands (HO) -) -(d:/texlive/2025/texmf-dist/tex/latex/auxhook/auxhook.sty -Package: auxhook 2019-12-17 v1.6 Hooks for auxiliary files (HO) -) -Package zref Info: New property list: main on input line 767. -Package zref Info: New property: default on input line 768. -Package zref Info: New property: page on input line 769. -) -\c@abspage=\count363 -Package zref Info: New property: abspage on input line 67. -) -(d:/texlive/2025/texmf-dist/tex/latex/needspace/needspace.sty -Package: needspace 2025/03/13 v1.3e reserve vertical space -) -\mdf@templength=\skip68 -\c@mdf@globalstyle@cnt=\count364 -\mdf@skipabove@length=\skip69 -\mdf@skipbelow@length=\skip70 -\mdf@leftmargin@length=\skip71 -\mdf@rightmargin@length=\skip72 -\mdf@innerleftmargin@length=\skip73 -\mdf@innerrightmargin@length=\skip74 -\mdf@innertopmargin@length=\skip75 -\mdf@innerbottommargin@length=\skip76 -\mdf@splittopskip@length=\skip77 -\mdf@splitbottomskip@length=\skip78 -\mdf@outermargin@length=\skip79 -\mdf@innermargin@length=\skip80 -\mdf@linewidth@length=\skip81 -\mdf@innerlinewidth@length=\skip82 -\mdf@middlelinewidth@length=\skip83 -\mdf@outerlinewidth@length=\skip84 -\mdf@roundcorner@length=\skip85 -\mdf@footenotedistance@length=\skip86 -\mdf@userdefinedwidth@length=\skip87 -\mdf@needspace@length=\skip88 -\mdf@frametitleaboveskip@length=\skip89 -\mdf@frametitlebelowskip@length=\skip90 -\mdf@frametitlerulewidth@length=\skip91 -\mdf@frametitleleftmargin@length=\skip92 -\mdf@frametitlerightmargin@length=\skip93 -\mdf@shadowsize@length=\skip94 -\mdf@extratopheight@length=\skip95 -\mdf@subtitleabovelinewidth@length=\skip96 -\mdf@subtitlebelowlinewidth@length=\skip97 -\mdf@subtitleaboveskip@length=\skip98 -\mdf@subtitlebelowskip@length=\skip99 -\mdf@subtitleinneraboveskip@length=\skip100 -\mdf@subtitleinnerbelowskip@length=\skip101 -\mdf@subsubtitleabovelinewidth@length=\skip102 -\mdf@subsubtitlebelowlinewidth@length=\skip103 -\mdf@subsubtitleaboveskip@length=\skip104 -\mdf@subsubtitlebelowskip@length=\skip105 -\mdf@subsubtitleinneraboveskip@length=\skip106 -\mdf@subsubtitleinnerbelowskip@length=\skip107 - -(d:/texlive/2025/texmf-dist/tex/latex/mdframed/md-frame-0.mdf -File: md-frame-0.mdf 2013/07/01\ 1.9b: md-frame-0 -) -\mdf@frametitlebox=\box88 -\mdf@footnotebox=\box89 -\mdf@splitbox@one=\box90 -\mdf@splitbox@two=\box91 -\mdf@splitbox@save=\box92 -\mdfsplitboxwidth=\skip108 -\mdfsplitboxtotalwidth=\skip109 -\mdfsplitboxheight=\skip110 -\mdfsplitboxdepth=\skip111 -\mdfsplitboxtotalheight=\skip112 -\mdfframetitleboxwidth=\skip113 -\mdfframetitleboxtotalwidth=\skip114 -\mdfframetitleboxheight=\skip115 -\mdfframetitleboxdepth=\skip116 -\mdfframetitleboxtotalheight=\skip117 -\mdffootnoteboxwidth=\skip118 -\mdffootnoteboxtotalwidth=\skip119 -\mdffootnoteboxheight=\skip120 -\mdffootnoteboxdepth=\skip121 -\mdffootnoteboxtotalheight=\skip122 -\mdftotallinewidth=\skip123 -\mdfboundingboxwidth=\skip124 -\mdfboundingboxtotalwidth=\skip125 -\mdfboundingboxheight=\skip126 -\mdfboundingboxdepth=\skip127 -\mdfboundingboxtotalheight=\skip128 -\mdf@freevspace@length=\skip129 -\mdf@horizontalwidthofbox@length=\skip130 -\mdf@verticalmarginwhole@length=\skip131 -\mdf@horizontalspaceofbox=\skip132 -\mdfsubtitleheight=\skip133 -\mdfsubsubtitleheight=\skip134 -\c@mdfcountframes=\count365 - -****** mdframed patching \endmdf@trivlist - -****** -- success****** - -\mdf@envdepth=\count366 -\c@mdf@env@i=\count367 -\c@mdf@env@ii=\count368 -\c@mdf@zref@counter=\count369 -Package zref Info: New property: mdf@pagevalue on input line 895. -) -(d:/texlive/2025/texmf-dist/tex/latex/mfirstuc/mfirstuc.sty -Package: mfirstuc 2025/04/03 v2.09 (NLCT) -\@glsmfirst=\toks28 -\@glsmrest=\toks29 -) -(d:/texlive/2025/texmf-dist/tex/generic/alphalph/alphalph.sty -Package: alphalph 2019/12/09 v2.6 Convert numbers to letters (HO) - -(d:/texlive/2025/texmf-dist/tex/generic/intcalc/intcalc.sty -Package: intcalc 2019/12/15 v1.3 Expandable calculations with integers (HO) -)) -(d:/texlive/2025/texmf-dist/tex/latex/fontspec/fontspec.sty -Package: fontspec 2025/09/29 v2.9g Font selection for XeLaTeX and LuaLaTeX -Lua module: fontspec 2025/09/29 v2.9g Font selection for XeLaTeX and LuaLaTeX -(d:/texlive/2025/texmf-dist/tex/latex/fontspec/fontspec-luatex.sty -Package: fontspec-luatex 2025/09/29 v2.9g Font selection for XeLaTeX and LuaLaT -eX -\l__fontspec_script_int=\count370 -\l__fontspec_language_int=\count371 -\l__fontspec_strnum_int=\count372 -\l__fontspec_tmp_int=\count373 -\l__fontspec_tmpa_int=\count374 -\l__fontspec_tmpb_int=\count375 -\l__fontspec_tmpc_int=\count376 -\l__fontspec_em_int=\count377 -\l__fontspec_emdef_int=\count378 -\l__fontspec_strong_int=\count379 -\l__fontspec_strongdef_int=\count380 -\l__fontspec_tmpa_dim=\dimen291 -\l__fontspec_tmpb_dim=\dimen292 -\l__fontspec_tmpc_dim=\dimen293 - -(d:/texlive/2025/texmf-dist/tex/latex/base/fontenc.sty -Package: fontenc 2025/07/18 v2.1d Standard LaTeX package -) -(d:/texlive/2025/texmf-dist/tex/latex/fontspec/fontspec.cfg))) -\cup@space@pre@title=\skip135 -\cup@space@post@title=\skip136 -\cup@space@post@author=\skip137 -\cup@space@post@address=\skip138 -\cup@space@post@email=\skip139 -\cup@space@post@date=\skip140 -\cup@space@inter@extra=\skip141 -\cup@space@left@content=\skip142 -\cup@space@left@title=\skip143 -\cup@maketitle@width=\skip144 - -(d:/texlive/2025/texmf-dist/tex/latex/ragged2e/ragged2e.sty -Package: ragged2e 2023/06/22 v3.6 ragged2e Package -\CenteringLeftskip=\skip145 -\RaggedLeftLeftskip=\skip146 -\RaggedRightLeftskip=\skip147 -\CenteringRightskip=\skip148 -\RaggedLeftRightskip=\skip149 -\RaggedRightRightskip=\skip150 -\CenteringParfillskip=\skip151 -\RaggedLeftParfillskip=\skip152 -\RaggedRightParfillskip=\skip153 -\JustifyingParfillskip=\skip154 -\CenteringParindent=\skip155 -\RaggedLeftParindent=\skip156 -\RaggedRightParindent=\skip157 -\JustifyingParindent=\skip158 -) -(d:/texlive/2025/texmf-dist/tex/latex/lastpage/lastpage.sty -Package: lastpage 2025/08/14 v2.1h lastpage: 2.09 or 2e? (HMM) - -(d:/texlive/2025/texmf-dist/tex/latex/lastpage/lastpage2e.sty -Package: lastpage2e 2025/08/14 v2.1h Decide which 2e lastpage version to use (H -MM) - -(d:/texlive/2025/texmf-dist/tex/latex/lastpage/lastpagemodern.sty -Package: lastpagemodern 2025-08-14 v2.1h Refers to last page's name (HMM; JPG) -\c@lastpagecount=\count381 -) -)) -\cup@author@cnt=\count382 -\cup@affil@cnt=\count383 -\cup@affil@alt@cnt=\count384 -\cup@footnote@cnt=\count385 -\cup@affil@marker@cnt=\count386 -\cup@first@cnt=\count387 - (d:/texlive/2025/texmf-dist/tex/latex/hyperref/hyperref.sty -Package: hyperref 2025-07-12 v7.01o Hypertext links for LaTeX - -(d:/texlive/2025/texmf-dist/tex/generic/pdfescape/pdfescape.sty -Package: pdfescape 2019/12/09 v1.15 Implements pdfTeX's escape features (HO) -) -(d:/texlive/2025/texmf-dist/tex/latex/hycolor/hycolor.sty -Package: hycolor 2020-01-27 v1.10 Color options for hyperref/bookmark (HO) -) -(d:/texlive/2025/texmf-dist/tex/latex/hyperref/nameref.sty -Package: nameref 2025-06-21 v2.57 Cross-referencing by name of section - -(d:/texlive/2025/texmf-dist/tex/latex/refcount/refcount.sty -Package: refcount 2019/12/15 v3.6 Data extraction from label references (HO) -) -(d:/texlive/2025/texmf-dist/tex/generic/gettitlestring/gettitlestring.sty -Package: gettitlestring 2019/12/15 v1.6 Cleanup title references (HO) -) -\c@section@level=\count388 -) -(d:/texlive/2025/texmf-dist/tex/generic/stringenc/stringenc.sty -Package: stringenc 2019/11/29 v1.12 Convert strings between diff. encodings (HO -) -) -\@linkdim=\dimen294 -\Hy@linkcounter=\count389 -\Hy@pagecounter=\count390 - -(d:/texlive/2025/texmf-dist/tex/latex/hyperref/pd1enc.def -File: pd1enc.def 2025-07-12 v7.01o Hyperref: PDFDocEncoding definition (HO) -) -\Hy@SavedSpaceFactor=\count391 - -(d:/texlive/2025/texmf-dist/tex/latex/hyperref/puenc.def -File: puenc.def 2025-07-12 v7.01o Hyperref: PDF Unicode definition (HO) -) -Package hyperref Info: Hyper figures OFF on input line 4195. -Package hyperref Info: Link nesting OFF on input line 4200. -Package hyperref Info: Hyper index ON on input line 4203. -Package hyperref Info: Plain pages OFF on input line 4210. -Package hyperref Info: Backreferencing OFF on input line 4215. -Package hyperref Info: Implicit mode ON; LaTeX internals redefined. -Package hyperref Info: Bookmarks ON on input line 4462. -\c@Hy@tempcnt=\count392 -LaTeX Info: Redefining \url on input line 4801. -\XeTeXLinkMargin=\dimen295 - -(d:/texlive/2025/texmf-dist/tex/generic/bitset/bitset.sty -Package: bitset 2019/12/09 v1.3 Handle bit-vector datatype (HO) - -(d:/texlive/2025/texmf-dist/tex/generic/bigintcalc/bigintcalc.sty -Package: bigintcalc 2019/12/15 v1.5 Expandable calculations on big integers (HO -) -)) -\Fld@menulength=\count393 -\Field@Width=\dimen296 -\Fld@charsize=\dimen297 -Package hyperref Info: Hyper figures OFF on input line 6078. -Package hyperref Info: Link nesting OFF on input line 6083. -Package hyperref Info: Hyper index ON on input line 6086. -Package hyperref Info: backreferencing OFF on input line 6093. -Package hyperref Info: Link coloring OFF on input line 6098. -Package hyperref Info: Link coloring with OCG OFF on input line 6103. -Package hyperref Info: PDF/A mode OFF on input line 6108. -\Hy@abspage=\count394 -\c@Item=\count395 -\c@Hfootnote=\count396 -) -Package hyperref Info: Driver (autodetected): hluatex. - -(d:/texlive/2025/texmf-dist/tex/latex/hyperref/hluatex.def -File: hluatex.def 2025-07-12 v7.01o Hyperref driver for luaTeX -\Fld@listcount=\count397 -\c@bookmark@seq@number=\count398 - -(d:/texlive/2025/texmf-dist/tex/latex/rerunfilecheck/rerunfilecheck.sty -Package: rerunfilecheck 2025-06-21 v1.11 Rerun checks for auxiliary files (HO) - -(d:/texlive/2025/texmf-dist/tex/generic/uniquecounter/uniquecounter.sty -Package: uniquecounter 2019/12/15 v1.4 Provide unlimited unique counter (HO) -) -Package uniquecounter Info: New unique counter `rerunfilecheck' on input line 2 -84. -) -\Hy@SectionHShift=\skip159 -) -(d:/texlive/2025/texmf-dist/tex/latex/enumitem/enumitem.sty -Package: enumitem 2025/02/06 v3.11 Customized lists -\enitkv@toks@=\toks30 -\labelindent=\skip160 -\enit@outerparindent=\dimen298 -\enit@toks=\toks31 -\enit@inbox=\box93 -\enit@count@id=\count399 -\enitdp@description=\count400 -) -(d:/texlive/2025/texmf-dist/tex/latex/threeparttable/threeparttable.sty -Package: threeparttable 2003/06/13 v 3.0 -\@tempboxb=\box94 -) -(d:/texlive/2025/texmf-dist/tex/latex/endnotes/endnotes.sty -Package: endnotes 2020-01-02 endnotes package -\c@endnote=\count401 -\endnotesep=\dimen299 -\@enotes=\write3 -) -(d:/texlive/2025/texmf-dist/tex/latex/pgf/frontendlayer/tikz.sty -(d:/texlive/2025/texmf-dist/tex/latex/pgf/basiclayer/pgf.sty -(d:/texlive/2025/texmf-dist/tex/latex/pgf/utilities/pgfrcs.sty -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfutil-common.tex -\pgfutil@everybye=\toks32 -\pgfutil@tempdima=\dimen300 -\pgfutil@tempdimb=\dimen301 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfutil-latex.def -\pgfutil@abb=\box95 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfrcs.code.tex -(d:/texlive/2025/texmf-dist/tex/generic/pgf/pgf.revision.tex) -Package: pgfrcs 2025-08-29 v3.1.11a (3.1.11a) -)) -Package: pgf 2025-08-29 v3.1.11a (3.1.11a) - -(d:/texlive/2025/texmf-dist/tex/latex/pgf/basiclayer/pgfcore.sty -(d:/texlive/2025/texmf-dist/tex/latex/pgf/systemlayer/pgfsys.sty -(d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgfsys.code.tex -Package: pgfsys 2025-08-29 v3.1.11a (3.1.11a) - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfkeys.code.tex -\pgfkeys@pathtoks=\toks33 -\pgfkeys@temptoks=\toks34 - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfkeyslibraryfiltered.co -de.tex -\pgfkeys@tmptoks=\toks35 -)) -\pgf@x=\dimen302 -\pgf@y=\dimen303 -\pgf@xa=\dimen304 -\pgf@ya=\dimen305 -\pgf@xb=\dimen306 -\pgf@yb=\dimen307 -\pgf@xc=\dimen308 -\pgf@yc=\dimen309 -\pgf@xd=\dimen310 -\pgf@yd=\dimen311 -\w@pgf@writea=\write4 -\r@pgf@reada=\read2 -\c@pgf@counta=\count402 -\c@pgf@countb=\count403 -\c@pgf@countc=\count404 -\c@pgf@countd=\count405 -\t@pgf@toka=\toks36 -\t@pgf@tokb=\toks37 -\t@pgf@tokc=\toks38 -\pgf@sys@id@count=\count406 - (d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgf.cfg -File: pgf.cfg 2025-08-29 v3.1.11a (3.1.11a) -) -Driver file for pgf: pgfsys-luatex.def - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgfsys-luatex.def -File: pgfsys-luatex.def 2025-08-29 v3.1.11a (3.1.11a) - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgfsys-common-pdf.def -File: pgfsys-common-pdf.def 2025-08-29 v3.1.11a (3.1.11a) -))) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgfsyssoftpath.code.tex -File: pgfsyssoftpath.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfsyssoftpath@smallbuffer@items=\count407 -\pgfsyssoftpath@bigbuffer@items=\count408 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/systemlayer/pgfsysprotocol.code.tex -File: pgfsysprotocol.code.tex 2025-08-29 v3.1.11a (3.1.11a) -)) (d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcore.code.tex -Package: pgfcore 2025-08-29 v3.1.11a (3.1.11a) - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmath.code.tex -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathutil.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathparser.code.tex -\pgfmath@dimen=\dimen312 -\pgfmath@count=\count409 -\pgfmath@box=\box96 -\pgfmath@toks=\toks39 -\pgfmath@stack@operand=\toks40 -\pgfmath@stack@operation=\toks41 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.basic.code.te -x) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.trigonometric -.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.random.code.t -ex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.comparison.co -de.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.base.code.tex -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.round.code.te -x) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.misc.code.tex -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfunctions.integerarithm -etics.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathcalc.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmathfloat.code.tex -\c@pgfmathroundto@lastzeros=\count410 -)) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfint.code.tex) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorepoints.code.tex -File: pgfcorepoints.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@picminx=\dimen313 -\pgf@picmaxx=\dimen314 -\pgf@picminy=\dimen315 -\pgf@picmaxy=\dimen316 -\pgf@pathminx=\dimen317 -\pgf@pathmaxx=\dimen318 -\pgf@pathminy=\dimen319 -\pgf@pathmaxy=\dimen320 -\pgf@xx=\dimen321 -\pgf@xy=\dimen322 -\pgf@yx=\dimen323 -\pgf@yy=\dimen324 -\pgf@zx=\dimen325 -\pgf@zy=\dimen326 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorepathconstruct.cod -e.tex -File: pgfcorepathconstruct.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@path@lastx=\dimen327 -\pgf@path@lasty=\dimen328 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorepathusage.code.te -x -File: pgfcorepathusage.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@shorten@end@additional=\dimen329 -\pgf@shorten@start@additional=\dimen330 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorescopes.code.tex -File: pgfcorescopes.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfpic=\box97 -\pgf@hbox=\box98 -\pgf@layerbox@main=\box99 -\pgf@picture@serial@count=\count411 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoregraphicstate.code -.tex -File: pgfcoregraphicstate.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgflinewidth=\dimen331 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoretransformations.c -ode.tex -File: pgfcoretransformations.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@pt@x=\dimen332 -\pgf@pt@y=\dimen333 -\pgf@pt@temp=\dimen334 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorequick.code.tex -File: pgfcorequick.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoreobjects.code.tex -File: pgfcoreobjects.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorepathprocessing.co -de.tex -File: pgfcorepathprocessing.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorearrows.code.tex -File: pgfcorearrows.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfarrowsep=\dimen335 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoreshade.code.tex -File: pgfcoreshade.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@max=\dimen336 -\pgf@sys@shading@range@num=\count412 -\pgf@shadingcount=\count413 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoreimage.code.tex -File: pgfcoreimage.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoreexternal.code.tex -File: pgfcoreexternal.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfexternal@startupbox=\box100 -) (d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorelayers.code.tex -File: pgfcorelayers.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcoretransparency.code -.tex -File: pgfcoretransparency.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorepatterns.code.tex -File: pgfcorepatterns.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) (d:/texlive/2025/texmf-dist/tex/generic/pgf/basiclayer/pgfcorerdf.code.tex -File: pgfcorerdf.code.tex 2025-08-29 v3.1.11a (3.1.11a) -))) (d:/texlive/2025/texmf-dist/tex/generic/pgf/modules/pgfmoduleshapes.code.te -x -File: pgfmoduleshapes.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfnodeparttextbox=\box101 -) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/modules/pgfmoduleplot.code.tex -File: pgfmoduleplot.code.tex 2025-08-29 v3.1.11a (3.1.11a) -) -(d:/texlive/2025/texmf-dist/tex/latex/pgf/compatibility/pgfcomp-version-0-65.st -y -Package: pgfcomp-version-0-65 2025-08-29 v3.1.11a (3.1.11a) -\pgf@nodesepstart=\dimen337 -\pgf@nodesepend=\dimen338 -) -(d:/texlive/2025/texmf-dist/tex/latex/pgf/compatibility/pgfcomp-version-1-18.st -y -Package: pgfcomp-version-1-18 2025-08-29 v3.1.11a (3.1.11a) -)) (d:/texlive/2025/texmf-dist/tex/latex/pgf/utilities/pgffor.sty -(d:/texlive/2025/texmf-dist/tex/latex/pgf/utilities/pgfkeys.sty -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgfkeys.code.tex)) -(d:/texlive/2025/texmf-dist/tex/latex/pgf/math/pgfmath.sty -(d:/texlive/2025/texmf-dist/tex/generic/pgf/math/pgfmath.code.tex)) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/utilities/pgffor.code.tex -Package: pgffor 2025-08-29 v3.1.11a (3.1.11a) -\pgffor@iter=\dimen339 -\pgffor@skip=\dimen340 -\pgffor@stack=\toks42 -\pgffor@toks=\toks43 -)) -(d:/texlive/2025/texmf-dist/tex/generic/pgf/frontendlayer/tikz/tikz.code.tex -Package: tikz 2025-08-29 v3.1.11a (3.1.11a) - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/libraries/pgflibraryplothandlers.co -de.tex -File: pgflibraryplothandlers.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgf@plot@mark@count=\count414 -\pgfplotmarksize=\dimen341 -) -\tikz@lastx=\dimen342 -\tikz@lasty=\dimen343 -\tikz@lastxsaved=\dimen344 -\tikz@lastysaved=\dimen345 -\tikz@lastmovetox=\dimen346 -\tikz@lastmovetoy=\dimen347 -\tikzleveldistance=\dimen348 -\tikzsiblingdistance=\dimen349 -\tikz@figbox=\box102 -\tikz@figbox@bg=\box103 -\tikz@tempbox=\box104 -\tikz@tempbox@bg=\box105 -\tikztreelevel=\count415 -\tikznumberofchildren=\count416 -\tikznumberofcurrentchild=\count417 -\tikz@fig@count=\count418 - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/modules/pgfmodulematrix.code.tex -File: pgfmodulematrix.code.tex 2025-08-29 v3.1.11a (3.1.11a) -\pgfmatrixcurrentrow=\count419 -\pgfmatrixcurrentcolumn=\count420 -\pgf@matrix@numberofcolumns=\count421 -) -\tikz@expandcount=\count422 - -(d:/texlive/2025/texmf-dist/tex/generic/pgf/frontendlayer/tikz/libraries/tikzli -brarytopaths.code.tex -File: tikzlibrarytopaths.code.tex 2025-08-29 v3.1.11a (3.1.11a) -))) -luaotfload | cache : Lookup cache loaded from D:/texlive/2025/texmf-var/luatex-c -ache/generic/names/luaotfload-lookup-cache.luc. - -Package fontspec Info: -(fontspec) Font family 'CharisSIL(0)' created for font 'Charis -(fontspec) SIL' with options [BoldFont={Charis SIL -(fontspec) Bold},ItalicFont={Charis SIL -(fontspec) Italic},BoldItalicFont={Charis SIL Bold Italic}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <->"name:Charis -(fontspec) SIL:mode=node;script=latn;language=dflt;" -(fontspec) - 'small caps' (m/sc) with NFSS spec.: <->"name:Charis -(fontspec) SIL:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'bold' (b/n) with NFSS spec.: <->"name:Charis SIL -(fontspec) Bold:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold small caps' (b/sc) with NFSS spec.: -(fontspec) <->"name:Charis SIL -(fontspec) Bold:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'italic' (m/it) with NFSS spec.: <->"name:Charis SIL -(fontspec) Italic:mode=node;script=latn;language=dflt;" -(fontspec) - 'italic small caps' (m/scit) with NFSS spec.: -(fontspec) <->"name:Charis SIL -(fontspec) Italic:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'bold italic' (b/it) with NFSS spec.: <->"name:Charis -(fontspec) SIL Bold Italic:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold italic small caps' (b/scit) with NFSS spec.: -(fontspec) <->"name:Charis SIL Bold -(fontspec) Italic:mode=node;script=latn;language=dflt;+smcp;" - - -Package fontspec Info: -(fontspec) Font family 'Calibri(0)' created for font 'Calibri' -(fontspec) with options [BoldFont={Calibri -(fontspec) Bold},ItalicFont={Calibri -(fontspec) Italic},BoldItalicFont={Calibri Bold Italic}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: -(fontspec) <->"name:Calibri:mode=node;script=latn;language=dflt;" -(fontspec) - 'small caps' (m/sc) with NFSS spec.: -(fontspec) <->"name:Calibri:mode=node;script=latn;language=dflt;+sm -cp;" -(fontspec) - 'bold' (b/n) with NFSS spec.: <->"name:Calibri -(fontspec) Bold:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold small caps' (b/sc) with NFSS spec.: -(fontspec) <->"name:Calibri -(fontspec) Bold:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'italic' (m/it) with NFSS spec.: <->"name:Calibri -(fontspec) Italic:mode=node;script=latn;language=dflt;" -(fontspec) - 'italic small caps' (m/scit) with NFSS spec.: -(fontspec) <->"name:Calibri -(fontspec) Italic:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'bold italic' (b/it) with NFSS spec.: -(fontspec) <->"name:Calibri Bold -(fontspec) Italic:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold italic small caps' (b/scit) with NFSS spec.: -(fontspec) <->"name:Calibri Bold -(fontspec) Italic:mode=node;script=latn;language=dflt;+smcp;" - - -(d:/texlive/2025/texmf-dist/tex/latex/sansmath/sansmath.sty -Package: sansmath 2007/02/28 ver 1.1 Donald Arseneau -\c@mv@sans=\count423 -LaTeX Font Info: Overwriting math alphabet `\mathrm' in version `sans' -(Font) OT1/cmr/m/n --> OT1/lmss/m/n on input line 103. -LaTeX Font Info: Overwriting math alphabet `\mathsfsl' in version `sans' -(Font) OT1/lmss/m/sl --> OT1/lmss/m/sl on input line 104. -LaTeX Font Info: Overwriting symbol font `operators' in version `sans' -(Font) OT1/cmr/m/n --> OT1/lmss/m/n on input line 105. -LaTeX Font Info: Overwriting symbol font `letters' in version `sans' -(Font) OML/cmm/m/it --> OML/cmm/m/it on input line 109. -LaTeX Font Info: Overwriting symbol font `symbols' in version `sans' -(Font) OMS/cmsy/m/n --> OMS/cmsy/m/n on input line 110. -LaTeX Font Info: Overwriting math alphabet `\mathsfbf' in version `sans' -(Font) OT1/lmss/bx/sl --> OT1/lmss/bx/n on input line 112. -) -(d:/texlive/2025/texmf-dist/tex/latex/mathastext/mathastext.sty -Package: mathastext 2024/10/26 v1.4e Use the text font in math mode (JFB) - -Package mathastext Info: Starting the math mode configuration. -\mst@exists@muskip=\muskip18 -\mst@forall@muskip=\muskip19 -\mst@prime@muskip=\muskip20 -\mst@do@nonletters=\toks44 -\mst@undo@nonletters=\toks45 -\mst@do@easynonletters=\toks46 -\mst@undo@easynonletters=\toks47 -\symmtoperatorfont=\mathgroup4 -\symmtletterfont=\mathgroup5 -( mathastext: ) will use Euler font; command \MTEulerScale -\symmteulervm=\mathgroup6 -( mathastext: ) ! and ? -( mathastext: ) punctuation: , . : ; and \colon -LaTeX Info: Redefining \relbar on input line 1197. -LaTeX Info: Redefining \rightarrowfill on input line 1198. -LaTeX Info: Redefining \leftarrowfill on input line 1201. -( mathastext: ) + and = -LaTeX Info: Redefining \Relbar on input line 1344. -( mathastext: ) adding = ; and + to \nfss@catcodes -( mathastext: ) parentheses ( ) [ ] and slash / -( mathastext: ) alldelims: < > \backslash \setminus | \vert \mid \{ \} -LaTeX Font Info: Redeclaring math symbol \setminus on input line 1410. -LaTeX Info: Redefining \models on input line 1429. -( mathastext: ) \# \mathdollar \% \& -( mathastext: ) \imath and \jmath -LaTeX Font Info: Overwriting math alphabet `\Mathnormalbold' in version `nor -mal' -(Font) TU/lmr/b/it --> TU/lmr/b/it on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathnormalbold' in version `bol -d' -(Font) TU/lmr/b/it --> TU/lmr/b/it on input line 2934. -LaTeX Font Info: Overwriting symbol font `mtletterfont' in version `normal' -(Font) TU/lmr/m/it --> TU/lmr/m/it on input line 2934. -LaTeX Font Info: Overwriting symbol font `mtletterfont' in version `bold' -(Font) TU/lmr/m/it --> TU/lmr/b/it on input line 2934. -LaTeX Font Info: Overwriting symbol font `mtoperatorfont' in version `normal -' -(Font) TU/lmr/m/n --> TU/lmr/m/n on input line 2934. -LaTeX Font Info: Overwriting symbol font `mtoperatorfont' in version `bold' -(Font) TU/lmr/m/n --> TU/lmr/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathbf' in version `normal' -(Font) TU/lmr/b/n --> TU/lmr/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathbf' in version `bold' -(Font) TU/lmr/b/n --> TU/lmr/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathit' in version `normal' -(Font) TU/lmr/m/it --> TU/lmr/m/it on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathit' in version `bold' -(Font) TU/lmr/m/it --> TU/lmr/b/it on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathsf' in version `normal' -(Font) TU/lmss/m/n --> TU/lmss/m/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathsf' in version `bold' -(Font) TU/lmss/m/n --> TU/lmss/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathtt' in version `normal' -(Font) TU/lmtt/m/n --> TU/lmtt/m/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\Mathtt' in version `bold' -(Font) TU/lmtt/m/n --> TU/lmtt/b/n on input line 2934. -LaTeX Font Info: Overwriting symbol font `mteulervm' in version `bold' -(Font) U/zeur/m/n --> U/zeur/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\MathEulerBold' in version `norm -al' -(Font) U/zeur/b/n --> U/zeur/b/n on input line 2934. -LaTeX Font Info: Overwriting math alphabet `\MathEulerBold' in version `bold -' -(Font) U/zeur/b/n --> U/zeur/b/n on input line 2934. -( mathastext: ) Latin letters in the `normal', resp. `bold', -( mathastext: ) math versions are now set up to use the fonts -( mathastext: ) TU/lmr/m/it, resp. TU/lmr/b/it. -( mathastext: ) Other characters (digits, ...) and \log-like names will be -( mathastext: ) typeset with the n shape. -( mathastext: ) \hbar -( mathastext: ) minus either as endash, Unicode minus, emdash or hyphen -( mathastext: ) The italic option is in effect. -( mathastext: ) Greek letters will use the Euler font. -( mathastext: ) Use \MathastextEulerScale{} to scale the font. -( mathastext: ) \HUGE has been (re)-defined. -( mathastext: ) mathastext has declared larger sizes for subscripts. -( mathastext: ) To keep LaTeX defaults, use option `defaultmathsizes'. - -Package mathastext Info: Loading is complete. You can now use \Mathastext to -(mathastext) modify the normal and bold math versions. Use it -(mathastext) with optional argument or use \MTDeclareVersion to -(mathastext) declare additional math versions. -) -(d:/texlive/2025/texmf-dist/tex/latex/unicode-math/unicode-math.sty -Package: unicode-math 2023/08/13 v0.8r Unicode maths in XeLaTeX and LuaLaTeX - -(d:/texlive/2025/texmf-dist/tex/latex/unicode-math/unicode-math-luatex.sty -Package: unicode-math-luatex 2023/08/13 v0.8r Unicode maths in XeLaTeX and LuaL -aTeX - -(d:/texlive/2025/texmf-dist/tex/latex/l3packages/l3keys2e/l3keys2e.sty -Package: l3keys2e 2025-10-09 LaTeX2e option processing using LaTeX3 keys -) -(d:/texlive/2025/texmf-dist/tex/latex/base/fix-cm.sty -Package: fix-cm 2020/11/24 v1.1t fixes to LaTeX - -(d:/texlive/2025/texmf-dist/tex/latex/base/ts1enc.def -File: ts1enc.def 2001/06/05 v3.0e (jk/car/fm) Standard LaTeX file -LaTeX Font Info: Redeclaring font encoding TS1 on input line 47. -LaTeX Encoding Info: Redeclaring text command \capitalcedilla (encoding TS1) - on input line 49. -LaTeX Encoding Info: Redeclaring text command \capitalogonek (encoding TS1) -on input line 52. -LaTeX Encoding Info: Redeclaring text command \capitalgrave (encoding TS1) o -n input line 55. -LaTeX Encoding Info: Redeclaring text command \capitalacute (encoding TS1) o -n input line 56. -LaTeX Encoding Info: Redeclaring text command \capitalcircumflex (encoding T -S1) on input line 57. -LaTeX Encoding Info: Redeclaring text command \capitaltilde (encoding TS1) o -n input line 58. -LaTeX Encoding Info: Redeclaring text command \capitaldieresis (encoding TS1 -) on input line 59. -LaTeX Encoding Info: Redeclaring text command \capitalhungarumlaut (encoding - TS1) on input line 60. -LaTeX Encoding Info: Redeclaring text command \capitalring (encoding TS1) on - input line 61. -LaTeX Encoding Info: Redeclaring text command \capitalcaron (encoding TS1) o -n input line 62. -LaTeX Encoding Info: Redeclaring text command \capitalbreve (encoding TS1) o -n input line 63. -LaTeX Encoding Info: Redeclaring text command \capitalmacron (encoding TS1) -on input line 64. -LaTeX Encoding Info: Redeclaring text command \capitaldotaccent (encoding TS -1) on input line 65. -LaTeX Encoding Info: Redeclaring text command \t (encoding TS1) on input lin -e 66. -LaTeX Encoding Info: Redeclaring text command \capitaltie (encoding TS1) on -input line 67. -LaTeX Encoding Info: Redeclaring text command \newtie (encoding TS1) on inpu -t line 68. -LaTeX Encoding Info: Redeclaring text command \capitalnewtie (encoding TS1) -on input line 69. -LaTeX Encoding Info: Redeclaring text symbol \textcapitalcompwordmark (encod -ing TS1) on input line 70. -LaTeX Encoding Info: Redeclaring text symbol \textascendercompwordmark (enco -ding TS1) on input line 71. -LaTeX Encoding Info: Redeclaring text symbol \textquotestraightbase (encodin -g TS1) on input line 72. -LaTeX Encoding Info: Redeclaring text symbol \textquotestraightdblbase (enco -ding TS1) on input line 73. -LaTeX Encoding Info: Redeclaring text symbol \texttwelveudash (encoding TS1) - on input line 74. -LaTeX Encoding Info: Redeclaring text symbol \textthreequartersemdash (encod -ing TS1) on input line 75. -LaTeX Encoding Info: Redeclaring text symbol \textleftarrow (encoding TS1) o -n input line 76. -LaTeX Encoding Info: Redeclaring text symbol \textrightarrow (encoding TS1) -on input line 77. -LaTeX Encoding Info: Redeclaring text symbol \textblank (encoding TS1) on in -put line 78. -LaTeX Encoding Info: Redeclaring text symbol \textdollar (encoding TS1) on i -nput line 79. -LaTeX Encoding Info: Redeclaring text symbol \textquotesingle (encoding TS1) - on input line 80. -LaTeX Encoding Info: Redeclaring text command \textasteriskcentered (encodin -g TS1) on input line 81. -LaTeX Encoding Info: Redeclaring text symbol \textdblhyphen (encoding TS1) o -n input line 92. -LaTeX Encoding Info: Redeclaring text symbol \textfractionsolidus (encoding -TS1) on input line 93. -LaTeX Encoding Info: Redeclaring text symbol \textzerooldstyle (encoding TS1 -) on input line 94. -LaTeX Encoding Info: Redeclaring text symbol \textoneoldstyle (encoding TS1) - on input line 95. -LaTeX Encoding Info: Redeclaring text symbol \texttwooldstyle (encoding TS1) - on input line 96. -LaTeX Encoding Info: Redeclaring text symbol \textthreeoldstyle (encoding TS -1) on input line 97. -LaTeX Encoding Info: Redeclaring text symbol \textfouroldstyle (encoding TS1 -) on input line 98. -LaTeX Encoding Info: Redeclaring text symbol \textfiveoldstyle (encoding TS1 -) on input line 99. -LaTeX Encoding Info: Redeclaring text symbol \textsixoldstyle (encoding TS1) - on input line 100. -LaTeX Encoding Info: Redeclaring text symbol \textsevenoldstyle (encoding TS -1) on input line 101. -LaTeX Encoding Info: Redeclaring text symbol \texteightoldstyle (encoding TS -1) on input line 102. -LaTeX Encoding Info: Redeclaring text symbol \textnineoldstyle (encoding TS1 -) on input line 103. -LaTeX Encoding Info: Redeclaring text symbol \textlangle (encoding TS1) on i -nput line 104. -LaTeX Encoding Info: Redeclaring text symbol \textminus (encoding TS1) on in -put line 105. -LaTeX Encoding Info: Redeclaring text symbol \textrangle (encoding TS1) on i -nput line 106. -LaTeX Encoding Info: Redeclaring text symbol \textmho (encoding TS1) on inpu -t line 107. -LaTeX Encoding Info: Redeclaring text symbol \textbigcircle (encoding TS1) o -n input line 108. -LaTeX Encoding Info: Redeclaring text command \textcircled (encoding TS1) on - input line 109. -LaTeX Encoding Info: Redeclaring text symbol \textohm (encoding TS1) on inpu -t line 115. -LaTeX Encoding Info: Redeclaring text symbol \textlbrackdbl (encoding TS1) o -n input line 116. -LaTeX Encoding Info: Redeclaring text symbol \textrbrackdbl (encoding TS1) o -n input line 117. -LaTeX Encoding Info: Redeclaring text symbol \textuparrow (encoding TS1) on -input line 118. -LaTeX Encoding Info: Redeclaring text symbol \textdownarrow (encoding TS1) o -n input line 119. -LaTeX Encoding Info: Redeclaring text symbol \textasciigrave (encoding TS1) -on input line 120. -LaTeX Encoding Info: Redeclaring text symbol \textborn (encoding TS1) on inp -ut line 121. -LaTeX Encoding Info: Redeclaring text symbol \textdivorced (encoding TS1) on - input line 122. -LaTeX Encoding Info: Redeclaring text symbol \textdied (encoding TS1) on inp -ut line 123. -LaTeX Encoding Info: Redeclaring text symbol \textleaf (encoding TS1) on inp -ut line 124. -LaTeX Encoding Info: Redeclaring text symbol \textmarried (encoding TS1) on -input line 125. -LaTeX Encoding Info: Redeclaring text symbol \textmusicalnote (encoding TS1) - on input line 126. -LaTeX Encoding Info: Redeclaring text symbol \texttildelow (encoding TS1) on - input line 127. -LaTeX Encoding Info: Redeclaring text symbol \textdblhyphenchar (encoding TS -1) on input line 128. -LaTeX Encoding Info: Redeclaring text symbol \textasciibreve (encoding TS1) -on input line 129. -LaTeX Encoding Info: Redeclaring text symbol \textasciicaron (encoding TS1) -on input line 130. -LaTeX Encoding Info: Redeclaring text symbol \textacutedbl (encoding TS1) on - input line 131. -LaTeX Encoding Info: Redeclaring text symbol \textgravedbl (encoding TS1) on - input line 132. -LaTeX Encoding Info: Redeclaring text symbol \textdagger (encoding TS1) on i -nput line 133. -LaTeX Encoding Info: Redeclaring text symbol \textdaggerdbl (encoding TS1) o -n input line 134. -LaTeX Encoding Info: Redeclaring text symbol \textbardbl (encoding TS1) on i -nput line 135. -LaTeX Encoding Info: Redeclaring text symbol \textperthousand (encoding TS1) - on input line 136. -LaTeX Encoding Info: Redeclaring text symbol \textbullet (encoding TS1) on i -nput line 137. -LaTeX Encoding Info: Redeclaring text symbol \textcelsius (encoding TS1) on -input line 138. -LaTeX Encoding Info: Redeclaring text symbol \textdollaroldstyle (encoding T -S1) on input line 139. -LaTeX Encoding Info: Redeclaring text symbol \textcentoldstyle (encoding TS1 -) on input line 140. -LaTeX Encoding Info: Redeclaring text symbol \textflorin (encoding TS1) on i -nput line 141. -LaTeX Encoding Info: Redeclaring text symbol \textcolonmonetary (encoding TS -1) on input line 142. -LaTeX Encoding Info: Redeclaring text symbol \textwon (encoding TS1) on inpu -t line 143. -LaTeX Encoding Info: Redeclaring text symbol \textnaira (encoding TS1) on in -put line 144. -LaTeX Encoding Info: Redeclaring text symbol \textguarani (encoding TS1) on -input line 145. -LaTeX Encoding Info: Redeclaring text symbol \textpeso (encoding TS1) on inp -ut line 146. -LaTeX Encoding Info: Redeclaring text symbol \textlira (encoding TS1) on inp -ut line 147. -LaTeX Encoding Info: Redeclaring text symbol \textrecipe (encoding TS1) on i -nput line 148. -LaTeX Encoding Info: Redeclaring text symbol \textinterrobang (encoding TS1) - on input line 149. -LaTeX Encoding Info: Redeclaring text symbol \textinterrobangdown (encoding -TS1) on input line 150. -LaTeX Encoding Info: Redeclaring text symbol \textdong (encoding TS1) on inp -ut line 151. -LaTeX Encoding Info: Redeclaring text symbol \texttrademark (encoding TS1) o -n input line 152. -LaTeX Encoding Info: Redeclaring text symbol \textpertenthousand (encoding T -S1) on input line 153. -LaTeX Encoding Info: Redeclaring text symbol \textpilcrow (encoding TS1) on -input line 154. -LaTeX Encoding Info: Redeclaring text symbol \textbaht (encoding TS1) on inp -ut line 155. -LaTeX Encoding Info: Redeclaring text symbol \textnumero (encoding TS1) on i -nput line 156. -LaTeX Encoding Info: Redeclaring text symbol \textdiscount (encoding TS1) on - input line 157. -LaTeX Encoding Info: Redeclaring text symbol \textestimated (encoding TS1) o -n input line 158. -LaTeX Encoding Info: Redeclaring text symbol \textopenbullet (encoding TS1) -on input line 159. -LaTeX Encoding Info: Redeclaring text symbol \textservicemark (encoding TS1) - on input line 160. -LaTeX Encoding Info: Redeclaring text symbol \textlquill (encoding TS1) on i -nput line 161. -LaTeX Encoding Info: Redeclaring text symbol \textrquill (encoding TS1) on i -nput line 162. -LaTeX Encoding Info: Redeclaring text symbol \textcent (encoding TS1) on inp -ut line 163. -LaTeX Encoding Info: Redeclaring text symbol \textsterling (encoding TS1) on - input line 164. -LaTeX Encoding Info: Redeclaring text symbol \textcurrency (encoding TS1) on - input line 165. -LaTeX Encoding Info: Redeclaring text symbol \textyen (encoding TS1) on inpu -t line 166. -LaTeX Encoding Info: Redeclaring text symbol \textbrokenbar (encoding TS1) o -n input line 167. -LaTeX Encoding Info: Redeclaring text symbol \textsection (encoding TS1) on -input line 168. -LaTeX Encoding Info: Redeclaring text symbol \textasciidieresis (encoding TS -1) on input line 169. -LaTeX Encoding Info: Redeclaring text symbol \textcopyright (encoding TS1) o -n input line 170. -LaTeX Encoding Info: Redeclaring text symbol \textordfeminine (encoding TS1) - on input line 171. -LaTeX Encoding Info: Redeclaring text symbol \textcopyleft (encoding TS1) on - input line 172. -LaTeX Encoding Info: Redeclaring text symbol \textlnot (encoding TS1) on inp -ut line 173. -LaTeX Encoding Info: Redeclaring text symbol \textcircledP (encoding TS1) on - input line 174. -LaTeX Encoding Info: Redeclaring text symbol \textregistered (encoding TS1) -on input line 175. -LaTeX Encoding Info: Redeclaring text symbol \textasciimacron (encoding TS1) - on input line 176. -LaTeX Encoding Info: Redeclaring text symbol \textdegree (encoding TS1) on i -nput line 177. -LaTeX Encoding Info: Redeclaring text symbol \textpm (encoding TS1) on input - line 178. -LaTeX Encoding Info: Redeclaring text symbol \texttwosuperior (encoding TS1) - on input line 179. -LaTeX Encoding Info: Redeclaring text symbol \textthreesuperior (encoding TS -1) on input line 180. -LaTeX Encoding Info: Redeclaring text symbol \textasciiacute (encoding TS1) -on input line 181. -LaTeX Encoding Info: Redeclaring text symbol \textmu (encoding TS1) on input - line 182. -LaTeX Encoding Info: Redeclaring text symbol \textparagraph (encoding TS1) o -n input line 183. -LaTeX Encoding Info: Redeclaring text symbol \textperiodcentered (encoding T -S1) on input line 184. -LaTeX Encoding Info: Redeclaring text symbol \textreferencemark (encoding TS -1) on input line 185. -LaTeX Encoding Info: Redeclaring text symbol \textonesuperior (encoding TS1) - on input line 186. -LaTeX Encoding Info: Redeclaring text symbol \textordmasculine (encoding TS1 -) on input line 187. -LaTeX Encoding Info: Redeclaring text symbol \textsurd (encoding TS1) on inp -ut line 188. -LaTeX Encoding Info: Redeclaring text symbol \textonequarter (encoding TS1) -on input line 189. -LaTeX Encoding Info: Redeclaring text symbol \textonehalf (encoding TS1) on -input line 190. -LaTeX Encoding Info: Redeclaring text symbol \textthreequarters (encoding TS -1) on input line 191. -LaTeX Encoding Info: Redeclaring text symbol \texteuro (encoding TS1) on inp -ut line 192. -LaTeX Encoding Info: Redeclaring text symbol \texttimes (encoding TS1) on in -put line 193. -LaTeX Encoding Info: Redeclaring text symbol \textdiv (encoding TS1) on inpu -t line 194. -)) -(d:/texlive/2025/texmf-dist/tex/latex/amsmath/amsmath.sty -Package: amsmath 2025/07/09 v2.17z AMS math features -\@mathmargin=\skip161 - -For additional information on amsmath, use the `?' option. -(d:/texlive/2025/texmf-dist/tex/latex/amsmath/amstext.sty -Package: amstext 2024/11/17 v2.01 AMS text - -(d:/texlive/2025/texmf-dist/tex/latex/amsmath/amsgen.sty -File: amsgen.sty 1999/11/30 v2.0 generic functions -\@emptytoks=\toks48 -\ex@=\dimen350 -)) -(d:/texlive/2025/texmf-dist/tex/latex/amsmath/amsbsy.sty -Package: amsbsy 1999/11/29 v1.2d Bold Symbols -\pmbraise@=\dimen351 -) -(d:/texlive/2025/texmf-dist/tex/latex/amsmath/amsopn.sty -Package: amsopn 2022/04/08 v2.04 operator names -) -\inf@bad=\count424 -LaTeX Info: Redefining \frac on input line 235. -\uproot@=\count425 -\leftroot@=\count426 -LaTeX Info: Redefining \overline on input line 398. -LaTeX Info: Redefining \colon on input line 409. -\classnum@=\count427 -\DOTSCASE@=\count428 -LaTeX Info: Redefining \ldots on input line 495. -LaTeX Info: Redefining \dots on input line 498. -LaTeX Info: Redefining \cdots on input line 619. -\Mathstrutbox@=\box106 -\strutbox@=\box107 -LaTeX Info: Redefining \big on input line 721. -LaTeX Info: Redefining \Big on input line 722. -LaTeX Info: Redefining \bigg on input line 723. -LaTeX Info: Redefining \Bigg on input line 724. -\big@size=\dimen352 -LaTeX Font Info: Redeclaring font encoding OML on input line 742. -LaTeX Font Info: Redeclaring font encoding OMS on input line 743. -\macc@depth=\count429 -LaTeX Info: Redefining \bmod on input line 904. -LaTeX Info: Redefining \pmod on input line 909. -LaTeX Info: Redefining \smash on input line 939. -LaTeX Info: Redefining \relbar on input line 969. -LaTeX Info: Redefining \Relbar on input line 970. -\c@MaxMatrixCols=\count430 -\dotsspace@=\muskip21 -\c@parentequation=\count431 -\dspbrk@lvl=\count432 -\tag@help=\toks49 -\row@=\count433 -\column@=\count434 -\maxfields@=\count435 -\andhelp@=\toks50 -\eqnshift@=\dimen353 -\alignsep@=\dimen354 -\tagshift@=\dimen355 -\tagwidth@=\dimen356 -\totwidth@=\dimen357 -\lineht@=\dimen358 -\@envbody=\toks51 -\multlinegap=\skip162 -\multlinetaggap=\skip163 -\mathdisplay@stack=\toks52 -LaTeX Info: Redefining \[ on input line 2950. -LaTeX Info: Redefining \] on input line 2951. -) -(d:/texlive/2025/texmf-dist/tex/lualatex/lualatex-math/lualatex-math.sty -Package: lualatex-math 2022/01/01 v1.12 Patches for mathematics typesetting wit -h LuaLaTeX -Lua module: lualatex-math 2013/08/03 v1.3 Patches for mathematics typesetting wi -th LuaLaTeX) -\g__um_fam_int=\count436 -\g__um_fonts_used_int=\count437 -\l__um_primecount_int=\count438 -\g__um_primekern_muskip=\muskip22 - -(d:/texlive/2025/texmf-dist/tex/latex/unicode-math/unicode-math-table.tex))) - -Package fontspec Info: -(fontspec) Could not resolve font "Latin Modern Math/B" (it -(fontspec) probably doesn't exist). - - -Package fontspec Info: -(fontspec) Font family 'LatinModernMath(0)' created for font -(fontspec) 'Latin Modern Math' with options -(fontspec) [Renderer=Basic,BoldItalicFont={},ItalicFont={},SmallCap -sFont={},Script=Math,RawFeature={mathfontdimen=xetex}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <->"name:Latin Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;" - - -Package fontspec Info: -(fontspec) Could not resolve font "Latin Modern Math/B" (it -(fontspec) probably doesn't exist). - - -Package fontspec Info: -(fontspec) Font family 'LatinModernMath(1)' created for font -(fontspec) 'Latin Modern Math' with options -(fontspec) [Renderer=Basic,BoldItalicFont={},ItalicFont={},SmallCap -sFont={},Script=Math,SizeFeatures={{Size=6.8-},{Size=4.8-6.8,Font=Latin -(fontspec) Modern Math,Style=MathScript},{Size=-4.8,Font=Latin -(fontspec) Modern -(fontspec) Math,Style=MathScriptScript}},RawFeature={mathfontdimen= -xetex}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <6.8->"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;"<4.8-6.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;+ssty=0;"<-4.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;+ssty=1;" - -LaTeX Font Info: Encoding `OT1' has changed to `TU' for symbol font -(Font) `operators' in the math version `normal' on input line 1655 -. -LaTeX Font Info: Overwriting symbol font `operators' in version `normal' -(Font) OT1/cmr/m/n --> TU/LatinModernMath(1)/m/n on input line - 1655. -LaTeX Font Info: Encoding `OT1' has changed to `TU' for symbol font -(Font) `operators' in the math version `bold' on input line 1655. -LaTeX Font Info: Overwriting symbol font `operators' in version `bold' -(Font) OT1/cmr/bx/n --> TU/LatinModernMath(1)/b/n on input lin -e 1655. - -Package fontspec Info: -(fontspec) Could not resolve font "Latin Modern Math/B" (it -(fontspec) probably doesn't exist). - - -Package fontspec Info: -(fontspec) Font family 'LatinModernMath(2)' created for font -(fontspec) 'Latin Modern Math' with options -(fontspec) [Renderer=Basic,BoldItalicFont={},ItalicFont={},SmallCap -sFont={},Script=Math,SizeFeatures={{Size=6.8-},{Size=4.8-6.8,Font=Latin -(fontspec) Modern Math,Style=MathScript},{Size=-4.8,Font=Latin -(fontspec) Modern -(fontspec) Math,Style=MathScriptScript}},RawFeature={mathfontdimen= -xetex},RawFeature={mathfontdimen=tex2}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <6.8->"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex2;"<4.8-6.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex2;+ssty=0;"<-4.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex2;+ssty=1;" - -LaTeX Font Info: Encoding `OMS' has changed to `TU' for symbol font -(Font) `symbols' in the math version `normal' on input line 1655. -LaTeX Font Info: Overwriting symbol font `symbols' in version `normal' -(Font) OMS/cmsy/m/n --> TU/LatinModernMath(2)/m/n on input lin -e 1655. -LaTeX Font Info: Encoding `OMS' has changed to `TU' for symbol font -(Font) `symbols' in the math version `bold' on input line 1655. -LaTeX Font Info: Overwriting symbol font `symbols' in version `bold' -(Font) OMS/cmsy/b/n --> TU/LatinModernMath(2)/b/n on input lin -e 1655. - -Package fontspec Info: -(fontspec) Could not resolve font "Latin Modern Math/B" (it -(fontspec) probably doesn't exist). - - -Package fontspec Info: -(fontspec) Font family 'LatinModernMath(3)' created for font -(fontspec) 'Latin Modern Math' with options -(fontspec) [Renderer=Basic,BoldItalicFont={},ItalicFont={},SmallCap -sFont={},Script=Math,SizeFeatures={{Size=6.8-},{Size=4.8-6.8,Font=Latin -(fontspec) Modern Math,Style=MathScript},{Size=-4.8,Font=Latin -(fontspec) Modern -(fontspec) Math,Style=MathScriptScript}},RawFeature={mathfontdimen= -xetex},RawFeature={mathfontdimen=tex3}]. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <6.8->"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex3;"<4.8-6.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex3;+ssty=0;"<-4.8>"name:Latin -(fontspec) Modern -(fontspec) Math:mode=base;script=math;language=dflt;mathfontdimen=x -etex;mathfontdimen=tex3;+ssty=1;" - -LaTeX Font Info: Encoding `OMX' has changed to `TU' for symbol font -(Font) `largesymbols' in the math version `normal' on input line 1 -655. -LaTeX Font Info: Overwriting symbol font `largesymbols' in version `normal' -(Font) OMX/cmex/m/n --> TU/LatinModernMath(3)/m/n on input lin -e 1655. -LaTeX Font Info: Encoding `OMX' has changed to `TU' for symbol font -(Font) `largesymbols' in the math version `bold' on input line 165 -5. -LaTeX Font Info: Overwriting symbol font `largesymbols' in version `bold' -(Font) OMX/cmex/m/n --> TU/LatinModernMath(3)/b/n on input lin -e 1655. -LaTeX Font Info: Trying to load font information for U+zeur on input line 16 -55. - -(d:/texlive/2025/texmf-dist/tex/latex/eulervm/uzeur.fd -File: uzeur.fd 2005/01/11 v4.0 (WaS) -) -(d:/texlive/2025/texmf-dist/tex/latex/xpatch/xpatch.sty -Package: xpatch 2020/03/25 v0.3a Extending etoolbox patching commands -) -(d:/texlive/2025/texmf-dist/tex/generic/xstring/xstring.sty -(d:/texlive/2025/texmf-dist/tex/generic/xstring/xstring.tex -\xs_counta=\count439 -\xs_countb=\count440 -) -Package: xstring 2023/08/22 v1.86 String manipulations (CT) -) -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/biblatex.sty -Package: biblatex 2025/07/10 v3.21 programmable bibliographies (PK/MW) - -(d:/texlive/2025/texmf-dist/tex/latex/logreq/logreq.sty -Package: logreq 2010/08/04 v1.0 xml request logger -\lrq@indent=\count441 - -(d:/texlive/2025/texmf-dist/tex/latex/logreq/logreq.def -File: logreq.def 2010/08/04 v1.0 logreq spec v1.0 -)) -\c@tabx@nest=\count442 -\c@listtotal=\count443 -\c@listcount=\count444 -\c@liststart=\count445 -\c@liststop=\count446 -\c@citecount=\count447 -\c@citetotal=\count448 -\c@multicitecount=\count449 -\c@multicitetotal=\count450 -\c@instcount=\count451 -\c@maxnames=\count452 -\c@minnames=\count453 -\c@maxitems=\count454 -\c@minitems=\count455 -\c@citecounter=\count456 -\c@maxcitecounter=\count457 -\c@savedcitecounter=\count458 -\c@uniquelist=\count459 -\c@uniquename=\count460 -\c@refsection=\count461 -\c@refsegment=\count462 -\c@maxextratitle=\count463 -\c@maxextratitleyear=\count464 -\c@maxextraname=\count465 -\c@maxextradate=\count466 -\c@maxextraalpha=\count467 -\c@abbrvpenalty=\count468 -\c@highnamepenalty=\count469 -\c@lownamepenalty=\count470 -\c@maxparens=\count471 -\c@parenlevel=\count472 -\blx@tempcnta=\count473 -\blx@tempcntb=\count474 -\blx@tempcntc=\count475 -\c@blx@maxsection=\count476 -\blx@maxsegment@0=\count477 -\blx@notetype=\count478 -\blx@parenlevel@text=\count479 -\blx@parenlevel@foot=\count480 -\blx@sectionciteorder@0=\count481 -\blx@sectionciteorderinternal@0=\count482 -\blx@entrysetcounter=\count483 -\blx@biblioinstance=\count484 -\labelnumberwidth=\skip164 -\labelalphawidth=\skip165 -\biblabelsep=\skip166 -\bibitemsep=\skip167 -\bibnamesep=\skip168 -\bibinitsep=\skip169 -\bibparsep=\skip170 -\bibhang=\skip171 -\blx@bcfin=\read3 -\blx@bcfout=\write5 -\blx@langwohyphens=\language3 -\c@mincomprange=\count485 -\c@maxcomprange=\count486 -\c@mincompwidth=\count487 -Package biblatex Info: Trying to load biblatex default data model... -Package biblatex Info: ... file 'blx-dm.def' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/blx-dm.def -File: blx-dm.def 2025/07/10 v3.21 biblatex datamodel (PK/MW) -) -Package biblatex Info: Trying to load biblatex style data model... -Package biblatex Info: ... file 'numeric.dbx' not found. -Package biblatex Info: Trying to load biblatex custom data model... -Package biblatex Info: ... file 'biblatex-dm.cfg' not found. -\c@afterword=\count488 -\c@savedafterword=\count489 -\c@annotator=\count490 -\c@savedannotator=\count491 -\c@author=\count492 -\c@savedauthor=\count493 -\c@bookauthor=\count494 -\c@savedbookauthor=\count495 -\c@commentator=\count496 -\c@savedcommentator=\count497 -\c@editor=\count498 -\c@savededitor=\count499 -\c@editora=\count500 -\c@savededitora=\count501 -\c@editorb=\count502 -\c@savededitorb=\count503 -\c@editorc=\count504 -\c@savededitorc=\count505 -\c@foreword=\count506 -\c@savedforeword=\count507 -\c@holder=\count508 -\c@savedholder=\count509 -\c@introduction=\count510 -\c@savedintroduction=\count511 -\c@namea=\count512 -\c@savednamea=\count513 -\c@nameb=\count514 -\c@savednameb=\count515 -\c@namec=\count516 -\c@savednamec=\count517 -\c@translator=\count518 -\c@savedtranslator=\count519 -\c@shortauthor=\count520 -\c@savedshortauthor=\count521 -\c@shorteditor=\count522 -\c@savedshorteditor=\count523 -\c@labelname=\count524 -\c@savedlabelname=\count525 -\c@institution=\count526 -\c@savedinstitution=\count527 -\c@lista=\count528 -\c@savedlista=\count529 -\c@listb=\count530 -\c@savedlistb=\count531 -\c@listc=\count532 -\c@savedlistc=\count533 -\c@listd=\count534 -\c@savedlistd=\count535 -\c@liste=\count536 -\c@savedliste=\count537 -\c@listf=\count538 -\c@savedlistf=\count539 -\c@location=\count540 -\c@savedlocation=\count541 -\c@organization=\count542 -\c@savedorganization=\count543 -\c@origlocation=\count544 -\c@savedoriglocation=\count545 -\c@origpublisher=\count546 -\c@savedorigpublisher=\count547 -\c@publisher=\count548 -\c@savedpublisher=\count549 -\c@language=\count550 -\c@savedlanguage=\count551 -\c@origlanguage=\count552 -\c@savedoriglanguage=\count553 -\c@pageref=\count554 -\c@savedpageref=\count555 -\shorthandwidth=\skip172 -\shortjournalwidth=\skip173 -\shortserieswidth=\skip174 -\shorttitlewidth=\skip175 -\shortauthorwidth=\skip176 -\shorteditorwidth=\skip177 -\locallabelnumberwidth=\skip178 -\locallabelalphawidth=\skip179 -\localshorthandwidth=\skip180 -\localshortjournalwidth=\skip181 -\localshortserieswidth=\skip182 -\localshorttitlewidth=\skip183 -\localshortauthorwidth=\skip184 -\localshorteditorwidth=\skip185 -Package biblatex Info: Trying to load enhanced support for Unicode engines... -Package biblatex Info: ... file 'blx-unicode.def' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/blx-unicode.def) -Package biblatex Info: Trying to load compatibility code... -Package biblatex Info: ... file 'blx-compat.def' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/blx-compat.def -File: blx-compat.def 2025/07/10 v3.21 biblatex compatibility (PK/MW) -) -Package biblatex Info: Trying to load generic definitions... -Package biblatex Info: ... file 'biblatex.def' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/biblatex.def -File: biblatex.def 2025/07/10 v3.21 biblatex compatibility (PK/MW) -\c@textcitecount=\count556 -\c@textcitetotal=\count557 -\c@textcitemaxnames=\count558 -\c@biburlbigbreakpenalty=\count559 -\c@biburlbreakpenalty=\count560 -\c@biburlnumpenalty=\count561 -\c@biburlucpenalty=\count562 -\c@biburllcpenalty=\count563 -\biburlbigskip=\muskip23 -\biburlnumskip=\muskip24 -\biburlucskip=\muskip25 -\biburllcskip=\muskip26 -\c@smartand=\count564 -) -Package biblatex Info: Trying to load natbib compatibility... -Package biblatex Info: ... file 'blx-natbib.def' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/blx-natbib.def -File: blx-natbib.def 2025/07/10 v3.21 biblatex compatibility (PK/MW) -Package biblatex Info: Delimiter 'nameyeardelim' in context '' already defined, - overwriting. -) -Package biblatex Info: Trying to load bibliography style 'numeric'... -Package biblatex Info: ... file 'numeric.bbx' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/bbx/numeric.bbx -File: numeric.bbx 2025/07/10 v3.21 biblatex bibliography style (PK/MW) -Package biblatex Info: Trying to load bibliography style 'standard'... -Package biblatex Info: ... file 'standard.bbx' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/bbx/standard.bbx -File: standard.bbx 2025/07/10 v3.21 biblatex bibliography style (PK/MW) -\c@bbx:relatedcount=\count565 -\c@bbx:relatedtotal=\count566 -)) -Package biblatex Info: Trying to load citation style 'numeric-comp'... -Package biblatex Info: ... file 'numeric-comp.cbx' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/cbx/numeric-comp.cbx -File: numeric-comp.cbx 2025/07/10 v3.21 biblatex citation style (PK/MW) -\c@cbx@tempcnta=\count567 -\c@cbx@tempcntb=\count568 -\c@cbx@tempcntc=\count569 -\c@cbx@tempcntd=\count570 -Package biblatex Info: Redefining '\cite'. -Package biblatex Info: Redefining '\parencite'. -Package biblatex Info: Redefining '\footcite'. -Package biblatex Info: Redefining '\footcitetext'. -Package biblatex Info: Redefining '\smartcite'. -Package biblatex Info: Redefining '\supercite'. -Package biblatex Info: Redefining '\textcite'. -Package biblatex Info: Redefining '\textcites'. -Package biblatex Info: Redefining '\cites'. -Package biblatex Info: Redefining '\parencites'. -Package biblatex Info: Redefining '\smartcites'. -) -Package biblatex Info: Trying to load configuration file... -Package biblatex Info: ... file 'biblatex.cfg' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/biblatex.cfg -File: biblatex.cfg -) -Package biblatex Info: LuaTeX detected. -(biblatex) Assuming input encoding 'utf8'. -Package biblatex Info: Document encoding is UTF8 .... -Package biblatex Info: ... and expl3 -(biblatex) 2025-10-24 L3 programming layer (loader) -(biblatex) is new enough (at least 2020/04/06), -(biblatex) setting 'casechanger=expl3'. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/blx-case-expl3.sty -Package: blx-case-expl3 2025/07/10 v3.21 expl3 case changing code for biblatex -))) -(d:/texlive/2025/texmf-dist/tex/latex/placeins/placeins.sty -Package: placeins 2005/04/18 v 2.2 -) -(d:/texlive/2025/texmf-dist/tex/latex/preprint/balance.sty -Package: balance 1999/02/23 4.3 (PWD) -\oldvsize=\dimen359 -) -(d:/texlive/2025/texmf-dist/tex/latex/microtype/microtype.sty -Package: microtype 2025/07/09 v3.2b Micro-typographical refinements (RS) -\MT@toks=\toks53 -\MT@tempbox=\box108 -\MT@count=\count571 -LaTeX Info: Redefining \noprotrusionifhmode on input line 1087. -LaTeX Info: Redefining \leftprotrusion on input line 1088. -\MT@prot@toks=\toks54 -LaTeX Info: Redefining \rightprotrusion on input line 1107. -LaTeX Info: Redefining \textls on input line 1449. -\MT@outer@kern=\dimen360 -LaTeX Info: Redefining \microtypecontext on input line 2053. -LaTeX Info: Redefining \textmicrotypecontext on input line 2070. -\MT@listname@count=\count572 - -(d:/texlive/2025/texmf-dist/tex/latex/microtype/microtype-luatex.def -File: microtype-luatex.def 2025/07/09 v3.2b Definitions specific to luatex (RS) - -Lua module: microtype 2025/07/09 v3.2b microtype module. -Module microtype Info: overwriting function `keepligature' on input line 63 -LaTeX Info: Redefining \lsstyle on input line 779. -LaTeX Info: Redefining \lslig on input line 779. -\MT@outer@space=\skip186 -) -Package microtype Info: Loading configuration file microtype.cfg. - -(d:/texlive/2025/texmf-dist/tex/latex/microtype/microtype.cfg -File: microtype.cfg 2025/07/09 v3.2b microtype main configuration file (RS) -) -LaTeX Info: Redefining \microtypesetup on input line 3065. -) -(d:/texlive/2025/texmf-dist/tex/latex/booktabs/booktabs.sty -Package: booktabs 2020/01/12 v1.61803398 Publication quality tables -\heavyrulewidth=\dimen361 -\lightrulewidth=\dimen362 -\cmidrulewidth=\dimen363 -\belowrulesep=\dimen364 -\belowbottomsep=\dimen365 -\aboverulesep=\dimen366 -\abovetopsep=\dimen367 -\cmidrulesep=\dimen368 -\cmidrulekern=\dimen369 -\defaultaddspace=\dimen370 -\@cmidla=\count573 -\@cmidlb=\count574 -\@aboverulesep=\dimen371 -\@belowrulesep=\dimen372 -\@thisruleclass=\count575 -\@lastruleclass=\count576 -\@thisrulewidth=\dimen373 -) -\@quotelevel=\count577 -\@quotereset=\count578 - -(./article_3113.aux) -\openout1 = article_3113.aux - -LaTeX Font Info: Checking defaults for OML/cmm/m/it on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for OMS/cmsy/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for OT1/cmr/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for T1/cmr/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for TS1/cmr/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for TU/lmr/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for OMX/cmex/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for U/cmr/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for PD1/pdf/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. -LaTeX Font Info: Checking defaults for PU/pdf/m/n on input line 70. -LaTeX Font Info: ... okay on input line 70. - -*geometry* driver: auto-detecting -*geometry* detected driver: luatex -*geometry* verbose mode - [ preamble ] result: -* driver: luatex -* paper: custom -* layout: -* layoutoffset:(h,v)=(0.0pt,0.0pt) -* modes: twoside -* h-part:(L,W,R)=(54.34486pt, 488.81815pt, 54.34486pt) -* v-part:(T,H,B)=(72.2698pt, 700.50723pt, 72.2698pt) -* \paperwidth=597.50787pt -* \paperheight=845.04684pt -* \textwidth=488.81815pt -* \textheight=700.50723pt -* \oddsidemargin=-17.92513pt -* \evensidemargin=-17.92513pt -* \topmargin=-40.45293pt -* \headheight=12.0pt -* \headsep=28.45274pt -* \topskip=10.0pt -* \footskip=30.0pt -* \marginparwidth=111.0pt -* \marginparsep=11.0pt -* \columnsep=12.0pt -* \skip\footins=13.0pt plus 6.0pt minus 2.0pt -* \hoffset=0.0pt -* \voffset=0.0pt -* \mag=1000 -* \@twocolumnfalse -* \@twosidetrue -* \@mparswitchtrue -* \@reversemarginfalse -* (1in=72.27pt=25.4mm, 1cm=28.453pt) - -(d:/texlive/2025/texmf-dist/tex/context/base/mkii/supp-pdf.mkii -[Loading MPS to PDF converter (version 2006.09.02).] -\scratchcounter=\count579 -\scratchdimen=\dimen374 -\scratchbox=\box109 -\nofMPsegments=\count580 -\nofMParguments=\count581 -\everyMPshowfont=\toks55 -\MPscratchCnt=\count582 -\MPscratchDim=\dimen375 -\MPnumerator=\count583 -\makeMPintoPDFobject=\count584 -\everyMPtoPDFconversion=\toks56 -) (d:/texlive/2025/texmf-dist/tex/latex/epstopdf-pkg/epstopdf-base.sty -Package: epstopdf-base 2020-01-24 v2.11 Base part for package epstopdf -Package epstopdf-base Info: Redefining graphics rule for `.eps' on input line 4 -85. - -(d:/texlive/2025/texmf-dist/tex/latex/latexconfig/epstopdf-sys.cfg -File: epstopdf-sys.cfg 2010/07/13 v1.3 Configuration of (r)epstopdf for TeX Liv -e -)) -Package caption Info: Begin \AtBeginDocument code. -Package caption Info: float package is loaded. -Package caption Info: floatrow package is loaded. -Package caption Info: floatrow package is loaded. -Package caption Info: hyperref package is loaded. -Package caption Info: threeparttable package is loaded. -Package caption Info: End \AtBeginDocument code. -Package hyperref Info: Link coloring OFF on input line 70. - -(./article_3113.out) (./article_3113.out) -\@outlinefile=\write6 - -\openout6 = article_3113.out -LaTeX Font Info: Overwriting math alphabet `\mathrm' in version `normal' -(Font) OT1/cmr/m/n --> TU/lmr/m/n on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathit' in version `normal' -(Font) OT1/cmr/m/it --> TU/lmr/m/it on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathbf' in version `normal' -(Font) OT1/cmr/bx/n --> TU/lmr/bx/n on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathsf' in version `normal' -(Font) OT1/cmss/m/n --> TU/lmss/m/n on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathsf' in version `bold' -(Font) OT1/cmss/bx/n --> TU/lmss/bx/n on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathtt' in version `normal' -(Font) OT1/cmtt/m/n --> TU/lmtt/m/n on input line 70. -LaTeX Font Info: Overwriting math alphabet `\mathtt' in version `bold' -(Font) OT1/cmtt/m/n --> TU/lmtt/bx/n on input line 70. -Package biblatex Info: Trying to load language 'english'... -Package biblatex Info: ... file 'english.lbx' found. - -(d:/texlive/2025/texmf-dist/tex/latex/biblatex/lbx/english.lbx -File: english.lbx 2025/07/10 v3.21 biblatex localization (PK/MW) -) -Package biblatex Info: LuaTeX detected. -(biblatex) Assuming input encoding 'utf8'. -Package biblatex Info: Automatic encoding selection. -(biblatex) Assuming data encoding 'utf8'. - -\openout5 = article_3113.bcf -Package biblatex Info: Trying to load bibliographic data... -Package biblatex Info: ... file 'article_3113.bbl' found. - -(./article_3113.bbl) -Package biblatex Info: Reference section=0 on input line 70. -Package biblatex Info: Reference segment=0 on input line 70. -LaTeX Info: Redefining \microtypecontext on input line 70. -LaTeX Info: Redefining \microtypesetup on input line 70. -Package microtype Info: Generating PDF output. -Package microtype Info: Character protrusion enabled (level 2). -Package microtype Info: Using default protrusion set `alltext'. -Package microtype Info: Automatic font expansion enabled (level 2), -(microtype) stretch: 20, shrink: 20, step: 1, non-selected. -Package microtype Info: Using default expansion set `alltext-nott'. -Package microtype Info: Patching command `\showhyphens'. -Package microtype Info: No adjustment of tracking. -Package microtype Info: No adjustment of spacing. -Package microtype Info: No adjustment of kerning. - -(d:/texlive/2025/texmf-dist/tex/latex/microtype/mt-CharisSIL.cfg -File: mt-CharisSIL.cfg 2017/07/07 v1.1 microtype config. file: Charis SIL (RS) -) - -File: tmr-logo.pdf Graphic file (type pdf) - -Package luatex.def Info: tmr-logo.pdf used on input line 70. -(luatex.def) Requested size: 51.21495pt x 16.65428pt. -Package microtype Info: Loading generic protrusion settings for font family -(microtype) `Calibri' (encoding: TU). -(microtype) For optimal results, create family-specific settings. -(microtype) See the microtype manual for details. -Package microtype Info: Loading generic protrusion settings for font family -(microtype) `lmss' (encoding: TU). -(microtype) For optimal results, create family-specific settings. -(microtype) See the microtype manual for details. -LaTeX Font Info: Font shape `TU/Calibri(0)/bx/n' in size <8> not available -(Font) Font shape `TU/Calibri(0)/b/n' tried instead on input line -70. -LaTeX Font Info: Font shape `TU/Calibri(0)/bx/n' in size <14.4> not availabl -e -(Font) Font shape `TU/Calibri(0)/b/n' tried instead on input line -70. -Package microtype Info: Loading generic protrusion settings for font family -(microtype) `LatinModernMath' (encoding: TU). -(microtype) For optimal results, create family-specific settings. -(microtype) See the microtype manual for details. - -(d:/texlive/2025/texmf-dist/tex/latex/microtype/mt-LatinModernRoman.cfg -File: mt-LatinModernRoman.cfg 2021/02/21 v1.1 microtype config. file: Latin Mod -ern Roman (RS) -) -(d:/texlive/2025/texmf-dist/tex/latex/microtype/mt-eur.cfg -File: mt-eur.cfg 2006/07/31 v1.1 microtype config. file: AMS Euler Roman (RS) -) - -File: orcid_icon.png Graphic file (type png) - -Package luatex.def Info: orcid_icon.png used on input line 70. -(luatex.def) Requested size: 7.19543pt x 7.20003pt. - -Underfull \hbox (badness 2318) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 PY, and Liu ZQ helped with in-for-ma-tion col-lec-tion and manuscript - [] - - -Underfull \hbox (badness 4391) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 through PD-1 reg-u-lat-ing NK cell func-tion (2020Q004) -”; Shan-dong - [] - - -Underfull \hbox (badness 1019) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 Provin-cial Med-i-cal and Health Sci-ence and Tech-nol-ogy De-vel-op-ment - [] - - -Underfull \hbox (badness 6978) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 PD-1+NK cells (202002070991)”. Nat-u-ral Sci-ence Foun-da --tion of - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 necro-sis factor-alpha; TGF-β, trans-form-ing growth facto -r-β; IL-6, - [] - - -Underfull \hbox (badness 2096) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 9; HDAC2, hi-s-tone deacetylase-2; PI3K, phosphoinositide-3 -- ki-nase; - [] - - -Underfull \hbox (badness 1308) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 Nrf2, nu-clear fac-tor ery-throid 2-related fac-tor 2; CXCL -, C-X-C mo-tif - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 70--70 -[]\TU/Calibri(0)/m/n/8 © 2025By Au-thor(s). Pub-lished by TMR Pub-lish-ing Grou -p - [] - - -Underfull \hbox (badness 3000) in paragraph at lines 70--70 -\TU/Calibri(0)/m/n/8 Lim-ited. This is an open ac-cess ar-ti-cle un-der the CC-B -Y li-cense. - [] - - -Underfull \hbox (badness 2027) in paragraph at lines 70--70 -\TU/CharisSIL(0)/m/n/8 strate-gies in daily di-etary prac-tices and to in-spire novel drug - [] - -<./image/c83075d3cbe5dd333419e6ecf1028e70.png, id=62, 2643.8775pt x 2562.57375p -t> -File: ./image/c83075d3cbe5dd333419e6ecf1028e70.png Graphic file (type png) - -Package luatex.def Info: ./image/c83075d3cbe5dd333419e6ecf1028e70.png used on -input line 70. -(luatex.def) Requested size: 244.40907pt x 236.87796pt. - -Package fontspec Info: -(fontspec) Font family 'CharisSIL(1)' created for font 'Charis -(fontspec) SIL' with options []. -(fontspec) -(fontspec) This font family consists of the following NFSS -(fontspec) series/shapes: -(fontspec) -(fontspec) - 'normal' (m/n) with NFSS spec.: <->"name:Charis -(fontspec) SIL:mode=node;script=latn;language=dflt;" -(fontspec) - 'small caps' (m/sc) with NFSS spec.: <->"name:Charis -(fontspec) SIL:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'bold' (b/n) with NFSS spec.: <->"name:Charis -(fontspec) SIL/B:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold small caps' (b/sc) with NFSS spec.: -(fontspec) <->"name:Charis -(fontspec) SIL/B:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'italic' (m/it) with NFSS spec.: <->"name:Charis -(fontspec) SIL/I:mode=node;script=latn;language=dflt;" -(fontspec) - 'italic small caps' (m/scit) with NFSS spec.: -(fontspec) <->"name:Charis -(fontspec) SIL/I:mode=node;script=latn;language=dflt;+smcp;" -(fontspec) - 'bold italic' (b/it) with NFSS spec.: <->"name:Charis -(fontspec) SIL/BI:mode=node;script=latn;language=dflt;" -(fontspec) - 'bold italic small caps' (b/scit) with NFSS spec.: -(fontspec) <->"name:Charis -(fontspec) SIL/BI:mode=node;script=latn;language=dflt;+smcp;" - -[1 - -{d:/texlive/2025/texmf-var/fonts/map/pdftex/updmap/pdftex.map}<./tmr-logo.pdf><. -/orcid_icon.png><./image/c83075d3cbe5dd333419e6ecf1028e70.png>] -Package mdframed Info: mdframed works in twoside mode on input line 76. - -Underfull \hbox (badness 10000) in paragraph at lines 76--76 - - [] - - -Underfull \hbox (badness 2165) in paragraph at lines 76--76 -[]\TU/Calibri(0)/m/n/8

1. The ef-fec-tive-ness and di-ver-sity of tra-di-tion -al Chi-nese - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 76--76 - - [] - - -Underfull \hbox (badness 1147) in paragraph at lines 76--76 -\TU/Calibri(0)/m/n/8 of lung dis-eases. For in-stance, the flower buds of \TU/C -alibri(0)/m/it/8 Tus-si-lago - [] - -Package mdframed Info: Not enough space on this page on input line 76. -LaTeX Font Info: Font shape `TU/lmss/bx/it' in size <8> not available -(Font) Font shape `TU/lmss/bx/sl' tried instead on input line 78. - -Underfull \hbox (badness 1389) in paragraph at lines 80--80 -\TU/CharisSIL(1)/m/n/8 res-pi-ra-tory symp-toms, pre-sent-ing a con-sid-er-able pub-lic health - [] - - -Underfull \hbox (badness 6477) in paragraph at lines 81--81 -[]\TU/CharisSIL(1)/m/n/8 The main patho-log-i-cal fea-tures of COPD in-clude air --way - [] - - -Underfull \hbox (badness 2253) in paragraph at lines 82--82 -\TU/CharisSIL(1)/m/n/8 dis-eases. Nat-u-ral flavonoids are cat-e-go-rized based on their - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 82--82 -\TU/CharisSIL(1)/m/n/8 in-clud-ing anti-inflammatory, an-tiox-ida-tive, cell-pro -tective, - [] - - -Underfull \hbox (badness 1910) in paragraph at lines 82--82 -\TU/CharisSIL(1)/m/n/8 an-timi-cro-bial, and ECM degra-da-tion [][11, 12][]. Fur --ther-more, - [] - -<./image/file_682161fb0fcfd.png, id=83, 2886.58424pt x 1908.53024pt> -File: ./image/file_682161fb0fcfd.png Graphic file (type png) - -Package luatex.def Info: ./image/file_682161fb0fcfd.png used on input line 86. - -(luatex.def) Requested size: 439.93333pt x 290.86842pt. - -Underfull \hbox (badness 3849) in paragraph at lines 92--92 -\TU/CharisSIL(1)/m/n/8 air-flow lim-i-ta-tion, mu-cus over-pro-duc-tion, chronic - bron-chi-tis, - [] - - -Underfull \hbox (badness 1728) in paragraph at lines 92--92 -\TU/CharisSIL(1)/m/n/8 em-phy-sema, or dam-age to the alve-o-lar sep-tal walls. These - [] - - -Underfull \hbox (badness 6944) in paragraph at lines 93--93 -[]\TU/CharisSIL(1)/m/n/8 CS, pathogens, and var-i-ous en-vi-ron-men-tal ex-po-su -res are - [] - - -Underfull \hbox (badness 1622) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 of COPD; no-tably, the re-moval of these risk fac-tors ha -s the - [] - - -Underfull \hbox (badness 2653) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 po-ten-tial to halt the patho-log-i-cal pro-gres-sion of the dis-ease - [] - - -Underfull \hbox (badness 1406) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 in-fec-tions, also sig-nif-i-cantly con-tribute to the pa -tho-gen-e-sis of - [] - - -Underfull \hbox (badness 1442) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 parenchyma, also known as em-phy-sema [][18, 19][]. COPD is - [] - - -Underfull \hbox (badness 1072) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 com-pli-cat-edly reg-u-lated by var-i-ous bi-o-log-i-cal mech-a-nisms and - [] - - -Underfull \hbox (badness 1635) in paragraph at lines 93--93 -\TU/CharisSIL(1)/m/n/8 their crosstalk, in-clud-ing ox-ida-tive stress, in-flam- -ma-tion, ECM - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 3623) in paragraph at lines 97--97 -\TU/CharisSIL(1)/m/n/8 a large amount of ox-i-dants, lead-ing to the in-ac-ti-va --tion of - [] - - -Underfull \hbox (badness 3547) in paragraph at lines 97--97 -\TU/CharisSIL(1)/m/n/8 of mu-cus genes like mucin 5AC (\TU/CharisSIL(0)/m/it/8 -MUC5AC\TU/CharisSIL(1)/m/n/8 ) and mucin 5B - [] - - -Underfull \hbox (badness 1565) in paragraph at lines 97--97 -\TU/CharisSIL(1)/m/n/8 (\TU/CharisSIL(0)/m/it/8 MUC5B\TU/CharisSIL(1)/m/n/8 ) [ -][[]10[]–[]12[]][]. Epi-der-mal growth fac-tor re-cep-tor (EGFR) - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 6944) in paragraph at lines 97--97 -\TU/CharisSIL(1)/m/n/8 fac-tor, and nu-clear fac-tor kappa-B (NF-κ󰀀B). These - fac-tors - [] - - -Underfull \hbox (badness 4013) in paragraph at lines 97--97 -[]\TU/CharisSIL(1)/m/n/8 [[]16[]][]. How-ever, ox-ida-tive stress can di-rectly pro-mote the - [] - - -Underfull \hbox (badness 7704) in paragraph at lines 97--97 -\TU/CharisSIL(1)/m/n/8 phos-pho-ry-la-tion and ubiq-ui-ti-na-tion of hi-s-tone -deacetylase-2 - [] - -[2 - - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Underfull \hbox (badness 1454) in paragraph at lines 102--102 -[]\TU/CharisSIL(1)/m/n/8 CS stim-u-lates both air-way ep-ithe-lial cells and mac -rophages - [] - - -Underfull \hbox (badness 1107) in paragraph at lines 102--102 -\TU/CharisSIL(1)/m/n/8 to pro-duce a range of chemo-tac-tic cy-tokines and chemo -kines, - [] - - -Underfull \hbox (badness 1584) in paragraph at lines 102--102 -\TU/CharisSIL(1)/m/n/8 cas-cades that in-duce macrophage po-lar-ized to M1 phe-n -o-type, - [] - - -Underfull \hbox (badness 1460) in paragraph at lines 102--102 -\TU/CharisSIL(1)/m/n/8 which in-deed pro-duces pro-inflammatory cy-tokines. Such - as, - [] - - -Underfull \hbox (badness 2012) in paragraph at lines 102--102 -\TU/CharisSIL(1)/m/n/8 con-nec-tive tis-sue and elastin in the alve-oli, lead-in -g to both - [] - - -Underfull \hbox (badness 2205) in paragraph at lines 102--102 -\TU/CharisSIL(1)/m/n/8 ep-ithe-lium, smooth mus-cle and fi-brob-lasts. Thus, bot -h the - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 105--105 -\TU/CharisSIL(1)/m/n/8 phase in-duced by per-sis-tent in-flam-ma-tory stim-u-la- -tion and - [] - - -Underfull \hbox (badness 2653) in paragraph at lines 105--105 -\TU/CharisSIL(1)/m/n/8 vas-cu-lar per-me-abil-ity, al-low-ing fib-rino-gen and -fi-bronectin to - [] - - -Underfull \hbox (badness 1132) in paragraph at lines 105--105 -\TU/CharisSIL(1)/m/n/8 epi-der-mal growth fac-tors (EGF) and chemokines to en-co -ur-age - [] - - -Underfull \hbox (badness 5231) in paragraph at lines 105--105 -\TU/CharisSIL(1)/m/n/8 sub-se-quently fa-cil-i-tates epithelial-mesenchymal tran --si-tion and - [] - - -Underfull \hbox (badness 1983) in paragraph at lines 105--105 -\TU/CharisSIL(1)/m/n/8 pro-motes the dif-fer-en-ti-a-tion of fi-brob-lasts into my-ofi-brob-lasts - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2027) in paragraph at lines 106--106 -\TU/CharisSIL(1)/m/n/8 (EMT) by up-regulating NF-κ󰀀B sig-nalling, toll-like re-cep-tor 4 - [] - -[3<./image/file_682161fb0fcfd.png>] -Underfull \hbox (badness 1205) in paragraph at lines 110--110 -\TU/CharisSIL(1)/m/n/8 the treat-ment of COPD due to its in-her-ent nat-u-ral pr -op-er-ties - [] - - -Underfull \hbox (badness 2961) in paragraph at lines 110--110 -\TU/CharisSIL(1)/m/n/8 and demon-strated ef-fi-cacy. Note-wor-thy, flavonoids, -as the - [] - - -Underfull \hbox (badness 1377) in paragraph at lines 110--110 -\TU/CharisSIL(1)/m/n/8 prin-ci-pal con-stituents of nat-u-ral in-gre-di-ents, of --fer out-stand-ing - [] - - -Underfull \hbox (badness 7030) in paragraph at lines 110--110 -\TU/CharisSIL(1)/m/n/8 in-ter-est and at-ten-tion in sci-en-tific and in-dus-tri -al do-mains. - [] - -<./image/image-60721.png, id=154, 4063.18pt x 5986.365pt> -File: ./image/image-60721.png Graphic file (type png) - -Package luatex.def Info: ./image/image-60721.png used on input line 115. -(luatex.def) Requested size: 439.93333pt x 648.08893pt. -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! - -Underfull \hbox (badness 1242) in paragraph at lines 120--120 -\TU/CharisSIL(1)/m/n/8 air-way and lung in-flam-ma-tion, im-prov-ing air-way re- -mod-elling, - [] - -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! - -Underfull \hbox (badness 1502) in paragraph at lines 126--126 -[]\TU/CharisSIL(1)/m/n/8 Flavonoids have been re-ported to pre-vent and in-hibit - lung - [] - - -Underfull \hbox (badness 1248) in paragraph at lines 126--126 -\TU/CharisSIL(1)/m/n/8 an-tiox-i-dant ca-pac-ity by in-creas-ing the lev-els and - ac-tiv-i-ties of - [] - - -Underfull \hbox (badness 4467) in paragraph at lines 126--126 -\TU/CharisSIL(1)/m/n/8 an-tiox-i-dant en-zymes such as cata-lase, su-per-ox-ide dis-mu-tase - [] - - -Underfull \hbox (badness 1400) in paragraph at lines 126--126 -\TU/CharisSIL(1)/m/n/8 ROS-generating en-zymes like xan-thine ox-i-dase. For ex- -am-ple, - [] - - -Underfull \hbox (badness 2443) in paragraph at lines 126--126 -\TU/CharisSIL(1)/m/n/8 by en-hanc-ing SOD, haem oxy-ge-nase 1 (HO-1) and re-duc- -ing - [] - - -Underfull \hbox (badness 2452) in paragraph at lines 126--126 -\TU/CharisSIL(1)/m/n/8 and al-ka-line phos-phatase in a rat model of PM$[][]$ ex --po-sure - [] - - -Underfull \hbox (badness 1067) in paragraph at lines 126--126 -[]\TU/CharisSIL(1)/m/n/8 [[]80[]][]. Api-genin en-hanced the ac-ti-va-tion of si -lent in-for-ma-tion - [] - - -Underfull \hbox (badness 3291) in paragraph at lines 127--127 -\TU/CharisSIL(1)/m/n/8 fac-tor that gov-erns the ex-pres-sion of genes as-so-ci- -ated with - [] - - -Underfull \hbox (badness 1742) in paragraph at lines 127--127 -\TU/CharisSIL(1)/m/n/8 in the cy-to-plasm. How-ever, un-der ox-ida-tive stress, Nrf2 is - [] - - -Underfull \hbox (badness 1360) in paragraph at lines 128--128 -\TU/CharisSIL(1)/m/n/8 ef-fects on air-way ep-ithe-lial cells and in-flam-ma-tor -y cells. In - [] - - -Underfull \hbox (badness 4328) in paragraph at lines 128--128 -\TU/CharisSIL(1)/m/n/8 sum-mary, flavonoids were found to in-hibit ox-ida-tive -stress - [] - - -Underfull \hbox (badness 1418) in paragraph at lines 128--128 -\TU/CharisSIL(1)/m/n/8 cells, The mech-a-nism of ac-tion can be vi-su-ally il-lu -s-trated in - [] - - -Underfull \hbox (badness 3503) in paragraph at lines 128--128 -\TU/CharisSIL(1)/m/n/8 in CS-damaged RAW 264.7 cells [][[]37[]][]. Lu-te-olin de --creased - [] - -<./image/file_67aee377039e2.jpg, id=168, 2554.29282pt x 1939.245pt> -File: ./image/file_67aee377039e2.jpg Graphic file (type jpg) - -Package luatex.def Info: ./image/file_67aee377039e2.jpg used on input line 132 -. -(luatex.def) Requested size: 439.93333pt x 333.9875pt. - -Underfull \hbox (badness 1755) in paragraph at lines 135--135 -[]\TU/CharisSIL(1)/m/n/8 In mice and rat mod-els of COPD, var-i-ous flavonoids -have - [] - - -Underfull \hbox (badness 1028) in paragraph at lines 135--135 -\TU/CharisSIL(1)/m/n/8 like-wise been proved to in-hibit the de-vel-op-ment of -COPD by - [] - - -Underfull \hbox (badness 1596) in paragraph at lines 135--135 -\TU/CharisSIL(1)/m/n/8 In a CS-induced mouse model, isoliquir-it-i-genin re-duce -d MDA - [] - - -Underfull \hbox (badness 2799) in paragraph at lines 135--135 -\TU/CharisSIL(1)/m/n/8 lev-els by en-hanc-ing the ex-pres-sion of Nrf2 and HO-1 [][[]32[]][]. - [] - - -Underfull \hbox (badness 1342) in paragraph at lines 135--135 -\TU/CharisSIL(1)/m/n/8 en-zymes such as SOD, GSH [][[]48[]][]. Epi-cat-e-chin re --pressed the - [] - - -Underfull \hbox (badness 1097) in paragraph at lines 139--139 -\TU/CharisSIL(1)/m/n/8 cor-re-la-tion with the sever-ity of air-flow ob-struc-ti -on. Harm-ful - [] - - -Underfull \hbox (badness 2707) in paragraph at lines 139--139 -\TU/CharisSIL(1)/m/n/8 sub-stances in-duce the res-pi-ra-tory tract ep-ithe-lium - to se-crete - [] - - -Underfull \hbox (badness 4981) in paragraph at lines 139--139 -[]\TU/CharisSIL(1)/m/n/8 [[]101[]][]. IL-6 ac-ti-vates neu-trophils, re-leas-ing - NE and ROS, - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 7631) in paragraph at lines 140--140 -\TU/CharisSIL(1)/m/n/8 in-flam-ma-tory dis-eases, ef-fec-tively in-hibit-ing the - on-set and - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -[4 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -] [5<./image/image-60721.png>] -Missing character: There is no κ (U+03BA) in font "name:Charis SIL Bold:mode=no -de;script=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL Bold:mode=no -de;script=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL Bold:mode=no -de;script=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1831) in paragraph at lines 141--141 -[]\TU/CharisSIL(0)/b/n/8 Tar-get-ing NF-κ󰀀B path-way. \TU/CharisSIL(1)/m/n/ -8 The ac-ti-va-tion of the NF-κ󰀀B - [] - - -Underfull \hbox (badness 2772) in paragraph at lines 141--141 -\TU/CharisSIL(1)/m/n/8 path-way is be-lieved to play a piv-otal role in in-flam- -ma-tory - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -<./image/file_68999e3c72e62.png, id=212, 2990.7735pt x 2295.17474pt> -File: ./image/file_68999e3c72e62.png Graphic file (type png) - -Package luatex.def Info: ./image/file_68999e3c72e62.png used on input line 145 -. -(luatex.def) Requested size: 439.93333pt x 337.60727pt. -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 3049) in paragraph at lines 148--148 -\TU/CharisSIL(1)/m/n/8 mod-u-late NF-κ󰀀B sig-nalling in COPD, ac-knowl-edg-i -ng NF-κ󰀀B’s - [] - - -Underfull \hbox (badness 1776) in paragraph at lines 148--148 -\TU/CharisSIL(1)/m/n/8 p-p65 but in-creas-ing Nrf2 in LPS-induced BEAS-2B cell -[][[]52[]][]. - [] - - -Underfull \hbox (badness 1303) in paragraph at lines 148--148 -\TU/CharisSIL(1)/m/n/8 pro-duc-tion and in-flam-ma-tion me-di-a-tor lev-els (COX --2, NADPH - [] - - -Underfull \hbox (badness 1783) in paragraph at lines 148--148 -\TU/CharisSIL(1)/m/n/8 ox-i-dase 4 (NOX4), NOS2, IL-6 and IL-8) by sup-press-ing - the - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1221) in paragraph at lines 149--149 -\TU/CharisSIL(1)/m/n/8 of in-flam-ma-tory cells and pro-inflammatory cy-tokines such as - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1348) in paragraph at lines 151--151 -\TU/CharisSIL(1)/m/n/8 in the COPD co-infection model. Upon stim-u-la-tion, myel -oid - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1540) in paragraph at lines 151--151 -\TU/CharisSIL(1)/m/n/8 COPD rat model, baicalin re-duced TLR2 and TLR4, fol-lowe -d - [] - - -Underfull \hbox (badness 1902) in paragraph at lines 151--151 -\TU/CharisSIL(1)/m/n/8 by low-er-ing MYD88, phos-pho-ry-la-tion of p65, and in-c -reas-ing - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 3803) in paragraph at lines 151--151 -[]\TU/CharisSIL(1)/m/n/8 [[]51[]][]. TLRs are cru-cial tar-gets of flavonoids in - in-hibit-ing - [] - -[6 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL Bold:mode=no -de;script=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -<./image/file_67aee377039e2.jpg>] -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2376) in paragraph at lines 152--152 -\TU/CharisSIL(1)/m/n/8 lo-cal-i-sa-tions and func-tions, is the first sir-tuin -that reg-u-lates - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2205) in paragraph at lines 153--153 -\TU/CharisSIL(1)/m/n/8 through down-regulating air-way in-flam-ma-tory in-fil-tr -a-tion and - [] - - -Underfull \hbox (badness 1275) in paragraph at lines 153--153 -\TU/CharisSIL(1)/m/n/8 de-creas-ing the in-flam-ma-tory fac-tors (the lev-els of - TNF-α and - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1132) in paragraph at lines 154--154 -[]\TU/CharisSIL(1)/m/n/8 To-tal flavonoid ex-tract also has the ef-fect of in-hi -bit-ing the - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1895) in paragraph at lines 154--154 -\TU/CharisSIL(1)/m/n/8 NF-κ󰀀B path-way. For ex-am-ple, to-tal flavonoids fro -m \TU/CharisSIL(0)/m/it/8 Nigella - [] - - -Underfull \hbox (badness 1642) in paragraph at lines 154--154 -\TU/CharisSIL(1)/m/n/8 of neu-trophils and macrophages into the lung and de-crea -sed - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 3219) in paragraph at lines 154--154 -\TU/CharisSIL(1)/m/n/8 flavonoids from lo-quat (\TU/CharisSIL(0)/m/it/8 Eri-obot -rya japon-ica\TU/CharisSIL(1)/m/n/8 ) leaves al-le-vi-ated - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 4291) in paragraph at lines 155--155 -[]\TU/CharisSIL(0)/b/n/8 Tar-get-ing MAPK path-way. \TU/CharisSIL(1)/m/n/8 MAPKs - rep-re-sent a di-verse - [] - - -Underfull \hbox (badness 5475) in paragraph at lines 155--155 -\TU/CharisSIL(1)/m/n/8 trans-duc-tion path-ways. The MAPK fam-ily com-prises fou -r - [] - - -Underfull \hbox (badness 2662) in paragraph at lines 155--155 -\TU/CharisSIL(1)/m/n/8 sub-fam-i-lies: ex-tra-cel-lu-lar reg-u-lated pro-tein ki --nases (ERK)1/2 - [] - - -Underfull \hbox (badness 2213) in paragraph at lines 155--155 -\TU/CharisSIL(1)/m/n/8 (ex-tra-cel-lu-lar signal-regulated ki-nases 1 and 2), ER -K5, JNKs, - [] - - -Underfull \hbox (badness 1052) in paragraph at lines 155--155 -\TU/CharisSIL(1)/m/n/8 and p38s (p38 MAPKs). No-tably, p38 MAPK is ac-ti-vated -in - [] - - -Underfull \hbox (badness 1122) in paragraph at lines 156--156 -\TU/CharisSIL(1)/m/n/8 the in-hi-bi-tion of the ERK, p38, and JNK sig-nalling pa -th-ways - [] - - -Underfull \hbox (badness 1253) in paragraph at lines 156--156 -[]\TU/CharisSIL(1)/m/n/8 [[]72[]][]. Sily-marin sig-nif-i-cantly al-le-vi-ated -the thick-en-ing of the - [] - -[7 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -<./image/file_68999e3c72e62.png>] -Underfull \hbox (badness 1048) in paragraph at lines 157--157 -[]\TU/CharisSIL(1)/m/n/8 Bac-te-rial in-fec-tion stands as a pri-mary cul-prit -be-hind acute - [] - - -Underfull \hbox (badness 1845) in paragraph at lines 157--157 -\TU/CharisSIL(1)/m/n/8 al-le-vi-ate the patho-log-i-cal in-flam-ma-tion as-so-ci --ated with COPD - [] - - -Underfull \hbox (badness 2277) in paragraph at lines 158--158 -\TU/CharisSIL(1)/m/n/8 are es-sen-tial for caus-ing and pro-mot-ing var-i-ous ce -ll growth, - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 3930) in paragraph at lines 159--159 -\TU/CharisSIL(1)/m/n/8 re-duced the ex-pres-sion level of MUC5AC by in-hibit-ing - the - [] - - -Underfull \hbox (badness 1939) in paragraph at lines 159--159 -\TU/CharisSIL(1)/m/n/8 ac-ti-va-tion of the EGFR, as ev-i-denced by de-creased -lev-els of - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2486) in paragraph at lines 159--159 -\TU/CharisSIL(1)/m/n/8 tilianin also re-duced MUC5AC ex-pres-sion by mod-u-lat-i -ng the - [] - - -Underfull \hbox (badness 1107) in paragraph at lines 159--159 -\TU/CharisSIL(1)/m/n/8 cells [][[]77[]][]. Fur-ther-more, icariin was shown to -pro-mote lung - [] - - -Underfull \hbox (badness 1342) in paragraph at lines 161--161 -\TU/CharisSIL(1)/m/n/8 and mono-cyte chemo-tac-tic protein-1 lev-els in bron-cho -alve-o-lar - [] - - -Underfull \hbox (badness 1484) in paragraph at lines 161--161 -\TU/CharisSIL(1)/m/n/8 and al-le-vi-ated gob-let cells meta-pla-sia and em-phy-s -e-ma-tous by - [] - - -Underfull \hbox (badness 3118) in paragraph at lines 161--161 -\TU/CharisSIL(1)/m/n/8 cells (such as leuko-cytes, to-tal lym-pho-cytes, CD11b$ -[][]$CD11c$[][]$ - [] - - -Underfull \hbox (badness 2393) in paragraph at lines 161--161 -\TU/CharisSIL(1)/m/n/8 sig-nal path-ways in the COPD mice model [][[]78[]][]. Gi -nkgetin - [] - - -Underfull \hbox (badness 1107) in paragraph at lines 161--161 -\TU/CharisSIL(1)/m/n/8 path-way in CSE-induced A549 cells, which is as-so-ci-ate -d with - [] - -<./image/zipimg67aea6fbb71406.png, id=300, 4328.17pt x 2634.84375pt> -File: ./image/zipimg67aea6fbb71406.png Graphic file (type png) - -Package luatex.def Info: ./image/zipimg67aea6fbb71406.png used on input line 1 -68. -(luatex.def) Requested size: 439.93333pt x 267.80168pt. - -Underfull \hbox (badness 1292) in paragraph at lines 171--171 -\TU/CharisSIL(1)/m/n/8 them, MMPs are a promi-nent and in-flu-en-tial fam-ily. -Tis-sue - [] - - -Underfull \hbox (badness 1237) in paragraph at lines 171--171 -\TU/CharisSIL(1)/m/n/8 of MMPs; usu-ally, TIMP-1 in-hibits ac-tive MMPs, and TIM -P-1 - [] - - -Underfull \hbox (badness 1817) in paragraph at lines 171--171 -\TU/CharisSIL(1)/m/n/8 binds to pro-MMP-9 to pre-vent the ac-ti-va-tion of pro-M -MP-9. - [] - - -Underfull \hbox (badness 1490) in paragraph at lines 173--173 -\TU/CharisSIL(1)/m/n/8 as \TU/CharisSIL(0)/m/it/8 α-SMA \TU/CharisSIL(1)/m/n/8 - and col-la-gen. This pro-cess al-ters the EMT [][[]119[]][]. - [] - - -Underfull \hbox (badness 1033) in paragraph at lines 174--174 -\TU/CharisSIL(1)/m/n/8 im-prov-ing lung func-tion [][[]33[]][]. In four-day CS-e -xposure mice, - [] - -[8 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Underfull \hbox (badness 2418) in paragraph at lines 177--177 -\TU/CharisSIL(1)/m/n/8 re-sponse of cells to var-i-ous stim-uli, in-clud-ing DNA - dam-age, - [] - - -Underfull \hbox (badness 1048) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 apop-to-sis in the patho-gen-e-sis of COPD. For in-stance -, baicalin - [] - - -Underfull \hbox (badness 1107) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 apop-to-sis in CSE-treated MLE-12 cells, which are mouse lung - [] - - -Underfull \hbox (badness 1540) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 type II ep-ithe-lial cells [][[]66[]][]. Ad-di-tion-ally, - baicalin mit-i-gates - [] - - -Underfull \hbox (badness 1087) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 flavonoids reg-u-late autophagy-related apop-to-sis. Puer --arin has - [] - - -Underfull \hbox (badness 1521) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 been demon-strated to in-hibit FUNDC1-mediated mi-to-chon --drial - [] - - -Underfull \hbox (badness 1024) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 Puer-arin also pro-tects lung func-tion and in-hibits apo -p-to-sis by - [] - - -Underfull \hbox (badness 1521) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 down-regulating the Bax level and up-regulating Bcl-2 in the - [] - - -Underfull \hbox (badness 1939) in paragraph at lines 178--178 -\TU/CharisSIL(1)/m/n/8 lung, a pro-cess that de-pends on the PINK1-parkin sig-na -lling - [] - - -Underfull \hbox (badness 1132) in paragraph at lines 179--179 -\TU/CharisSIL(1)/m/n/8 Ad-di-tion-ally, acyl-CoA syn-thetase long-chain fam-ily mem-ber 4 - [] - - -Underfull \hbox (badness 2229) in paragraph at lines 180--180 -[]\TU/CharisSIL(1)/m/n/8 Scutel-larein may help treat COPD by in-hibit-ing fer-r -op-to-sis - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 through iron chela-tion and in-ter-ac-tion with the en-zy -me - [] - - -Underfull \hbox (badness 1389) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 arachi-do-nate 15-lipoxygenase, which is in-volved in fat -ty acid - [] - - -Underfull \hbox (badness 2293) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 lethal small molecule 3-induced fer-rop-to-sis and mi-to- -chon-dria - [] - - -Underfull \hbox (badness 2753) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 It no-tably im-peded the in-creas-ing of lipid per-ox-i-d -a-tion and - [] - - -Underfull \hbox (badness 3343) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 mor-pho-log-i-cal changes in the mi-to-chon-dria by up-re -gulating - [] - - -Underfull \hbox (badness 1082) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 SLC7A11, GPx4, and SOD by down-regulating MDA and ROS - [] - - -Underfull \hbox (badness 1019) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 level of CSE-induced alve-o-lar macrophages and in-hib-it -ed lung - [] - - -Underfull \hbox (badness 1552) in paragraph at lines 180--180 -\TU/CharisSIL(1)/m/n/8 by chelat-ing iron and ac-ti-vat-ing the down-stream anti --oxidant - [] - -[9<./image/zipimg67aea6fbb71406.png>] -Underfull \hbox (badness 1430) in paragraph at lines 183--183 -\TU/CharisSIL(1)/m/n/8 Flavonoids have a long his-tory of con-sump-tion in di-et -s with - [] - -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1303) in paragraph at lines 191--191 -\TU/CharisSIL(1)/m/n/8 ther-a-peu-tic ef-fects on COPD vary sig-nif-i-cantly. No --tably, the - [] - - -Underfull \hbox (badness 1502) in paragraph at lines 191--191 -\TU/CharisSIL(1)/m/n/8 num-ber and po-si-tion of hy-droxyl groups in-flu-ence fl -avonoids’ - [] - - -Underfull \hbox (badness 4543) in paragraph at lines 191--191 -\TU/CharisSIL(1)/m/n/8 rep-re-sents an-other im-por-tant struc-tural fea-ture th -at im-pacts - [] - - -Underfull \hbox (badness 2460) in paragraph at lines 192--192 -\TU/CharisSIL(1)/m/n/8 cos-met-ics, and health foods, such as ginkgo flavonoids, - tea - [] - - -Underfull \hbox (badness 2717) in paragraph at lines 193--193 -\TU/CharisSIL(1)/m/n/8 which flavonoid is most suit-able for COPD ther-apy re-ma -ins - [] - - -Underfull \hbox (badness 1107) in paragraph at lines 193--193 -\TU/CharisSIL(1)/m/n/8 re-search. Cur-rently, there have been only two clin-i-ca -l tri-als - [] - - -Underfull \hbox (badness 1132) in paragraph at lines 194--194 -\TU/CharisSIL(1)/m/n/8 sources, struc-tural clas-si-fi-ca-tions, and the var-i-o -us mech-a-nisms - [] - - -Underfull \hbox (badness 5954) in paragraph at lines 201--201 -\TU/CharisSIL(1)/m/n/8 of liver fi-bro-sis through PD-1 reg-u-lat-ing NK cell fu -nc-tion - [] - - -Underfull \hbox (badness 1533) in paragraph at lines 201--201 -\TU/CharisSIL(1)/m/n/8 Nat-u-ral Sci-ence Foun-da-tion of Shan-dong Province -“As-tra-galus - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1527) in paragraph at lines 205--205 -[]\TU/CharisSIL(1)/m/n/8 COPD, chronic ob-struc-tive pul-monary dis-ease; CS, ci -garette - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1418) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 growth factor-β; IL-6, interleukin-6; IL-1β, interleuki -n-1 beta; - [] - - -Underfull \hbox (badness 1436) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 2-related fac-tor 2; CXCL, C-X-C mo-tif chemokine lig-and -; NE, - [] - - -Underfull \hbox (badness 3375) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 re-cep-tor 4; JNK, c-Jun N-terminal ki-nase; SOD, su-per- -ox-ide - [] - - -Underfull \hbox (badness 1796) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 dis-mu-tase; GSH, glu-tathione; GSH-Px, glu-tathione per- -ox-i-dase; - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2744) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 ep-ithe-lial cells; TLRs, toll-like re-cep-tors; IRAK, in -terleukin-1 - [] - - -Underfull \hbox (badness 1484) in paragraph at lines 205--205 -\TU/CharisSIL(1)/m/n/8 ox-i-dase 4; TIMP, tis-sue in-hibitors of met-al-lo-pro-t -einase; EMT, - [] - - -Underfull \hbox (badness 2065) in paragraph at lines 207--207 -[]\TU/CharisSIL(1)/m/n/8 Shi PL, Zhang GX, Wang PY, Liu ZQ, Zheng BQ. Nat-u-ral - [] - - -Underfull \hbox (badness 1112) in paragraph at lines 207--207 -\TU/CharisSIL(1)/m/n/8 flavonoids for the treat-ment of chronic ob-struc-tive pu -l-monary - [] - -[10 -Missing character: There is no 执 (U+6267) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 行 (U+884C) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 附 (U+9644) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 表 (U+8868) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 程 (U+7A0B) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no 序 (U+5E8F) in font "name:Charis SIL:mode=node;s -cript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -File: ./image/zipimg67aea6fbb71406.png Graphic file (type png) - -Package luatex.def Info: ./image/zipimg67aea6fbb71406.png used on input line 2 -11. -(luatex.def) Requested size: 439.93333pt x 267.80168pt. - [11] -Underfull \hbox (badness 4279) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 causes of death. Cause spe-cific mor-tal-ity 2000–2019. - - [] - - -Underfull \hbox (badness 1642) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Math-ers CD, Lon-car D. Pro-jec-tions of global mor-tal --ity - [] - - -Underfull \hbox (badness 1365) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and bur-den of dis-ease from 2002 to 2030. \TU/CharisSIL -(0)/m/it/8 PLoS Med\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chris-ten-son SA, Smith BM, Bafad-hel M, et al. - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Chronic ob-struc-tive pul-monary dis-ease. \TU/CharisSIL -(0)/m/it/8 Lancet\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 4291) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 treat-ment, pre-ven-tion and dis-ease im-pact. \TU/Chari -sSIL(0)/m/it/8 Respirol-ogy\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 4981) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 van der Toorn M, Reza-yat D, Kauff-man HF, et al. - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Lipid-soluble com-po-nents in cigarette smoke in-duce - [] - - -Underfull \hbox (badness 1231) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 mi-to-chon-drial pro-duc-tion of re-ac-tive oxy-gen speci -es in - [] - - -Underfull \hbox (badness 1137) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 in-hibitors on air-way mucin: Molec-u-lar in-sight into -the - [] - - -Underfull \hbox (badness 1062) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 ther-a-peu-tic po-ten-tial tar-get-ing MUC5AC ex-pres-sio -n and - [] - - -Underfull \hbox (badness 1533) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Shih YM, Chang YJ, Cooke MS, et al. Alky-lat-ing and - [] - - -Underfull \hbox (badness 1038) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Lee G, Walser TC, Du-bi-nett SM. Chronic in-flam-ma-tio -n, - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 To Y, Ito K, Kizawa Y, et al. Tar-get-ing - [] - - -Underfull \hbox (badness 2856) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Phosphoinositide-3-Kinase-δ with Theo-phylline Re-verses - - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Cor-ti-cos-teroid In-sen-si-tiv-ity in Chronic Ob-struc-t -ive - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Pul-monary Dis-ease. \TU/CharisSIL(0)/m/it/8 Am J Respir Crit Care Med\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 1552) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Yao HW, Rah-man I. Role of hi-s-tone deacety-lase 2 in - [] - -[12] -Underfull \hbox (badness 6125) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Cheng SE, Lee IT, Lin CC, et al. Cigarette smoke - [] - - -Underfull \hbox (badness 2142) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Brus-selle GG, Joos GF, Bracke KR. New in-sights into - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 met-al-lo-pro-teinases in the de-vel-op-ment of air-way - [] - - -Underfull \hbox (badness 6001) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 in-flam-ma-tion and re-mod-el-ing. \TU/CharisSIL(0)/m/it -/8 Braz J Med Biol Res\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2237) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Burgel PR. Roles of epi-der-mal growth fac-tor re-cep-t -or - [] - - -Underfull \hbox (badness 4366) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Shao MXG, Nakanaga T, Nadel JA. Cigarette smoke - [] - - -Underfull \hbox (badness 1603) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 factor-α-converting en-zyme in hu-man air-way ep-ithe-li -al - [] - - -Underfull \hbox (badness 2608) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 (NCI-H292) cells. \TU/CharisSIL(0)/m/it/8 Am J Phys-iol -Lung Cell Mol Phys-iol\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2318) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chen P, Parks WC. Role of ma-trix met-al-lo-pro-teinase -s - [] - - -Underfull \hbox (badness 6380) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Al‐Tamari HM, Dabral S, Schmall A, et al. FoxO3 - [] - - -Underfull \hbox (badness 6708) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 an im-por-tant player in fi-bro-ge-n-e-sis and ther-a-peu --tic - [] - - -Underfull \hbox (badness 1360) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang H, Yang T, Wang T, et al. Phloretin at-ten-u-ates - [] - - -Underfull \hbox (badness 1755) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 by cigarette smoke. \TU/CharisSIL(0)/m/it/8 Int Im-munoph -ar-ma-col\TU/CharisSIL(1)/m/n/8 . 2018;55:112. - [] - - -Underfull \hbox (badness 1888) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Birru RL, Bein K, Bon-darchuk N, et al. An-timi-cro-bia -l - [] - - -Underfull \hbox (badness 7944) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and Anti-Inflammatory Ac-tiv-ity of Ap-ple Polyphe-nol - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1418) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Yu D, Liu X, Zhang G, et al. Isoliquir-it-i-genin In-hi -bits - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Cigarette Smoke-Induced COPD by At-ten-u-at-ing - [] - - -Underfull \hbox (badness 2799) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 In-flam-ma-tion and Ox-ida-tive Stress via the Reg-u-la-t -ion - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1189) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Sup-presses Platelet Ac-ti-vat-ing Factor-Induced Ac-ti-v -a-tion - [] - - -Underfull \hbox (badness 4316) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Jin M, Xue C, Wang Y, et al. Pro-tec-tive Ef-fect of - [] - - -Underfull \hbox (badness 1052) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Ob-struc-tive Pul-monary Dis-ease Rats. \TU/CharisSIL(0) -/m/it/8 Chin J In-tegr Med\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 1490) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Liu L, Zhang Y, Wang L, et al. Scutel-larein al-le-vi-a -tes - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of fer-rop-to-sis by chelat-ing iron and in-ter-act-ing - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 with arachi-do-nate 15‐lipoxy-ge-nase. \TU/CharisSIL(0 -)/m/it/8 Phy-tother Res\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2865) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Gane-san S, Faris AN, Com-stock AT, et al. Quercetin - [] - - -Underfull \hbox (badness 1377) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 pre-vents pro-gres-sion of dis-ease in elas-tase/LPS-expo -sed - [] - - -Underfull \hbox (badness 5908) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Mi-tani A, Azam A, Vup-pusetty C, et al. Quercetin - [] - - -Underfull \hbox (badness 1552) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 re-stores cor-ti-cos-teroid sen-si-tiv-ity in cells from pa-tients - [] - - -Underfull \hbox (badness 1515) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 rhinovirus-induced pro-gres-sion of lung dis-ease in mice - - [] - - -Underfull \hbox (badness 1205) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Caused by Ex-po-sure to Cigarette Smoke in Male Mice. - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Lee S, Ro H, In HJ, et al. Fisetin in-hibits - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1178) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and in-flam-ma-tion in Wis-tar rat lungs. \TU/CharisSIL( -0)/m/it/8 J Food Biochem\TU/CharisSIL(1)/m/n/8 . - [] - -[13 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2452) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chen M, Chen Z, Huang D, et al. Myricetin in-hibits - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 TNF-α-induced in-flam-ma-tion in A549 cells via - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 the SIRT1/NF-κ󰀀B path-way. \TU/CharisSIL(0)/m/it/8 Pu -lm Phar-ma-col Ther\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 4416) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Lee H, Jung KH, Lee H, et al. Cas-ticin, an ac-tive - [] - - -Underfull \hbox (badness 1264) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 com-pound iso-lated from Vi-tex Fruc-tus, ame-lio-rates -the - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Dys-func-tion and At-ten-u-ates Ox-ida-tive Stress and - [] - - -Underfull \hbox (badness 6893) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 In-flam-ma-tion via In-hi-bi-tion of NF-ĸB in a Chronic - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1502) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Lu LJ, Tian H, Zheng Y, et al. Ef-fects of cas-ticin on - - [] - - -Underfull \hbox (badness 6510) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Lipopolysaccharide-induced BEAS-2B cell dam-age and - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 NF-κ󰀀B-KEAP1-NRF2/ARE path-way. \TU/CharisSIL(0)/m/i -t/8 Chin J Im-munol\TU/CharisSIL(1)/m/n/8 . - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 5231) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Li MF, Wang HF, Lu Y, et al. Lu-te-olin sup-presses - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 NF‐κ󰀀B sig-nal-ing path-way. \TU/CharisSIL(0)/m/it -/8 Im-mun In-flamm Dis\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 5985) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Zhou L, Jian T, Wan Y, et al. Lu-te-olin Al-le-vi-ates - [] - - -Underfull \hbox (badness 1226) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and CYP2A13/NRF2 Sig-nal-ing Path-ways. \TU/CharisSIL(0) -/m/it/8 Int J Mol Sci\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2310) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Luo YL, Zhang CC, Li PB, et al. Naringin at-ten-u-ates - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 in-duced by cigarette smoke. \TU/CharisSIL(0)/m/it/8 Int Im-munophar-ma-col\TU/CharisSIL(1)/m/n/8 . - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2384) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chen Z, Wu H, Fan W, et al. Narin-genin sup-presses - [] - - -Underfull \hbox (badness 1009) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 BEAS-2B-derived ex-tra-cel-lu-lar vesic-u-lar car-goes di -s-or-der - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1406) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang S, He N, Xing H, et al. Func-tion of hes-peridin - [] - - -Underfull \hbox (badness 1838) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 al-le-vi-at-ing in-flam-ma-tion and ox-ida-tive stress re --sponses - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1377) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of chronic ob-struc-tive pul-monary dis-ease by ac-ti-vat --ing - [] - - -Underfull \hbox (badness 2293) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Nrf2-mediated path-way. \TU/CharisSIL(0)/m/it/8 Phy-tomed -icine\TU/CharisSIL(1)/m/n/8 . 2022;96:153894. - [] - - -Underfull \hbox (badness 8132) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Liu X, Ma Y, Luo L, et al. Tax-i-folin ame-lio-rates - [] - - -Underfull \hbox (badness 2460) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 cigarette smoke-induced chronic ob-struc-tive pul-monary - [] - - -Underfull \hbox (badness 2753) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 dis-ease via in-hibit-ing in-flam-ma-tion and apop-to-sis -. \TU/CharisSIL(0)/m/it/8 Int - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1533) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Zeng LX, Dong JC, Yu WQ, et al. Baicalin at-ten-u-ates - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2111) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and in vitro: A pos-si-ble role for HDAC2 ac-tiv-ity. \T -U/CharisSIL(0)/m/it/8 Int - [] - - -Underfull \hbox (badness 3989) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang G, Mo-ham-mad-tur-sun N, Lv Y, et al. Baicalin - [] - - -Underfull \hbox (badness 2556) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Ex-erts Anti-Airway In-flam-ma-tion and Anti-Remodelling - [] - - -Underfull \hbox (badness 7832) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 ob-struc-tive pul-monary dis-ease through reg-u-la-tion -of - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 6842) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 HDAC2/NF-κ󰀀B/PAI-1 sig-nalling. \TU/CharisSIL(0)/m/i -t/8 Pulm Phar-ma-col Ther\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2671) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 miR-4451ef-fect on lipopolysaccharide-induced apop-to-sis - - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2790) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 sig-nal-ing path-way. \TU/CharisSIL(0)/m/it/8 J Army Med Univ\TU/CharisSIL(1)/m/n/8 . 2022;44(5):441. - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 2913) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Ju J, Li Z, Shi Q. Baicalin In-hibits In-flam-ma-tion -in - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1953) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 TLR2/MYD88/NF-κ󰀀Bp65 Sig-nal-ing Path-way. \TU/Chari -sSIL(0)/m/it/8 Evid Based - [] - - -Underfull \hbox (badness 2245) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Jing X, Huo J, Li L, et al. Baicalin Re-lieves Air-way - [] - - -Underfull \hbox (badness 2103) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Kim YH, Kang MK, Lee EJ, et al. As-tra-galin In-hibits - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Cigarette Smoke-Induced Pul-monary Throm-bo-sis and - [] - - -Underfull \hbox (badness 1184) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 cigarette smoke ex-tract. \TU/CharisSIL(0)/m/it/8 Exp The -r Med\TU/CharisSIL(1)/m/n/8 . 2020;20(1):283. - [] - - -Underfull \hbox (badness 7291) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of Icariin Com-bined with No-biletin against Chronic - [] - - -Underfull \hbox (badness 1199) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Ob-struc-tive Pul-monary Dis-eases. \TU/CharisSIL(0)/m/i -t/8 Evid Based Com-ple-ment - [] - - -Underfull \hbox (badness 4927) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Li QP, Zhang HY, Yan XP, et al. Up-regulation of - [] - -[14 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Underfull \hbox (badness 2310) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Song WY, Song YS, Ryu HW, et al. Tilianin In-hibits - [] - - -Underfull \hbox (badness 1859) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 MUC5AC Ex-pres-sion Me-di-ated Via Down-Regulation of - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 EGFR-MEK-ERK-Sp1 Sig-nal-ing Path-way in NCI-H292 - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Med-i-ca-tion of Gly-cyrrhiza glabra, Agas-tache ru-gosa - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Con-tain-ing Gly-cyrrhizic Acid, Tilianin In-hibits - [] - - -Underfull \hbox (badness 6775) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Neu-trophilic Lung In-flam-ma-tion by Af-fect-ing CXCL2, - [] - - -Underfull \hbox (badness 3690) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 biochanin A. \TU/CharisSIL(0)/m/it/8 Eco-tox-i-col En-v-i --ron Saf\TU/CharisSIL(1)/m/n/8 . 2020;202:110878. - [] - - -Underfull \hbox (badness 3907) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang L, Jiang W, Wang J, et al. Puer-arin in-hibits - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 FUNDC1-mediated mi-to-chon-drial au-tophagy and - [] - - -Underfull \hbox (badness 6493) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 CSE-induced apop-to-sis of hu-man bronchial ep-ithe-lial - [] - - -Underfull \hbox (badness 4108) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Pan XJ, Fan JQ, Xia GQ. Puer-arin in-hibits alve-o-lar - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 pathway-mediated mi-tophagy. \TU/CharisSIL(0)/m/it/8 Chin - J Patho-phys-iol\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Li XM, Jiang XH, Zeng RH, et al. For-mononetin - [] - - -Underfull \hbox (badness 3668) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 at-ten-u-ates cigarette smoke-induced COPD in mice by - [] - - -Underfull \hbox (badness 1558) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 sup-press-ing in-flam-ma-tion, en-do-plas-mic retic-u-lum - stress, - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and AKT/mTOR sig-nal-ing path-ways. \TU/CharisSIL(0)/m/i -t/8 Phy-tother Res\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 3568) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Park JW, Shin NR, Shin IS, et al. Sili-b-inin In-hibits - - [] - - -Underfull \hbox (badness 4647) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Ko JW, Shin NR, Park SH, et al. Sili-b-inin in-hibits - [] - - -Underfull \hbox (badness 2205) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 the fi-brotic re-sponses in-duced by cigarette smoke via - [] - - -Underfull \hbox (badness 1303) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 sup-pres-sion of TGF-β1/Smad 2/3 sig-nal-ing. \TU/Chari -sSIL(0)/m/it/8 Food Chem - [] - - -Underfull \hbox (badness 4739) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Li DD, Xu D, Wang T, et al. Sily-marin At-ten-u-ates - [] - - -Underfull \hbox (badness 6859) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 smoke extract-induced in-flam-ma-tion via si-mul-ta-ne-ou -s - [] - - -Underfull \hbox (badness 1394) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 the c/EBPβ sig-nal-ing path-way and CCL2 ex-pres-sion. -\TU/CharisSIL(0)/m/it/8 J - [] - - -Underfull \hbox (badness 3954) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chen XL, Geng DS. Ef-fect of To-tal Flavonoids from - [] - - -Underfull \hbox (badness 2460) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Ren QC, Li XH, Li QY, et al. To-tal flavonoids from - [] - - -Underfull \hbox (badness 7221) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 sea buck-thorn ame-lio-rates lipopolysac-cha-ride/cigaret -te - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 smoke‐in-duced air-way in-flam-ma-tion. \TU/CharisSIL( -0)/m/it/8 Phy-tother Res\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 1377) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of To-tal Flavonoids from Scutel-laria Baicalen-sis Georg -i - [] - - -Underfull \hbox (badness 1067) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 in the In-flam-ma-tion and Ox-ida-tive Stress in Rats wit -h - [] - - -Underfull \hbox (badness 8113) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Chronic Ob-struc-tive Pul-monary Dis-ease. \TU/CharisSIL -(0)/m/it/8 Chin Pharm\TU/CharisSIL(1)/m/n/8 . - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1082) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 flavonoids of Trol-lius al-taicus on a chronic ob-struc-t -ive - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 4168) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Van Ee-den SF, Sin DD. Ox-ida-tive Stress in Chronic - [] - - -Underfull \hbox (badness 3148) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Ob-struc-tive Pul-monary Dis-ease: A Lung and Sys-temic - [] - - -Underfull \hbox (badness 1939) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Suzuki M, Bet-suyaku T, Ito Y, et al. Down-Regulated - [] - - -Underfull \hbox (badness 1596) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Eu-rlings IMJ, Rey-naert NL, van de We-ter-ing C, et al -. - [] - - -Underfull \hbox (badness 3271) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Aug-ments Neu-trophil Cy-to-toxic Po-ten-tial via Se-lec- -tive - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1237) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and IKK func-tion. \TU/CharisSIL(0)/m/it/8 Nat Rev Mol Ce -ll Biol\TU/CharisSIL(1)/m/n/8 . 2007;8(1):49. - [] - -[15 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 1728) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Lora JM, Zhang DM, Liao SM, et al. Tu-mor Necro-sis - [] - -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! - -Underfull \hbox (badness 7397) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Takeuchi O, Takeda K, Hoshino K, et al. Cel-lu-lar - [] - - -Underfull \hbox (badness 1546) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Ra-jen-dra-sozhan S, Yang SR, Kin-nula VL, et al. SIRT1 -, - [] - - -Underfull \hbox (badness 2635) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Dis-ease. \TU/CharisSIL(0)/m/it/8 Am J Respir Crit Care -Med\TU/CharisSIL(1)/m/n/8 . 2008;177(8):861. - [] - - -Underfull \hbox (badness 6526) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 senes-cence in mice. \TU/CharisSIL(0)/m/it/8 J Clin In-ve -st\TU/CharisSIL(1)/m/n/8 . 2012;122(6):2032. - [] - - -Underfull \hbox (badness 1681) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 FEV1 in COPD pa-tients. \TU/CharisSIL(0)/m/it/8 Med Sci -Monit\TU/CharisSIL(1)/m/n/8 . 2013;19:1229. - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of Non-ty-peable Haemophilus in-fluen-zae Up-regulate - [] - - -Underfull \hbox (badness 6961) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Phos-pho-inosi-tide 3-Kinase-Akt Path-way. \TU/CharisSIL -(0)/m/it/8 J Biol Chem\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 3281) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 and af-ter Treat-ment of AE-COPD, a Lon-gi-tu-di-nal and - [] - - -Underfull \hbox (badness 4001) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Mah-mood M, So-hal SS, Shukla SD, et al. Ep-ithe-lial - [] - - -Underfull \hbox (badness 1742) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 mes-enchy-mal tran-si-tion in smok-ers: large ver-sus sma -ll - [] - - -Underfull \hbox (badness 1248) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 pro-file of ma-trix met-al-lo-pro-teinases (MMPs) and tis --sue - [] - - -Underfull \hbox (badness 3108) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 An-tunes MA, Rocco PRM. Elastase-induced pul-monary - [] - - -Underfull \hbox (badness 2343) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 key to EMT‐as-so-ci-ated COPD patho-gen-e-sis. \TU/Cha -risSIL(0)/m/it/8 Respirol-ogy\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 1789) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang Y, Xia S. Re-la-tion-ship Be-tween ACSL4-Mediated - [] - - -Underfull \hbox (badness 6094) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Liu Z, Li C, Li M, et al. The sub-chronic tox-i-c-ity - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of hy-drox-ysaf-flor yel-low A of 90 days re-peat-edly - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 in-traperi-toneal in-jec-tions in rats. \TU/CharisSIL(0) -/m/it/8 Tox-i-col-ogy\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 3019) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 a sys-tem-atic re-view and Meta-analysis of ran-dom-ized - [] - - -Underfull \hbox (badness 6236) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 con-trolled tri-als. \TU/CharisSIL(0)/m/it/8 J Tra-dit Ch -in Med\TU/CharisSIL(1)/m/n/8 . 2014;34(4):401. - [] - - -Underfull \hbox (badness 4752) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 across Dis-ease Sever-ity. \TU/CharisSIL(0)/m/it/8 Am J -Respir Crit Care Med\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 6236) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Yang IA, Jenk-ins CR, Salvi SS. Chronic ob-struc-tive - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 pul-monary dis-ease in never-smokers: risk fac-tors, - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 patho-gen-e-sis, and im-pli-ca-tions for pre-ven-tion and - - [] - - -Underfull \hbox (badness 5359) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Mart MF, Pee-bles RS Jr. Asthma-chronic ob-struc-tive - [] - -[16 -Missing character: There is no κ (U+03BA) in font "name:Charis SIL:mode=node;sc -ript=latn;language=dflt;"! -] -Underfull \hbox (badness 1931) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Shah AJ, Quek E, Alqah-tani JS, et al. Car-dio-vas-cu-l -ar - [] - - -Underfull \hbox (badness 1546) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 A sys-tem-atic re-view and meta-analysis. \TU/CharisSIL( -0)/m/it/8 Sleep Med Rev\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Brightling C, Green-ing N. Air-way in-flam-ma-tion in - [] - - -Underfull \hbox (badness 5681) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 COPD: progress to pre-ci-sion medicine. \TU/CharisSIL(0) -/m/it/8 Eur Respir J\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 2080) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Barnes PJ, Bur-ney PGJ, Sil-ver-man EK, et al. Chronic - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 ob-struc-tive pul-monary dis-ease. \TU/CharisSIL(0)/m/it -/8 Nat Rev Dis Primers\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 4072) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Burgess JK, Weiss DJ, Westergren-Thorsson G, et al. - [] - - -Underfull \hbox (badness 3568) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Feng YY, Li M, Yangzhong XT, et al. Py-rop-to-sis in - [] - - -Underfull \hbox (badness 1424) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 pul-monary dis-ease. \TU/CharisSIL(0)/m/it/8 J Ethnophar- -ma-col\TU/CharisSIL(1)/m/n/8 . 2023;307:116229. - [] - - -Underfull \hbox (badness 6461) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 McGuin-ness A, Sapey E. Ox-ida-tive Stress in COPD: - [] - - -Underfull \hbox (badness 1596) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Lung In-jury in Chronic Ob-struc-tive Pul-monary Dis-ease - - [] - - -Underfull \hbox (badness 1127) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 mark-ers in hu-man bron-choalve-o-lar lavage fluid ex-hib -it - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Wang R, Ramos C, Joshi I, et al. Hu-man lung - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 myofibroblast-derived in-duc-ers of alve-o-lar ep-ithe-li -al - [] - - -Underfull \hbox (badness 4556) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 is a dif-fusible paracrine sig-nal for the in-duc-tion of - - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Adler KB, Holden-Stauffer WJ, Re-pine JE. Oxy-gen - [] - - -Underfull \hbox (badness 4391) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 metabo-lites stim-u-late re-lease of high-molecular-weigh -t - [] - - -Underfull \hbox (badness 3108) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 gly-co-con-ju-gates by cell and or-gan cul-tures of ro-de -nt - [] - - -Underfull \hbox (badness 1655) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Bor-mann T, Maus R, Stolper J, et al. Role of ma-trix - [] - - -Underfull \hbox (badness 4403) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Dimic-Janjic S, Hoda MA, Milenkovic B, et al. The - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Hod-gin KS, Dono-van EK, Kekes-Szabo S, et al. A - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Placebo-Controlled, Pseudo-Randomized, Crossover - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Trial of Botan-i-cal Agents for Gulf War Ill-ness: - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Resver-a-trol (Poly-gonum cus-p-i-da-tum), Lu-te-olin, an -d - [] - - -Underfull \hbox (badness 3428) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Re-bello CJ, Beyl RA, Ler-tora JJL, et al. Safety and - [] - - -Underfull \hbox (badness 1484) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 sin-gle‐as-cend-ing‐dose clin-i-cal trial. \TU/Chari -sSIL(0)/m/it/8 Di-a-betes Obes Metab\TU/CharisSIL(1)/m/n/8 . - [] - -[17] -Underfull \hbox (badness 3128) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Mori-waki M, Kito K, Nak-a-gawa R, et al. Mu-ta-genic, - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 Acute, and Sub-chronic Tox-i-c-ity Stud-ies of the - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 EFSA Panel on Di-etetic Prod-ucts, Nu-tri-tion (NDA), - [] - - -Underfull \hbox (badness 2158) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 ex-tract from Dahurian Larch (Larix gmelinii). \TU/Chari -sSIL(0)/m/it/8 EFSA J\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 10000) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 par-tial phar-ma-co-dy-namic and ini-tial safety anal-y-s -is - [] - - -Underfull \hbox (badness 4366) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of (−)-epicatechin in healthy vol-un-teers. \TU/Charis -SIL(0)/m/it/8 Food Funct\TU/CharisSIL(1)/m/n/8 . - [] - - -Underfull \hbox (badness 3815) in paragraph at lines 219--219 -[]\TU/CharisSIL(1)/m/n/8 Chen IJ, Liu CY, Chiu JP, et al. Ther-a-peu-tic ef-fect - - [] - - -Underfull \hbox (badness 1331) in paragraph at lines 219--219 -\TU/CharisSIL(1)/m/n/8 of high-dose green tea ex-tract on weight re-duc-tion: A - [] - -[18] -enddocument/afterlastpage (AED): lastpage setting LastPage. -(./article_3113.aux) - *********** -LaTeX2e <2025-11-01> -L3 programming layer <2020/03/25> - *********** -Package rerunfilecheck Info: File `article_3113.out' has not changed. -(rerunfilecheck) Checksum: 7B52A03EFE07BE8A31EA959EC7943EEF;2440. -Package logreq Info: Writing requests to 'article_3113.run.xml'. - -\openout1 = article_3113.run.xml -) Here is how much of LuaTeX's memory you used: - 46659 strings out of 476081 - 244307,1977958 words of node,token memory allocated - 896 words of node memory still in use: - 6 hlist, 2 vlist, 2 rule, 2 glue, 4 kern, 1 glyph, 7 attribute, 133 glue_spec -, 7 attribute_list, 2 write nodes - avail lists: 1:6,2:2164,3:1420,4:553,5:1565,6:100,7:21655,8:54,9:600,10:13,11 -:1873 - 67969 multiletter control sequences out of 65536+600000 - 122 fonts using 48762831 bytes - 104i,7n,128p,2469b,1260s stack positions out of 10000i,1000n,20000p,200000b,200000s - -Output written on article_3113.pdf (18 pages, 9541428 bytes). - -PDF statistics: 749 PDF objects out of 1000 (max. 8388607) - 671 compressed objects within 7 object streams - 209 named destinations out of 1000 (max. 131072) - 120 words of extra memory for PDF output out of 10000 (max. 100000000) - + 22 strings out of 476081 + 100000,460012 words of node,token memory allocated 301 words of node memory still in use: + 1 hlist, 1 dir, 3 kern, 1 glyph, 1 attribute, 39 glue_spec, 1 attribute_list +nodes + avail lists: 2:10,3:3,4:1 + 22577 multiletter control sequences out of 65536+600000 + 14 fonts using 591679 bytes + 19i,0n,29p,64b,17s stack positions out of 10000i,1000n,20000p,200000b,200000s +! ==> Fatal error occurred, no output PDF file produced! diff --git a/article_3113.synctex.gz b/article_3113.synctex.gz deleted file mode 100644 index 957ad24..0000000 Binary files a/article_3113.synctex.gz and /dev/null differ diff --git a/article_3113.tex b/article_3113.tex index 399cf32..193d7bc 100644 --- a/article_3113.tex +++ b/article_3113.tex @@ -7,7 +7,7 @@ volume=10,%卷 articletype=REVIWER, no=9,%期 page=57,%号 -]{tmr-tex} +]{../tmr-tex} \doi{10.53388/TMR20241121001} \journalweb{https://www.tmrjournals.com/tmr} diff --git a/tmr-tex.cls b/tmr-tex.cls index 18e3ba3..87f399f 100644 --- a/tmr-tex.cls +++ b/tmr-tex.cls @@ -345,7 +345,7 @@ \fi \newpage \vspace*{\dimexpr-\headsep-\headheight + 6pt\relax} - \includegraphics[width=18mm]{tmr-logo.pdf}% 你的Logo路径 + \includegraphics[width=18mm]{../tmr-logo.pdf}% 你的Logo路径 \hfill \parbox[b]{150mm}{% \raggedleft @@ -864,7 +864,7 @@ \newcommand*\cup@author@orcid{% \cup@ifundefined{@orcid@\@roman\@tempcnta}{}{% \href{https://orcid.org/\csname @orcid@\@roman\@tempcnta\endcsname}{% - \includegraphics[height=0.8em]{orcid_icon.png}% 确保orcid_icon.png在路径中 + \includegraphics[height=0.8em]{../orcid_icon.png}% 确保orcid_icon.png在路径中 } }% }